Intracytoplasmic lipid droplets in high grade glioma: metabolism and target for therapy by Murren, Robert John
   
 
Intracytoplasmic Lipid Droplets in 
High Grade Glioma –  
Metabolism and Target for Therapy 
 
By 
Robert John Murren 
 
A thesis submitted to the University of Birmingham for 
the degree of DOCTOR OF PHILOSOPHY 
 
 
 
 
 
 
Institute of Cancer and Genomic Sciences 
College of Medical and Dental Sciences 
University of Birmingham 
February 2018 
 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
   
i 
 
Abstract 
Glioblastoma is a highly malignant and aggressive high grade glioma with a poor 
prognosis. The low survival rates stem from tumour progression, late intervention, 
ineffective therapies and drug resistance, requiring new therapeutic and diagnostic 
approaches. Lipid droplets are dynamic organelles suggested to be influential facets 
of cancer metabolism and biology in many tumours. In glioblastoma, lipid droplets 
have been associated with hypoxia, higher clinical grades and poor survival; 
however, the cellular pathways underlying lipid droplet metabolism remain unclear. 
Using a publically available database of grade 2 to 4 glioma gene expression, we 
observed that genes associated with lipid droplet metabolism were important 
prognostic survival and tumour progression indicators. Moreover, through confocal 
microscopy, flow cytometry and NMR-based methods, we observed that uptake of 
exogenous lipids and adipose triglyceride lipase-mediated lipid shuttling produced 
lipid droplets whilst autophagy was vital to lipid droplet breakdown. ATGL-mediated 
lipid shuttling was further observed to prevent unsaturated fatty acid oxidative 
damage. Finally, we investigated the effect of pharmacological lipid droplet 
manipulation and observed that autophagy inhibition can improve temozolomide and 
irradiation cytotoxicity. Taken together our data suggests that understanding lipid 
droplet metabolic pathways may generate prognostic bio-markers of survival and 
progression and improve current therapies. 
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1.1. Introduction 
The world health organisation (WHO) reported that cancer was responsible for 8.8 
million deaths in 2016, accounting for approximately a sixth of all deaths, and is a 
significant burden on medical resources (1). The category “Brain and CNS tumours” 
is comprised of many types of cancer including glioma, medulloblastoma, 
ependymoma, meningioma and metastases from other cancers localised to the 
brain.  Although brain and CNS tumours represent a small percentage of cancer 
cases they contribute significantly to overall cancer mortality. Indeed, in 2014 brain 
and CNS tumours represented just 3% of all cases in the UK but had a 10 year 
survival of 14% (2). The majority of brain and CNS tumours occur in older patients, 
with 46% diagnosed in patients over 65 years (2); however, they also represent the 
most frequently occurring group of tumours in patients aged 0-19 (3). Although the 
mortality is far lower than their adult counterparts, brain and CNS tumours represent 
40-50% of paediatric tumours (4) and are associated with the highest mortality rate 
in paediatric cancers. Despite significant research, little progress has been made in 
the improvement of treating many of these tumours and therefore effective novel 
therapeutic approaches have been long awaited. 
 
1.2. Gliomas 
1.2.1. Introduction to gliomas 
The most common group of intrinsic CNS tumours is the gliomas, derived from glial 
cells which provide physical, metabolic and neurotrophic support to neurons within 
the brain (Figure 1.1.). Oligodendrocytes provide a myelin sheath similar to 
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peripheral nervous system Schwann cells (5) whilst microglia have a macrophage-
like protective function (6). In contrast, astrocytes provide a diverse range of support 
including nutrient supply, brain repair and support for blood brain barrier endothelial 
cells (7). We have elected to focus upon astrocyte-derived gliomas, termed 
astrocytomas, which represent three quarters of all gliomas (8). 
  
1.2.2. The WHO grading system 
In contrast, to many cancers, brain tumours are separated by severity, progression 
and phenotype into representative groups called clinical grades as opposed to 
stages. The WHO classifies gliomas into 4 clinical grades of increasing severity (9). 
Grade 1 gliomas are well defined, have a low proliferative potential, rarely progress 
and are considered distinct from the other three glioma grades. Grade 2 gliomas also 
have low proliferative potential but are more invasive and infiltrative with more 
frequent recurrence and tumour progression. Similarly, grade 3 gliomas have 
increased infiltration and proliferation and are distinguished by increased malignant 
cytological indicators. Finally, grade 4 gliomas are highly invasive, aggressive and 
Figure 1.1. The glial progenitor cells and the corresponding tumours. Image from Rao 
et al. (292) 
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necrotic and have a very poor survival. Previously tumour grade was predominantly 
classified through histology; however, the updated WHO glioma classification now 
includes molecular and genetic parameters within the definitions of glioma grades 
(9). Most notably, grade 2 and 3 gliomas are classified according to the mutational 
status of the metabolic IDH genes with IDH mutant tumours being the most frequent 
(10). As previously mentioned, grade 1 gliomas are considered notably distinct from 
the other glioma grades and therefore, in the interest of clarity, we have focussed 
upon grades 2 to 4. 
 
1.2.3. Grade 2 gliomas 
Grade 2 gliomas are predominantly slow growing diffuse astrocytomas with high 
differentiation (11) which most frequently present at the insular and supplementary 
motor area in Caucasian men aged approximately 40 years (12). The prognosis is 
relatively good with a 5 year survival of 47.4% (13) and tumours are characteristically 
noted to have ATRX loss and mutant IDH and TP53 (10). As previously mentioned, 
grade 2 tumours can progress to higher clinical grades and this has led to the 
proposal of an intermediate diffuse glioma between grades 2 and 3 (14). 
 
1.2.4. Grade 3 gliomas 
Grade 3 gliomas, most frequently presenting as anaplastic astrocytomas, can be 
difficult to define due to their similarities to grade 2 gliomas; however, the prognosis 
is inevitably poorer and more severe (15). 5 year survival is decreased to 27.3% in 
grade 3 gliomas (13) which are more aggressive, invasive and heterogeneous. 
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Indeed, grade 3 gliomas often display areas of high and low grade glioma biology 
(16). The frequency of tumour progression is also increased and it can be difficult to 
separate grade 3 and 4 gliomas by MRI and histology alone (17). Therefore, 
molecular markers such as the IDH, TP53 and NOTCH genes are used to 
complement histological markers and assist tumour classification. 
 
1.2.5. Grade 4 gliomas 
Grade 4 gliomas, known as glioblastoma (GBM), are the most common and severe 
group of gliomas accounting for 54% of all gliomas (8). The standard treatment 
regimen of surgery, radiotherapy and chemotherapy is largely ineffective (18-20) and 
the 5 year survival is less than 5% (13). These tumours are characteristically highly 
invasive, aggressive and proliferative and inadequate perfusion results in severely 
hypoxic areas forming necrotic foci surrounded by pseudopallisading cells (21-23). 
This stimulates the diffuse spread of cells throughout the entire brain, frequently 
generating new tumours and preventing effective resection. Indeed, some GBMs 
have a widely diffuse, infiltrative nature, in which cells are spread throughout the 
brain with no central foci (24). 
GBMs are clinically delineated into two types, known as primary and secondary 
GBM, and are markedly distinct and believed to stem from different precursor cells 
(25). Primary GBMs are the most common type of GBM representing about 90% of 
all cases and are believed to occur spontaneously at grade 4 (9). These tumours are 
more invasive with a more rapid progression and worse prognosis. Moreover, they 
can be further subdivided into 4 sub-groups based upon several molecular features 
(26,27) (Figure 1.2.). The classical GBM sub-group is associated with alterations in 
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EGFR, PTEN, CDKN2A and NOTCH while the mesenchymal sub-group is 
associated with alterations in NF1, TP53, PTEN and MET. The pro-neural sub-group 
is similarly associated with alterations in PTEN and TP53 but also PDGFRA, IDH 
and PI3K whereas the neural subgroup is poorly defined but retains more similarity 
to normal brain structure. However, despite this, primary GBMs are not frequently 
associated with IDH and TP53 mutations. In contrast, to the spontaneous occurrence 
of primary GBMs at grade 4, secondary GBMs are believed to be the result of 
progression from lower tumour grades and retain the alterations in IDH and TP53 
characteristic of grade 2 and 3 gliomas. Moreover, these tumours typically arise in 
younger patients and are associated with a better prognosis, emphasising the 
importance of these molecular markers across glioma grades. 
 
 
 
 
 
 
 
 
Figure 1.2. GBM can be split into primary and secondary GBM whilst primary 
GBM can be further divided by molecular subgroups. Image from Van Meir et al. 
(27). Tumour-initiating cell (TIC), Brain cancer progenitor cell (BCPC). 
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1.2.6. Molecular markers in gliomas 
Several mutations are frequently observed in a large proportion of gliomas. For 
example GBMs have been noted to display mutations in the following proportions of 
tumours: PTEN (29%), TP53 (29%), EGFR (20%), NF1 (9%), RB1 (8%), IDH1 (5%) 
(28). Indeed, several of these mutations have particular importance as molecular 
markers of glioma grade. 
 
1.2.6.1. IDH mutations 
As previously mentioned, IDH mutations now define intra-grade tumour groups in 
gliomas due to the high frequency of observation. The IDH genes encode a group of 
isocitrate dehydrogenase enzymes 1, 2 and 3 and mutations in IDH 1 and 2 are 
observed in over 80% of grade 2 gliomas (29). IDH1 is located in the cytosol whilst 
IDH2 and 3 function within the mitochondria and together these enzymes carry out 
the synthesis of α-ketoglutarate from isocitrate in the tricarboxylic acid (TCA) cycle 
(30). Alternatively, IDH enzymes are also vital to glutamine-derived lipogenesis 
through reductive carboxylation, although the relatively slow kinetics of this pathway 
compared to oxidative glutamine metabolism mean that it only predominates in 
conditions in which oxidative metabolism is limiting, such as hypoxia (31). Finally, 
these enzymes may mediate electron and metabolite shutting between the 
mitochondria and cytosol and IDH1 mutations have been associated with reduced 
NADPH production (32). The diverse metabolic roles of the IDH enzymes therefore 
make them prime targets for subversion in tumorigenesis. Intriguingly mutations in 
IDH enzymes map exclusively to key structural residues within the active binding 
site, specifically three arginine residues critical to isocitrate binding (33). The choice 
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of amino acid that replaces the arginine appears unimportant implying that only 
physical active site structure and function disruption is required whilst obligatory 
heterozygosity suggests a gain of function effect. Indeed, the major effect of an IDH 
mutation may be the increased production of the oncometabolite 2-hydroxyglutarate 
(2-HG) which has neomorphic metabolic activity (Figure 1.3.). Although 2-HG is also 
produced by wildtype IDH enzymes as a minor product it is quickly cleared by a 
number of possible dehydrogenases. In contrast, the increased 2-HG production by 
mutant IDH enzymes overwhelms this process to the extent that 2-HG becomes one 
of the most abundant cellular metabolites. At such concentrations 2-HG dramatically 
alters the cellular metabolic and epigenetic profile and may promote tumorigenic 
activity (34). Indeed, mutations in IDH enzymes are understood to occur very early in 
glioma tumorigenesis and represent an important step within this process (35,36). 
Interestingly, IDH mutation is associated with improved survival and may also affect 
treatment efficacy (37). Nevertheless, due to the importance and frequency of these 
mutations, pharmacological inhibitors targeting oncogenic IDH enzymes are currently 
under trial (38). 
 
 
 
 
 
 Figure 1.3. Mutant IDH enzymes have neomorphic metabolic 
activity. Image from Yang et al. (291) 
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1.4.6.2. TP53 mutations 
Mutations in the TP53 tumour suppressor gene also represent one of the most 
common genetic alterations in grade 2 and 3 gliomas, mutated in up to 70% of cases 
(39). Indeed, glioma TP53 mutations occur almost invariably with IDH mutations 
(40). TP53 encodes the tumour suppressor p53 which is vital in many processes 
including DNA repair, cell cycle arrest and cell death (41,42). Mutations can result in 
loss of activity through protein degradation, truncation or suppression of the 
heterozygote wild type protein as a dominant negative oncogene. Mutations in TP53 
are one of the most frequent genetic alteration observed in human cancers (43) and 
therefore its importance in gliomas is unsurprising. Nevertheless, the frequent 
association of TP53 and IDH mutations across glioma grades suggests a common 
importance in the process of glioma tumorigenesis. 
 
1.4.6.3. Other common mutations 
IDH and TP53 mutations represent the majority of genetic alterations in grade 2 and 
3 gliomas; however, several other genes have been noted to occur with a high 
frequency at grade 4. Epidermal growth factor receptor (EGFR) gene amplification 
and mutation events cause constitutive activation and are the most common 
oncogenic alterations in GBM, amplified in up to 60% of cases (44). EGFR is a 
transmembrane tyrosine kinase receptor for epidermal growth factors which 
promotes growth, proliferation and angiogenesis through down-stream signalling 
pathways. The EGFR alteration that is observed most frequently in GBM is the 
EGFRvIII truncation which is constitutively active (45). Intriguingly this mutation is 
usually observed within a scattered subpopulation of the tumour surrounded by 
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tumour cells overexpressing wild-type EGFR (46). Although the late occurrence of 
this mutation could prevent diffuse migration and occurrence throughout the tumour, 
it has been suggested that expression of truncated EGFRvIII enhances the 
tumorigenic activity of the neighbouring tumours cells with amplified wild-type EGFR 
expression (47). 
The phosphatase tumour suppressor PTEN is also mutated in GBM, occurring in 5-
40% of cases and providing a prognostic marker in patients over 45 years (48). 
PTEN regulates re-entry into the cell cycle and loss of function genetic alterations to 
this gene often promote tumorigenic activity.  
Neurofibromatosis type 1 is an autosomal dominant disorder characterised by 
mutations in the NF1 gene which suppresses the RAS kinase pathway. Mutations to 
this gene are oncogenic due to the role of NF1 in cell regulation and gliomas 
commonly occur in NF1 patients (49,50). 
Mutation or loss of the alpha-thalassemia/mental retardation syndrome X-linked 
(ATRX) gene commonly occurs with IDH1 and TP53 mutation, mirroring their 
prognostic indication (51). Interestingly, loss of this gene lengthens cell mortality 
through telomerase lengthening and increases epigenetic instability through 
disruption of histone variant deposition (52,53). 
Finally, epigenetic methylation of genes including tumour suppressors, growth 
regulators and drug resistance mechanisms provide interesting alterations 
throughout the glioma grades (54). 
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1.2.7. Tumour progression 
Tumour progression presents one of the greatest challenges in glioma treatment as 
tumours become increasingly more aggressive and therapy resistant. Nevertheless, 
recurrent features across tumour grades such as alterations in the molecular 
markers IDH1 and TP53 may indicate aspects of an underlying progression route to 
higher clinical grades. TP53 and IDH1 mutations occur in the majority of grade 2 and 
3 gliomas, although this is not reflected at grade 4. Indeed, IDH1 mutations occur in 
83% of secondary GBMs but only 5% of primary GBMs (55). This suggests that 
these mutations are an important feature in the biology of a tumour progressing from 
a grade 2 glioma to a grade 4 secondary GBM but not a spontaneously occurring 
primary GBM. Moreover, IDH mutations occur very early in tumour progression often 
preceding other alterations in genes such as TP53 which again precede alterations 
in genes such as PTEN and EGFR (35,36). The occurrence of these mutations in an 
apparent common sequence shared by progressing tumours, again suggests that 
these genes may represent aspects of the tumour progression process (Figure 1.4.). 
These mutations are also stable molecular events, remaining throughout the 
transition from low to high grade, emphasising their oncogenic importance (56). 
However, despite the trends in mutation occurrence, a mechanistic link to tumour 
progression remains to be demonstrated. Although these genes clearly represent 
common alterations gained by tumours as they progress to higher clinical grades, 
the underlying features of tumour progression and a theoretical shared progression 
pathway remain uncertain. Nevertheless, it is reasonable to speculate that other 
genetic alterations may also contribute to or represent tumour progression and that, 
through understanding this process, we may be able to address and target the 
clinical problems associated with advancing tumour grade.  
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1.2.8. Glioma therapy and why it fails 
Another major issue in the treatment of gliomas is ineffective therapies and therapy 
resistance. Standard therapy for gliomas is extensive resection with radiotherapy 
and adjuvant chemotherapy with regimen aggressiveness determined according to 
tumour grade and patient status (Figure 1.5.). Patient-specific variables such as old 
age and decreased vitality are important factors in determining the extent of 
treatment and can contraindicate high dose therapies and repeated surgeries. 
However, irrespective of aggressive therapies, this disease remains incurable due to 
intrinsic and acquired tumour resistance mechanisms. Extensive and early resection 
can improve patient survival with tumour resection over 90%, significantly increasing 
one year survival (57), although the infiltrative nature of gliomas means recurrence in 
Glioma precursor cells 
IDH mutation 
TP53, ATRX mutation 
EGFR, PTEN, further mutations 
Primary GBM Secondary GBM 
Grade 2 & 3 
Grade 4 
Figure 1.4. IDH, TP53 and ATRX mutations are associated with grade 2 and 3 
gliomas and secondary GBM but not observed in primary GBM.  
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the surrounding tissue is inevitable. This is especially true in highly invasive GBM 
where complete resection is impossible. Radiotherapy also constitutes a standard 
feature in glioma treatment regimens; however, it is frequently resisted through a 
variety of cellular mechanisms. DNA repair enzymes are upregulated in response to 
radiation (58) and cell death can be inhibited (59). Indeed, Ape1 has been suggested 
to be of particular importance in gliomas due to its role in base excision repair (60) 
whilst EGFRvIII can upregulate DNA double strand break machinery (61). Similarly, 
cancer stem cells are known to have high radio-resistance (62) which can also be 
effected by the tumour microenvironment and oxygen concentration (63). 
Chemotherapy constitutes the final component in glioma treatment and relies 
predominantly on temozolomide. Temozolomide is an alkylating agent which 
methylates guanine at the O6 position, inducing cell death (64). However, this lesion 
can be removed by the DNA repair enzyme MGMT which is frequently upregulated 
in gliomas, limiting temozolomide efficacy (65). As such, the current treatment 
regimens of glioma remain ineffective and novel therapeutic approaches are 
required. 
 
 
 
 
 
Figure 1.5. Surgery, radiotherapy and chemotherapy constitute the three major 
components of glioma treatment regimens and are escalated according to grade 
and tumour severity. Patient survival decreases according to clinical grade. Right 
image adapted from Prados et al. (295) 
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1.2.9. Novel therapeutics 
Whilst current therapy efficacy remains low altered approaches will continue to be 
investigated, although these have been mostly limited to grade 3 and 4 glioma. 
Sloan et al. (66) reported in their systematic review that no novel therapies were 
being investigated for low grade gliomas (grades 1 and 2). Persistent 
hyperglycaemia was independently associated with poor survival and high 
recurrence in low grade gliomas implicating dietary options for improving current 
therapies (67). However, this remains to be further investigated. Consistent 
obstacles in the investigation of novel therapies in low grade gliomas remain cost 
and frequency of occurrence. Long follow up times increase study expense whilst 
low tumour frequency necessitates multi-centre studies. Moreover, the increased 
survival of these tumours compared to higher grades ensures novel therapeutics 
remain a lower priority in low grade gliomas. 
In contrast, a variety of different approaches have been investigated in high grade 
gliomas. Several monoclonal antibodies targeting surface receptors to prevent down-
stream activation or induce cell death have been trialled. Bevacizumab, an anti-
VEGFR antibody, was designed to prevent neovascularisation but had no effect on 
survival (68). In contrast, AMG595, an anti-EGFRvIII antibody conjugated to a 
cytotoxic agent that is internalised upon binding, showed good in vitro and pre-
clinical efficacy (69). However, cytotoxicity will be limited to the EGFRvIII subset of 
tumour cells and in vivo efficacy remains to be tested in clinical trials. Similarly, 
several synthetic glioma-associated antigen peptides, designed to stimulate the anti-
tumour immune response, have passed the phase 1 clinical trial but require further 
investigation (70). Dendritic vaccines which mobilise the host’s innate immune 
system against individual tumours have also been investigated in GBM but their 
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efficacy may be limited to a small patient sub-group (71). Moreover, oncolytic viruses 
such as herpes simplex and adenovirus which proliferate selectively in tumour cells 
and induce lysis are under current investigation (72) whilst antioxidants have shown 
inconsistent and unreliable results (73). As observed in many cancers, small 
molecule inhibitors have failed to reach expectations in gliomas and the EGFR 
tyrosine kinase inhibitor erlotinib (74) and an IDH1 mutant enzyme inhibitor (38) have 
shown limited efficacy. Despite extensive investigation, novel therapies have thus 
failed to provide significant breakthroughs and glioma therapy has remained 
unchanged. Therefore, many novel therapies are now targeting alternative key 
tumorigenic mechanisms in cancer biology, including tumour metabolism.  
 
1.3. Tumour metabolism 
1.3.1. Introduction to tumour metabolism 
Altered metabolism is vital to support the increased demands of a tumour and is 
considered a “hallmark” of cancer (75). There are three main focuses for metabolic 
reprogramming; the production of energy (i.e. ATP), the maintenance of homeostatic 
reactions such as balancing the redox state and the generation of macromolecules 
and their pre-cursors for growth and proliferation. The increased metabolic activity of 
a tumour cell therefore requires an increased uptake of metabolic fuels such as 
glucose (76), acetate (77) and glutamine (78). Glucose uptake is dramatically 
increased in many cancers and provides a major source of energy (76). Glucose 
metabolism switches from linked glycolysis and oxidative phosphorylation to 
significantly increased glycolysis with subsequent production of lactate from pyruvate 
in a condition known as the Warburg effect (79,80). Although ATP production per 
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glucose molecule is lower, it is produced at a far quicker rate and can be maintained 
in the absence of oxygen providing a significant growth advantage within a tumour. 
Similarly, increased acetate metabolism provides an increased production of acetyl 
CoA to support a variety of metabolic processes (77). Exogenous glutamine can also 
be used to support several different cellular processes including the production of α-
ketoglutarate for TCA cycle metabolism and reductive carboxylation or nitrogen 
donation for nucleotide biosynthesis (78). Indeed, many tumours, including some 
gliomas, are considered “glutamine addicted” emphasising the importance of 
glutamine in tumour metabolism (81,82). The increased tumour metabolic rate 
increases precursor supply for the production of macromolecules and drives 
upregulated growth and proliferation. Indeed, the importance of the subverted 
macromolecule production pathways in proliferation suggests they are key areas of 
tumour biology which must be understood to achieve real therapeutic progress. 
 
1.3.2. Overview of the lipid class of macromolecules 
Lipids represent a major class of macromolecules vital for life composed of three 
groups; isoprenoids, polyketides and acylglycerides/fatty acids (83). Isoprenoids are 
5 carbon subunits such as steroids and bile acids whereas polyketides are a range 
of poly-β-ketoacid derived secondary metabolites containing aromatic and polycyclic 
groups. Acylglycerides and fatty acids represent the most universally important 
group of lipids. Fatty acids are comprised of long hydrocarbon chains with a distinct 
hydrophobic character that can be conferred to molecules such as proteins through 
conjugation. Moreover, they can be conjugated to glycerol “backbones” to produce 
acylglycerides including triglycerides and phospholipids. Fatty acids and 
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acylglycerides have a diverse range of roles including energy production through β-
oxidation, protein modification and lipid signalling and are the major component of 
membranes as phospholipids. This investigation has focussed exclusively on the 
fatty acid and acylglyceride group of lipids to which the term “lipid” will refer to from 
hereon. 
 
1.3.3. The importance of lipid metabolism in cancer 
As previously discussed the activity of lipid metabolic pathways must be increased to 
meet the demands of energy production, signalling and biosynthesis in cancer and 
has long been established as a vital tumorigenic change (84). Indeed, lipid 
metabolism has been linked to the malignant phenotype of prostate cancer cells (85-
87) and is an important factor in tumour growth and progression (88). Moreover, 
many lipid metabolic enzymes have been linked to prostate tumour growth (89,90) 
whilst obesity has been linked to patient survival (91). Similarly, lipid metabolism has 
been linked to metastatic disease in triple negative breast cancer (92) whilst lipid 
metabolism proteins have also been associated with decreased survival in several 
breast cancer subtypes (93). Altered lipid metabolism has been observed in nearly 
all cancers; however, the mechanism through which these changes aid 
tumorigenesis is often cancer-specific. 
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1.4. Lipid droplets 
1.4.1. Introduction to lipid droplets 
One major area of interest in cancer lipid metabolism is lipid droplets also known as 
mobile lipids, adiposomes, lipid bodies and magnetic resonance spectroscopy 
(MRS)-visible lipids. Although previously thought to be limited to large fat storage 
droplets within adipocytes, all human and animal cells have been observed to have 
the ability to form lipid droplets to some extent (94). These lipid-rich cytoplasmic 
organelles are involved in many cellular processes both physiological and 
pathological and can be visualised and detected with chemical staining and MRS 
(95). Classically lipid droplets were viewed as inert membrane bound stores of fatty 
acids awaiting catabolism; however, their complex metabolic roles and unique 
interactions with other organelles including the endoplasmic reticulum (ER), 
mitochondria and peroxisomes is such that they are now considered dynamic 
organelles (96). It is therefore unsurprising that they have been investigated in many 
diseases including atherosclerosis, obesity, heart disease, diabetes and viral 
pathogenesis. Most notably, lipid droplets have been linked with many types of 
cancer and are often considered negative pathological indicators and intrinsic to 
tumorigenic metabolism. 
 
1.4.2. Lipid droplet composition 
Membrane bilayers are inadequate for lipid storage as functionality and structural 
integrity can quickly be lost whilst high cytoplasmic lipid concentrations risk lipotoxic 
damage. Therefore, lipid droplets provide a system through which homeostasis can 
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be maintained. Lipid droplets are composed of a hydrophobic core of neutral lipids 
and cholesteryl esters surrounded by a single phospholipid monolayer membrane 
(Figure 1.6.). Pan et al. (97) observed that triglycerides within lipid droplets were 
composed of saturated, unsaturated and polyunsaturated fatty acids which were 
predominantly oleic and linoleic fatty acids. Interestingly, they also noted that the 
composition of lipid droplets is notably different to cell membranes due to the 
increased hydrophobic area of a droplet compared to a membrane bilayer. Similarly, 
Mirbahai et al. (98) observed that the polyunsaturated fatty acid concentration could 
increase in response to lipid droplet promoting conditions suggesting that these 
ratios are dynamic and condition-specific. Indeed, mobilisation of saturated fatty 
acids from lipid droplets for β-oxidation resulted in an increased proportion of 
monounsaturated fatty acids within the lipid droplet (99). It is therefore difficult to 
define lipid droplet contents from a general perspective as this can be cell type and 
condition specific and must be considered on a case by case basis. 
 
 
 
 
 
 
 
 Figure 1.6. The major features in the structure and content of lipid 
droplets. 
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The amphipathic nature of phospholipids causes them to align at the lipid droplet 
surface to form a membrane and provide stability through emulsion principles 
(100,101). As surfactants they decrease surface tension and provide elasticity and 
flexibility, supported by their specialised structure. For example the hydrophilic head 
of phosphatidylcholine is cylindrical providing increased surface area and decreased 
surface tension compared to the conically shaped phosphatidylethanolamine.  
 
1.4.3. Lipid droplet origin and size 
Lipid droplets are thought to initially derive from the ER; however, the exact 
mechanism has remained poorly defined (96). A “lens” was observed between ER 
membranes and nascent lipid droplets suggesting a budding mechanism (102) which 
may involve apolipoprotein B-100 and the lipid droplet-associated protein TIP47 
(103). Similarly, it has been suggested that small lipid droplets use ER enzymes to 
generate lipid content, requiring continued attachment to the ER (104). In contrast, 
large lipid droplets were suggested to relocate ER triglyceride synthesis enzymes 
such as GPAT4 to the lipid droplet surface suggesting ER independent mechanisms 
for mature lipid droplets (104). Interestingly, the ER membrane protein seipin has 
been shown to localise to the lipid droplet-ER contact site and control lipid and 
protein sorting in lipid droplet maturation; however, again the mechanism remains 
unclear (105-107). Moreover, larger lipid droplets have increased saturated fatty 
acids in the surrounding monolayer further supporting alterations in lipid droplet 
biology during maturation (108). Although our understanding of lipid droplet 
biogenesis remains limited, alterations to pre-existing lipid droplets appear to be of 
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far greater importance to lipid droplet functionality in health and disease and this is 
discussed in greater detail further in this review. 
As previously mentioned, lipid droplet size can imply maturation status; however, it 
can also indicate metabolic activity and cell condition. Early reports suggested that 
lipid droplets were typically between 0.1-0.4 µm in diameter (109) and this has been 
supported in more recent studies (110). However, Pan et al. (110) also reported lipid 
droplet diameters up to 1µm and that the inverse association of droplet number to 
size was cell line-specific, further highlighting unique cell line-specific lipid droplet 
profiles. Cell condition can also affect lipid droplet size as intracellular lipid droplets 
within apoptotic cells and extracellular lipid droplets from necrotic cells can have 
diameters up to 2 µm and 10 µm respectively (111). Notably, however, detection of 
small droplets can be limited with current methodologies and lipid droplets with a 
diameter below 0.1 µm are considered NMR invisible (112). 
 
1.4.4. Lipid droplet proteins 
The single phospholipid layer and hydrophobic core of a lipid droplet prevents the 
anchoring of proteins via standard luminal insertion domains (96). Instead, lipid 
droplet-specific proteins have been suggested to often contain a hydrophobic hairpin 
domain for attachment (113). The most notable group associated with lipid droplets 
is the PAT family of proteins, named after the three main members perilipin 1, 
adipophilin and TIP47 (114). The PAT family of proteins shares a conserved PAT 
domain and encompasses the genes PLIN1 and PLIN2 and the isoforms PLIN3, 
PLIN4 and PLIN5; representing perilipin 1, adipophilin, TIP47, PLIN4 and PLIN5 
respectively (Figure 1.7.).  
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Perilipin 1 is frequently associated with adipocytes but has been noted in many 
tissues (114). Through complexing with CGI58, a lipase activator protein, perilipin 1 
prevents lipase activation and subsequently lipid droplets do not undergo lipolysis 
(115). However, once phosphorylated, perilipin 1 releases CGI58 and lipolysis is 
activated implicating perilipin 1 as a key regulator in inactivating lipid droplet 
metabolic pathways. 
In contrast, adipophilin is expressed more ubiquitously (116) and is observed 
frequently in other tissues such as hepatocytes (117), macrophage foam cells (118), 
sebocytes (119) and epithelial cells (120). Adipophilin is thought to stabilise lipid 
droplets in high lipid conditions and is associated strongly with the metabolic process 
of autophagy (121). Indeed, it has been noted as an important lipid droplet marker in 
several cancers including renal cell carcinoma (122) and GBM (123). Interestingly, it 
is thought to often replace periliin 1 as lipid droplets mature and have a different role 
in the regulation of lipid droplet metabolism (114). 
Figure 1.7. Protein structure remains similar 
throughout the PAT family of proteins. Image adapted 
from Itabe et al. (114). 
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TIP47 is considered similar to adipophilin in role and structure but remains a distinct 
protein (114). Notably, neither adipophilin nor TIP47 bind to CGI58 (124) and 
therefore are believed to impact lipid droplet metabolism through an alternative 
mechanism. 
Little is known regarding the biological functions of PLIN4; however, it is thought to 
have many similarities to perilipin 1 and is most notably distinct from other PLIN 
proteins through the absence of a PAT domain (114). Similarly, the role of PLIN5 is 
relatively unexplored; however, it has been associated with small lipid droplets and 
mitochondria in cardiomyocytes (125,126).  
Hypoxia inducible protein 2 (HIG2) is encoded by the HILPDA gene and is an 
important lipid droplet-associated protein in hypoxic lipolytic regulation. Indeed, HIG2 
has an established role in lipid utilisation (127) and hepatic (128) and macrophage 
(129) lipid storage. The HILPDA gene is a target of the hypoxic transcription factor 
HIF1α and is upregulated in hypoxia (130) which is also known to upregulate lipid 
droplet accumulation in GBM (123). Similarly, HILPDA is established as an important 
marker in renal cell carcinoma (131) and represents an important link between lipid 
droplets and hypoxia, discussed in greater detail in section 4.6. 
Lipid droplets have also been associated with a wide variety of proteins from many 
different cellular pathways, reflecting the diversity of lipid droplet metabolism. This 
includes intracellular fatty acid transporters called fatty acid binding proteins (FABPs) 
(123), autophagy proteins (132) and a variety of organelle transport proteins such as 
SNARE (133), dynein (134) and microtubules (109,135). Together these proteins 
contribute towards the diverse functionality of lipid droplet metabolism. 
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1.4.5. Factors affecting lipid droplets 
The large number of external and internal factors capable of influencing lipid droplets 
are a direct reflection of the diverse range of processes in which lipid droplets are 
involved. Environmental factors such as pH (95), oxidised lipids (136) and 
surrounding fatty acid content have been demonstrated to affect the number of lipid 
droplets. Similarly, lipid droplet number correlates positively with confluency (94) 
whist the core composition remains unchanged (112). 
The effects of cell death on lipid droplet accumulation are frequently reported and 
cell stresses capable of inducing cell death, such as cytotoxic drugs, are known to 
induce lipid droplets (98,137). Indeed, increased numbers of lipid droplets has been 
proposed as a characteristic of the programmed cell death process, apoptosis (138). 
The characteristic increase in lipid droplet accumulation occurs early in the apoptotic 
process, preceding traditional markers and allowing the earlier detection of treatment 
responses compared to traditional apoptosis assays (98). Interestingly, apoptosis 
induces a decrease in malonyl CoA, expected to increase mitochondrial lipid uptake 
and β-oxidation and decrease lipid droplet number; however, the observation of an 
opposing effect suggests the involvement of other lipid droplet metabolic processes. 
Lipid droplets have also been linked to necrosis and are thought to be responsible 
for the high lipid content of necrotic GBM cores (94,98). Lipid droplets therefore 
represent interesting markers in cell death pathways but also a potential 
experimental pitfall from the accidental induction of death-related lipid droplet 
responses. 
Hypoxia is a deficiency in the amount of oxygen reaching cells and is considered a 
hallmark of cancer (75) occurring in tumours with inadequate perfusion such as GBM 
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(23). Under sufficient oxygen conditions the α-subunits of the hypoxia inducible 
transcription factors, HIF1 and HIF2, are continuously targeted for proteasome 
degradation by the action of prolyl hydroxylases and the Von Hippel-Lindau protein. 
However, under hypoxic conditions the HIF α-subunits are stabilised and can form 
active dimers, activating numerous cellular mechanisms including angiogenesis and 
metabolic rewiring. Hypoxia is associated with lipid droplets in GBM in a HIF1α 
dependent manner (123) whilst in renal cell carcinoma HIF2α has been shown to 
induce PLIN2 expression and lipid droplet accumulation (122). Moreover, hypoxia 
stimulates several metabolic processes capable of fuelling lipogenesis including 
glycolysis (139,140) and reductive carboxylation (31,141,142). Indeed, hypoxia can 
also increase lipid uptake and promotes increased expression of the very low density 
lipoprotein uptake receptor (VLDL-R) in a HIF1α and HILPDA dependent manner 
(143). Due to the increased metabolic demand of a tumour cell and the high 
frequency of hypoxia within a tumour mass it is unsurprising that many of these 
pathways promote tumorigenesis in hypoxia and are strongly associated with lipid 
droplets. 
 
1.4.6. Lipid droplet production mechanisms 
Although lipid droplet biogenesis is relatively poorly understood, the metabolic 
mechanisms underlying lipid droplet accumulation have been investigated in many 
cell types and cancers. 
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1.4.6.1. Exogenous lipid uptake in lipid droplet production 
A key biological source of lipids is the extracellular lipid pool, supplied in vivo by the 
circulatory system. Triglycerides and cholesterol are transported around the body 
from the intestines and liver in specialised vesicles called lipoproteins and 
chylomicrons (144). Typically very low density lipoproteins (VLDLs) are associated 
with endogenously produced lipids whereas chylomicrons are associated with 
exogenously acquired dietary lipids (144). These vesicles can be recognised by cell 
surface receptors whereupon they are degraded enzymatically by lipases such as 
lipoprotein lipase (LPL) and the contents internalised through specific 
transmembrane transporter proteins such as CD36 (145). The extracellular lipid pool 
is well characterised as an important source of lipids in many cancers. CD36 was 
observed to be important in breast cancer tissues (146) whilst CD36 and LPL in 
combination were noted as vital mediators in the uptake of exogenous lipoproteins in 
a number of cancers (147). Similarly, lipid uptake is increased in renal cell carcinoma 
and breast cancer through increased expression of low density lipoprotein receptor 
(143) and the associated protein LRP-1 (148) respectively. In both cases these 
upregulations are strongly associated with hypoxia and hypoxia-mimicking 
conditions, also known to increase exogenous lipid uptake (143). Ovarian and colon 
cancer cells have been observed to obtain exogenous lipids from the surrounding 
adipose tissue (149,150) whilst hypoxic prostate cancer cells were observed to have 
an increased uptake of extracellular lipid vesicles produced by normoxic cancer cells 
(151).These processes are important to fuelling lipid droplet production (Figure 1.8.) 
and GBM and breast cancer cell lines were observed to be reliant upon the uptake of 
exogenous serum lipids to produce lipid droplets in hypoxia (123). Interestingly, this 
study also indicated that this process relies upon the activity of FABPs to transport 
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intracellular lipids, a finding mirrored by Nieman et al. (150) who observed the 
importance of FABP4 in ovarian cancer cell lipid uptake. Giampietri et al. (152) also 
found that increased lipid uptake is responsible for increased lipid droplet 
accumulation in melanoma cancer stem cells suggesting that exogenous lipid uptake 
may correlate with a more aggressive cell phenotype.  
 
 
 
 
 
 
 
 
1.4.6.2. De novo fatty acid synthesis in lipid droplet production 
Fatty acids can also be supplied through de novo fatty acid synthesis (Figure 1.9.), a 
pathway strongly linked to tumorigenesis. De novo fatty acid synthesis is the 
production of fatty acids from metabolic precursors such as glucose, acetate and 
glutamine (153). Glucose is converted to acetyl CoA and then citrate through 
glycolysis and the TCA cycle in order to be used for de novo fatty acid synthesis. 
Similarly, acetyl CoA can be produced from acetate by the enzyme acyl-CoA 
synthetase (ACSS2) and can also fuel de novo fatty acid synthesis. Glutamine can 
be converted to glutamate and α-ketoglutarate by glutaminase (GLS) and glutamate 
Figure 1.8. Exogenous lipid uptake. Lipids can be transported across cell 
membranes by transporters such as CD36 to enter the cell for lipid droplet 
production. 
   
28 
 
dehydrogenase whereupon it enters the TCA cycle. α-ketoglutarate can then be 
converted to citrate through a reverse TCA cycle reaction known as reductive 
carboxylation which can provide up to 80% of acetyl CoA used in de novo fatty acid 
synthesis (31,154). Acetyl CoA is transported across the mitochondrial membrane as 
citrate where it is reconverted to acetyl CoA by ATP citrate lyase (ACLY). It is then 
converted to malonyl CoA by acetyl CoA carboxylase (ACACA) and forms the basic 
precursor for fatty acid synthesis. Fatty acid synthesis is performed by a multi-
enzyme complex termed fatty acid synthase (FASN), composed of 7 simultaneously 
active enzymes encoded by the FASN gene. Through a process of condensation, 
reduction and thiolation, malonyl CoA is used to add repeated two carbon subunits 
and produce a fatty acid chain. 
This process has been well established as an important aspect in cancer due to the 
increased lipid demands of a tumour and can be supported through a variety of 
genetic and metabolic alterations. Glycolysis is often increased in cancer through the 
Warburg effect providing an increased source of pyruvate for the generation of acetyl 
CoA (79) whilst cancer hallmarks such as hypoxia have been observed to increase 
fatty acid synthesis in several cancers (151,155). Similarly, the contribution of 
glutamine to fatty acid synthesis necessitates increased glutamine uptake which has 
been observed in many cancers including some gliomas (81,82). Moreover, many 
cancers have increased expression of fatty acid synthesis genes which are 
associated with poor prognosis (156). Indeed, FASN expression has been 
associated with increased colorectal cancer stage (157) whilst pancreatic cancer 
patients have been observed to have elevated serum FASN (158). ACLY associates 
with tumour specific cyclin E isoforms in invasive breast cancer cell lines and this 
association is required for in vitro transformation, migration and invasion and in vivo 
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tumour growth (159). Moreover, inhibition of ACLY attenuates proliferation and 
invasion and promotes apoptosis in osteosarcoma, prostate, cervical and lung 
cancer cell lines and mouse models (160). Similarly, ACACA expression is important 
in breast cancer survival (161) and inhibition of this enzyme can reduce proliferation 
and de novo lipogenesis in some GBM cell lines (162) whist ACSS2 has been 
observed to increase in hypoxia in breast and prostate cancer cells (163). The 
importance of the de novo fatty acid synthesis pathway in cancer is therefore clear 
and has been strongly associated with lipid droplets. Accioly et al. (136) observed 
that the CACO-2 colon cancer cell line requires de novo fatty acid synthesis to build 
lipid droplets and this could be interrupted with the FASN inhibitor C75. The 
importance of de novo fatty acid synthesis in lipid droplet production was supported 
in metastatic breast cancer by Wilmanski et al. (164) whilst Wang et al. (165) 
demonstrated that inhibited glutamine uptake reduced the number of lipid droplets in 
prostate cancer cells. However, Bensaad et al. (123) demonstrated that de novo fatty 
synthesis does not impact lipid droplet production in some GBM and breast cancer 
cell lines, indicating that this process is cell line and cancer-specific and requires 
further investigation.  
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1.4.6.3. Exogenous lipid uptake and de novo fatty acid synthesis are interlinked 
pathways 
Increasing evidence suggests that exogenous lipid uptake and de novo fatty acid 
synthesis are intrinsically linked and must not be considered independently. The 
absence of the exogenous lipid pool increased de novo fatty acid synthesis in a 
number of cell lines (166) and was required for sensitivity to de novo fatty acid 
synthesis inhibition in prostate cancer cells (167). Similarly, hypoxia was observed to 
increase both de novo fatty acid synthesis and exogenous lipid uptake in prostate 
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Figure 1.9. De novo fatty acid synthesis. Glucose, glutamine and 
acetate are all precursors for the production of fatty acids. Citrate is 
exported out of the mitochondria for fatty acid synthesis. ACLY, ACACA 
and FASN are vital enzymes in fatty acid synthesis. 
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cancer cells (151) supporting a complementary relationship between both pathways. 
Nevertheless, an inverse relationship has also been observed. Oncogenic Ras-
activated cancer cells increased unsaturated fatty acid uptake at the expense of de 
novo fatty acid synthesis (168) whilst de novo fatty acid synthesis was increased at 
the expense of exogenous lipid uptake in breast and prostate cancer cells (163). 
This further demonstrates that, despite the clear importance of these pathways in 
cancer and lipid droplet metabolism, it is vital to understand these processes in 
specific cancers and experimental conditions. 
 
1.4.6.4. Autophagy in lipid droplet production 
The autophagy process has also been suggested as an important factor in lipid 
droplet production. Autophagy is the catabolic process of “self-digestion” wherein 
specialised endosomes called autophagosomes engulf intracellular content before 
lysosomal degradation (Figure 1.10.). There are 3 types of autophagy; 
macroautophagy, microautophagy and chaperone mediated autophagy and these 
are comprehensively reviewed by Galluzzi et al. (169). The best characterised form 
of autophagy is macroautophagy which is referred to as autophagy hereon. 
Autophagosomes form at the ER and can engulf organelles, misfolded proteins and 
excess macromolecular content in a targeted process (169). Lysosomes then fuse to 
form autophagolysosomes which digest the engulfed contents and release 
macromolecular building blocks and metabolites such as amino acids. This process 
can provide metabolites for energy production and macromolecule synthesis under 
starvation conditions as well as recycle and remove damaged organelles, 
maintaining organelle function and preventing cell death (170). In contrast, 
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autophagy is also believed to be a tumour suppressor and can initiate and enact 
autophagic cell death, a programmed cell death pathway similar to apoptosis (171). 
Autophagy is therefore an interesting oncological pathway and has been noted to be 
of importance in many cancers including GBM (172) and is under investigation as a 
therapeutic cancer target (173). Rambold et al. (174) observed that autophagy 
inhibition decreased lipid droplet replenishment in mouse embryo fibroblasts (MEFs) 
and hypothesised that lipid droplets were produced through autophagic organelle 
turnover. Similarly, Nguyen et al. (175) observed that autophagy-released lipids were 
transferred to lipid droplets by the enzyme DGAT1 in MEFs and provide a lipid 
buffering system to prevent lipotoxicity. However, these studies have not been 
replicated in human cancer cell lines and autophagy has been typically associated 
with lipid droplet breakdown in human tissues, discussed further in section 4.7. 
 
 
Figure 1.10. The process of autophagy. Autophagosomes engulf cellular components 
before fusing with lysosomes to degrade the vesicle contents. Image from Melendez et al. 
(293) 
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1.4.6.5. Lipolytic enzymes in lipid droplet production 
Lipases have been reported to impact lipid droplet biogenesis (176) whilst secreted 
phospholipase A2 is thought to release fatty acids extracellularly for incorporation 
into lipid droplets (177). However, similarly to autophagy, lipases are typically 
associated with lipid droplet breakdown. 
 
1.4.7. Lipid droplet breakdown mechanisms 
1.4.7.1. Autophagy in lipid droplet breakdown 
A type of autophagy, well characterised as a specialised lipid droplet breakdown 
mechanism, is termed lipophagy wherein lipid droplets are partially or entirely 
engulfed and degraded by autophagosomes (178). Lipophagy occurs in a wide 
range of tissues; however, it is best characterised in hepatocytes which frequently 
have high intracellular lipid content (179,180). Hepatic lipophagy is important in liver 
functionality and is tightly controlled by proteins such as the lipid droplet-associated 
protein adipophilin which is an established hepatic lipophagy inhibitor (181). Notably, 
adipophilin also prevents autophagic degradation of lipid droplets in pancreatic β-
cells (182) whilst there are increased lipid droplets in neurons affected with 
Huntington’s disease, known to have impaired autophagy (183). Interestingly, 
chaperone mediated autophagy has been observed as a lipid droplet breakdown 
mechanism in mouse fibroblasts, but is likely to be distinct from lipophagy (121). 
Lipophagy has also been established as an important mechanism of lipid droplet 
breakdown in many cancers including prostate (184), renal cell carcinoma (185,186), 
cervical (187) and ovarian cancer (188). Moreover, decreased autophagy was 
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observed to increase lipid droplet accumulation in lung cancer stem cells (152) 
further supporting a role for lipid droplets in more severe cancers. 
 
1.4.7.2. Lipolytic enzymes in lipid droplet breakdown 
In addition to lipophagy lipid droplets can be broken down by cytoplasmic lipases 
which enzymatically cleave fatty acid chains from lipids such as triglycerides in a 
structured sequence of lipolytic reactions. Adipose triglyceride lipase (ATGL) 
catalyses the initial rate limiting step of triglyceride hydrolysis, producing 
diacylglycerol and a single fatty acid (189). A second fatty acid chain is then 
removed by hormone sensitive lipase (HSL) to produce monoacylglycerol (190). 
Finally, monoglyceride lipase cleaves monoacylglycerol to produce a glycerol and a 
final fatty acid chain (191). As the initiating step, the activity of ATGL is most tightly 
regulated and requires activation by CGI58 for optimal enzymatic function (192). In 
contrast, CGI58 does not bind HSL which is regulated instead by ATGL activity. 
ATGL is known to localise to both cell membranes and lipid droplets (189) and has 
been reported as the major lipid droplet breakdown mechanism in mouse embryo 
fibroblasts (174) and rat stellate cells (193). Moreover, in conjunction with lipophagy, 
cytoplasmic lipases such as ATGL play a role in lipid droplet breakdown in 
hepatocytes which can be inhibited by HILPDA (194). Although lipophagy provides a 
quicker and more significant release of lipids, cytoplasmic lipase-mediated lipid 
release has tighter regulation. Therefore, HILPDA- and PLIN2-mediated inhibition of 
lipases and lipophagy respectively provides increased control of hepatic lipid 
release. Cytoplasmic lipases have also been noted as important elements in the 
biology of many cancers. Indeed, monoglyceride lipase activity has been observed to 
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be increased in highly aggressive forms of melanoma and ovarian and prostate 
cancer (195,196). Moreover, cytoplasmic lipases have been established as an 
important lipid droplet breakdown mechanism in cervical cancer (197) and have 
been suggested to be involved in many others.   
 
1.4.7.3. Autophagy and lipase-mediated lipid droplet breakdown are interlinked 
As was observed with the lipid droplet production mechanisms, these pathways are 
interlinked and mutually contribute to the degradative outcome (Figure 1.11.). 
Indeed, the activity and regulation of lipophagy and ATGL are heavily interlinked in 
lipid droplet breakdown in hepatocytes (198) while the PNPLA5 lipase was required 
for optimal autophagy initiation in HeLa cancer cells (199). 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Proposed routes of lipid droplet 
breakdown. Lipid droplet breakdown is predominantly 
reported to occur through cytoplasmic lipases (left) and 
lipophagy (right). Image from Singh et al. (294) 
   
36 
 
1.4.8. Summary of lipid droplet metabolic mechanisms 
Lipid droplet production and breakdown mechanisms can vary between cell types 
and species; however, several of these pathways are particularly prevalent in 
cancer. Lipid droplet production is predominantly reliant upon exogenous lipid 
uptake, de novo fatty acid synthesis or a combination of the two. In contrast, lipid 
droplet breakdown is predominantly performed through the actions of autophagy and 
cytoplasmic lipases which provide dual regulation over cellular lipid content and 
breakdown. Therefore, any experimental investigation attempting to underpin core 
lipid droplet metabolic mechanisms must consider the activity of these processes. 
 
1.4.9. The roles of lipid droplets 
Lipids droplets can be used for many purposes through both their physical presence 
and the release of the lipids they contain. Lipids are required for four primary 
processes; energy production, membrane synthesis, lipid signalling and protein 
modification which may all be impacted by lipid droplet metabolism. 
 
1.4.9.1. The role of lipid droplets in energy production 
The long hydrocarbon chains of fatty acids can be catabolised to provide a major 
source of energy through mitochondrial β-oxidation (200) (Figure 1.12.). Cytoplasmic 
free fatty acids are activated with a CoA molecule to facilitate mitochondrial transfer 
by the carnitine cycle. The acyltransferase CPT1 esterifies the activated fatty acid to 
a carnitine molecule, producing acylcarnitine, which can then be transported across 
the mitochondrial membrane by the mitochondrial transporter SLC25A20. The 
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carnitine is then removed by another acyltransferase, CPT2, and the fatty acid can 
undergo the cyclical reaction of fatty acid β-oxidation. Each fatty acid undergoes 
cycles of dehydrogenation, hydration, dehydrogenation and thiolation to repeatedly 
shorten the fatty acid chain by two carbon subunits. This produces acetyl CoA which 
can enter the TCA cycle and FADH2 and NADH for oxidative phosphorylation. 
Despite the higher energy production of β-oxidation, cancer cells frequently rely upon 
glycolysis due to reaction speed and efficacy in the absence of oxygen. 
Nevertheless, β-oxidation has been observed as an important energy production 
pathway in several cancers (201) including ovarian (150), prostate (85), colon (202) 
and breast cancer (203,204). Similarly, leukaemic cells can sequester in adipose 
tissues to fuel β-oxidation with adipocyte-derived lipids (205) whilst lung cancer cells 
upregulate CPT1C and β-oxidation to promote xenograft tumour growth (206). 
Perhaps unsurprisingly lipid droplets can be the major supply of lipids for 
mitochondrial β-oxidation in many healthy and cancerous cell types. Rambold et al. 
(174) and Nguyen et al. (175) found that, in mouse embryo fibroblasts, lipid droplets 
were predominantly broken down to fuel mitochondrial β-oxidation and prevent 
lipotoxicity. This was reliant upon good mitochondrial function and fusion. 
Interestingly, the lipid droplet-associated protein PLIN5 is involved in the recruitment 
of mitochondria to lipid droplets and the prevention of lipotoxic stress (207,208). 
Similarly, lipid droplets have been observed to re-localise to mitochondria for β-
oxidation along microtubules in response to nutrient scarcity (135) whilst inhibition of 
mitochondrial β-oxidation in hepatocytes resulted in lipid accumulation (209). Lipid 
droplets were further observed to fuel mitochondrial β-oxidation in triple negative 
breast cancer (92) whilst colon cancer cells subverted surrounding adipose tissue to 
supply fatty acids for lipid droplets prior to β-oxidation (149). It is therefore clear that, 
   
38 
 
in addition to their many other roles, lipid droplets retain their importance as energy 
stores in healthy and cancerous cells. 
 
1.4.9.2. The role of lipid droplets in membrane synthesis 
Lipid droplets also provide a store of precursors for the synthesis of cell and 
organelle membranes. Membranes are composed of amphipathic phospholipids 
such as phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine, of 
which phosphatidylcholine is the most common and important and 
phosphatidylserine the least. The basic subunit of phospholipids is phosphatidic acid 
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Figure 1.12. The mitochondrial β-oxidation pathway. Fatty acid chains are converted into 
acetyl CoA for energy production through cycles of β-oxidation in the mitochondria. Each 
cycle removes one acetyl CoA and shortens the fatty acid chain by two carbon units. 
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which is composed of diacylglycerol with a phosphate group occupying the final fatty 
acid chain site. This phosphate group can be conjugated to choline, ethanolamine or 
serine to produce the different classes of phospholipids (Figure 1.13.) and convey 
specialised functions. Choline kinase (CKA and B) and ethanolamine kinase 
(ETNK1) catalyse the initial reactions of phospholipid synthesis and generate 
phosphocholine or phosphoethanolamine respectively. These molecules are then 
conjugated to diacylglycerol by cholinephosphotransferases (CEPT1 and CHPT1) to 
produce phospholipids. Alternatively, conjugated phosphocholine and 
phosphoethanolamine can be exchanged for phosphoserine by phosphatidylserine 
synthase 1 and 2 (PTDSS1 and 2) respectively to produce phosphatidylserine.  
Abnormal choline metabolism is one of the most common and consistent 
observations in cancer due to its clear requirements during increased proliferation 
(210,211). Indeed, phosphatidylcholine was the most common phospholipid in breast 
cancer cells (212), concurrent with increased choline metabolism and CHPT1 
expression (213). Moreover, pharmacological choline kinase inhibition prevented 
xenograft tumour growth (214) whilst siRNA down regulation of choline kinase 
decreased breast cancer cell line proliferation (215). Interestingly, this siRNA was 
also observed to increase lipid droplet accumulation suggesting that they may 
provide a source for phospholipid synthesis in these cells. Similarly, exogenous fatty 
acids, known to be incorporated into lipid droplets, can be used preferentially for 
membrane synthesis (216) further suggesting lipid droplet involvement. However, the 
literature connecting lipid droplets and membrane synthesis has remained limited 
due to the difficulty of investigating this process.  
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1.4.9.3. The role of lipid droplets in signalling 
Lipid signalling molecules such as sphingosine-1-phosphate, diacyglycerol, IP3 and 
PIP3 are key signalling molecules and represent an important function of lipid 
metabolism (217,218). Indeed, sphingosine-1-phosphate and lysophosphatidic acid 
can modulate inflammation, cell migration and survival (219,220). Moreover, 
sphingosine-1-phosphate can be derived from lipid droplets and its bioactive 
signalling has been linked to cancer (221,222).  
 
1.4.9.4. The role of lipid droplets in cellular stress 
One of the key functions of lipid droplets is the maintenance of cellular homeostasis 
and the prevention of cellular stress. The upregulated macromolecule synthesis in 
cancer causes increased ER stress. Interestingly, it has been suggested that lipid 
Figure 1.13.Phospholipid synthesis pathways. Phosphocholine and 
phosphoethanolamine are synthesised by CKA/B and ETNK1 respectively. These are then 
conjugated to phosphatidic acid by CEPT1 and CHPT1 to produce phosphatidylcholine and 
phosphatidylethanolamine respectively. Phosphatidylserine can then be produced from 
phosphatidylchoine or posphatidylethanolamine by PTDSS1 and 2 respectively.  
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droplets associate with the proteasome (223) and may positively regulate its activity 
through surface protein interactions, decreasing ER stress (224). Similarly, lipid 
droplets are thought to protect against oxidative damage. Hypoxia and mitochondrial 
β-oxidation are major sources of reactive oxygen species (ROS) (225) which can 
damage many cellular components, particularly unsaturated fatty acids. Bailey et al. 
(226) observed that lipid droplets protected against ROS-induced oxidative damage 
in Drosophila glial cells by providing a storage site for vulnerable polyunsaturated 
fatty acids. Similarly, Bensaad et al. (123) observed that lipid droplets could provide 
protection from re-oxygenation-induced ROS in several human cancer cell lines. 
Therefore, lipid droplets provide a storage site for the sequestration of vulnerable 
cellular components to decrease oxidative stress and aid in survival, providing clear 
benefits to cancer biology. 
Excessive free fatty acids storage above the lipotoxic threshold induces lipotoxicity 
and cell death. Indeed, inhibition of triglyceride synthesis with TriascinC was 
observed to cause free fatty acid accumulation and apoptosis (138). Lipid droplets 
can therefore act as a buffering system, providing controlled regulation of 
intracellular lipid content and a robust lipid storage site (175). Moreover, lipid 
droplets can prevent cell stress through the sequestration of misfolded proteins 
(227,228) further demonstrating their importance as a stress resistance mechanism. 
 
1.4.9.5. The role of lipid droplets in drug resistance 
Lipid metabolism and lipid droplets have been suggested as important factors in drug 
resistance, a vital aspect of cancer biology. The altered membrane saturation 
observed with increased de novo fatty acid synthesis decreased chemotherapeutic 
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drug uptake (229) whilst increased FASN expression has been demonstrated as an 
important indicator of gemcitabine and radiation resistance in pancreatic cancer 
(230). Moreover, FASN protein levels were observed to correlate with cetuximab and 
bevacizumab efficacy both in vitro and in vivo in colorectal cancers (231), although 
the mechanism remains unclear. The characteristic increase in lipid droplet 
accumulation in apoptosis indicates a role for lipid droplets in drug response through 
either promoting or hindering cell death. In prostate and breast cancer cells, lipid 
droplet accumulation was increased in response to hormone drug treatment 
(151,232). Similarly, a vascular EGFR2 tyrosine kinase inhibitor promoted apoptosis 
and increased lipid droplet accumulation in GBM cell lines (233). Pan et al. (234) 
also observed that cisplatin treatment increased lipid droplet number and 
unsaturated fatty acid content in a medulloblastoma cell line further supporting 
increased lipid droplets as a response to drug treatment. However, although lipid 
droplets may increase during the cell death process, it has also been suggested that 
they represent a drug resistance response. Montopoli et al. (235) observed 
increased lipid droplets in cisplatin resistant ovarian cancer cells whilst Zietkowski et 
al. (236) noted a similar phenotype in paclitaxel resistant cervical cancer cell lines. 
Moreover, highly drug resistant colorectal cancer stem cells are often observed to 
have increased levels of lipid droplets, which correlates with the cancer stem cell 
marker CD133 (237). However, the underlying mechanism, linking lipid droplets to 
treatment resistance and response, remains unclear. One proposed mechanism for 
lipid droplet-induced drug resistance is through sequestration. As with misfolded 
protein and excess lipid, lipid droplets provide a nontoxic storage site for lipophilic 
drugs that may decrease their efficacy. Verbrugge et al. (238) observed that 
activation of an aminopeptidase inhibitor pro-drug was prevented through lipid 
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droplet sequestration in acute myeloid leukaemia cells. Similarly, Schlaepfer et al. 
(239) found high concentrations of docetaxel in the lipid droplets of a drug resistant 
breast cancer cell line, further suggesting that the role of lipid droplets in drug 
resistance may provide a therapeutic target. However, the metabolic influence of 
lipid droplets is also an important consideration regarding cell viability under 
cytotoxic stress and must also be further investigated. 
 
1.4.9.6. Summary of the roles of lipid droplets  
Lipid droplets have therefore been shown to interact with multiple cellular processes 
and organelles, as well as playing a role in the response to potentially cytotoxic 
stressors in a number of physiological and pathophysiological processes. However, 
they remain poorly understood, and more work is required to understand how they 
perform many of their suggested functions.  
 
1.4.10. The role of lipid droplets in gliomas 
As has been discussed, lipid droplets are important components of tumour 
metabolism in many different types of cancer. However, we chose to investigate lipid 
droplet metabolism in gliomas as, although lipid droplets have been strongly 
associated with several of the key clinical features of gliomas, the literature 
investigating the underlying biological pathways has remained limited. 
Lipid droplet accumulation is increased throughout tumour progression and is 
associated with poor survival, providing a potential biomarker of clinical grade and 
prognosis (94,240,241). Moreover, the relative ease of performing MRS in the brain, 
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compared with other regions of the body, makes the in vivo measurement of lipid 
droplets as metabolic biomarkers clinically viable (242). The speed of treatment 
response detection may also be improved through the association of lipid droplets 
and cell death pathways (98,242,243) whilst hypoxia-induced lipid droplets are 
thought to be influential in the highly hypoxic and necrotic GBM cores (94,98). 
Although these features are currently aiding clinical diagnosis, further utilisation and 
targeting of lipid droplets is severely limited by the incomplete understanding of 
glioma lipid droplet metabolism. Lipid droplet production in gliomas has been 
reported to occur through the uptake of exogenous lipids; however, this was only 
observed in hypoxia and the role of de novo fatty acid synthesis remains 
controversial (123,162). Similarly, glioma lipid droplet breakdown is yet to be 
investigated and the relative importance of pathways such as autophagy and 
cytoplasmic lipases remains to be explored. Lipid droplet metabolism varies between 
cancers and therefore greater understanding of glioma-specific lipid droplet 
pathways may clarify clinical observations and present therapeutic opportunities. 
Indeed, the poor prognosis of high grade gliomas and ineffective novel therapeutics 
clearly indicates a requirement for an altered clinical approach. It has been 
suggested that the manipulation of lipid droplet metabolism may improve the efficacy 
of current therapies; however, progress has again remained limited. Disruption of 
lipid droplet metabolic pathways such as the FABPs can impair GBM xenograft 
growth (123) whilst curcumin and temozolomide co-treatment may act synergistically 
but only with the support of autophagy inhibition (244). Therefore, improved 
understanding of glioma-specific lipid droplet metabolism may further improve glioma 
therapeutic options and aid in the development of clinical diagnostic tools. 
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1.5. Summary 
In the majority of cancers, prognosis has consistently improved throughout the 
modern era. However, glioma survival remains largely unchanged due to cancer 
severity and the lack of efficacious therapeutic options. Improved understanding of 
tumour metabolism has highlighted many areas of potential interest, including lipid 
droplets. Although lipid droplets show clear associations with many clinical features 
of gliomas, past attempts to harness them to improve current therapies have been 
hindered by insufficient understanding of the glioma-specific lipid droplet metabolism. 
We therefore sought to investigate the importance of lipid droplet metabolic 
pathways across the glioma tumour grades and clarify the relative involvement of 
these pathways using GBM cell lines. Moreover, we aimed to pharmacologically 
manipulate these pathways to improve current therapeutic options in vitro and 
suggest how this may be clinically applicable. 
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1.6 Project Hypotheses 
 Lipid droplet metabolism-associated genes are interlinked markers of survival 
and tumour progression 
o Gene expression is associated with prognostic indication in a grade-
specific manner 
o “Grade 3-like” gene expression predicts poor prognosis grade 2 
tumours 
o Gene expression correlates with other prognostic markers but is not 
limited to a tumour subset 
 Lipid droplet metabolism is governed by select metabolic pathways  
o Exogenous lipid uptake, ATGL activity and autophagy are important 
lipid droplet metabolic pathways 
o De novo fatty acid synthesis does not have a major role in lipid droplet 
metabolism 
o Hypoxia and starvation alter lipid droplet metabolism 
o Lipid droplet flux is maintained during inhibition of a key metabolic 
pathway through compensation with alternative pathways  
o Lipid droplet metabolic pathways provide protection from oxidative 
stress 
 Cytotoxic treatment efficacy is improved through interruption of lipid droplet 
flux 
o Temozolomide and irradiation cytotoxicity are improved through 
inhibition of lipid droplet breakdown 
o Cytotoxicity is improved through inhibition of metabolic pathways 
involved in lipid droplet production  
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Chapter 2 
 
Materials and methods 
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2.1. Methods used in Chapter 3 
2.1.1. The Cancer Genome Atlas (TCGA) tumour cohort 
Genomic and clinical data was downloaded from the TCGA cBioPortal download 
data function (245,246) on the 3rd October 2016. The Brain Lower Grade Glioma 
(TCGA, Provisional) and Glioblastoma (TCGA, Cell 2013) cohorts were selected 
from the CNS/Brain tumour classification group; Brain Lower Grade Glioma cohort 
(n=530) and Glioblastoma cohort (n=580). The clinical data assigned to each cohort 
was downloaded and data regarding sample ID, neoplasm histologic grade, overall 
survival (months) and overall survival status were retained. A further overall survival 
status column was created where “deceased” was designated ‘1’ and “living” was 
designated ‘0’. The corresponding genomic data was downloaded for each cohort 
using the following parameters. Genomic Profile: mRNA expression data (RNA Seq 
V2 RSEM). Patient/Case Set: Tumour Samples with mRNA data (RNA Seq V2); 
Brain Lower Grade Glioma cohort (n=530) and Glioblastoma cohort (n=154). Gene 
Set: User defined list (Table 3.1.). Microsoft Excel was used to sort and match the 
clinical and genomic data according to Sample ID. Tumours without corresponding 
genomic data or clinical data were removed. The data sets generated from the Brain 
Lower Grade Glioma and Glioblastoma cohorts were renamed the combined grade 2 
and 3 glioma cohort and the glioblastoma grade 4 cohort respectively.  In the case of 
the combined grade 2 and 3 glioma cohort this data set was split further into two 
data sets: grade 2 (n=256) and grade 3 (n=270). 
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2.1.2. Survival analysis and Kaplan-Meier generation 
Microsoft Excel was used to sort the data set by gene expression for each gene and 
find the median and mean gene expression. Median gene expression was used to 
separate the high and low gene expression groups. However, in the case of 
predicting “grade 3-like” tumours in the grade 2 cohort, the grade 3 mean gene 
expression was applied to the grade 2 cohort to separate high and low gene 
expression groups. GraphPad Prism 7.0 was used to produce Kaplan-Meier survival 
curves of all genes in the gene set. Overall survival (months) and overall survival 
status data for the high and low gene expression groups was entered into the data 
table. GraphPad Prism was used to generate a survival analysis for each survival 
curve including both Log-rank/Mantel-Cox (MC) and Gehan-Breslow-Wilcoxon 
(GBW) statistical tests. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. The MC 
statistical test is the standard statistical test in the analysis of survival curves. It 
assumes that deaths per time remains constant at all time points, providing better 
analysis of the overall survival curve. In contrast, the GBW statistical test better 
analyses more deaths at early time points. Cancer can be a chronic disease dictating 
the need to analyse survival at all time points; however, particularly in GBM, survival 
can be very short and it is important to also investigate earlier changes in survival. 
Therefore, both statistical analysis methods were included.  
 
2.1.3. Gene expression Boxplot generation. 
Gene expression values for each gene, separated by clinical grade, were analysed 
using GraphPad Prism 7.0 to generate boxplots. The “box” was set to display the 
median gene expression and upper and lower quartiles and the error bars were set 
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to minimum and maximum values. ROUT outlier removal was performed to remove 
definitive outliers (Q=0.1%). mRNA data is non parametric and therefore the Kruskal-
Wallis statistical test with a Dunn’s post-hoc correction was selected to analyse this 
data. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
The IDH1 gene expression boxplots were generated from tumours in the combined 
grade 2 and 3 glioma cohort with known IDH1 mutational status. IDH1 wildtype 
(n=34), IDH1 mutant (n=91). An unpaired two-tailed t-test statistical test was 
performed in all cases; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
2.1.4. Gene expression correlation analysis 
The combined grade 2 and 3 glioma cohort gene expression values were compared 
between genes. The expression values were plotted for each tumour on an XY 
scatter graph using GraphPad Prism 7.0. Spearman’s rank correlation analysis was 
performed on each gene pair to generate r-values. Spearman’s rank was selected 
over Pearson’s correlation analysis as it is less susceptible to outliers within the data 
set. A positive or negative r-value denotes a positive or negative correlation 
respectively. The closer the r-value is to 1 or -1 the stronger the correlation whilst 0 
signifies no correlation. 
 
2.1.5. Correlation heat map 
The r-values generated in the above correlation analysis were visualised in a 
histogram plotted using the corrplot package in the “R” statistical software. Green 
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and red denote positive and negative correlations respectively. The script is 
described in Appendix 7.1. 
The significance of the correlations was assessed using the Hmisc package of “R”. 
The script is described in Appendix 7.1. 
The p-values were copied into Microsoft Excel and assessed for significance using a 
Bonferroni correction to generate an adjusted p-value (q). q=p/n =0.05/135 =0.00037 
(p=p-value, n=number of tests) (Appendix 7.1. and 7.2.). Those correlations which 
reached significance were plotted on the heat map as red or green crosses 
dependent upon the correlation. 
Tables of the Spearman’s rank r-value and adjusted p-values can be found in 
Appendix 7.2. 
 
2.1.6. Cluster analysis 
A cluster analysis was performed on “R” using the gene expression data from the 
combined grade 2 and 3 glioma cohort. The gene expression of every tumour was 
first normalised to a percentage of the maximum gene expression of each gene. 
Green and red denote 100% and 0% of the maximum gene expression respectively. 
The script is described in Appendix 7.3. 
 
2.1.7. TCGA cBioPortal query function 
Using the TCGA cBioPortal query function the Brain Lower Grade Glioma (TCGA, 
Provisional) or Glioblastoma (TCGA, Cell 2013) cohorts were selected with the 
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following parameters: Genomic Profile: mRNA Expression z-scores (RNA Seq V2 
RSEM), z-score threshold ± 2.0. Patient/Case Set: Tumour Samples with mRNA 
data. Gene Set: User-defined list. The gene list was varied dependent upon the 
parameter being investigated. (Table 2.1.) The co-occurrence and correlation 
investigations gene lists included all genes selected for further investigation in initial 
survival analysis. The combined survival analysis gene lists were separated into poor 
and good prognostic markers. 
Co-occurrence/mutual 
exclusivity 
PLIN1, PLIN2, PLIN3, PLIN4, PNPLA2, PNPLA3, 
PNPLA4, CD36, HILPDA, ACACA, FASN, 
MAP1LC3A, CEPT1, CPT2, ETNK1, PTDSS1, 
SLC25A20 
Gene correlation PLIN1, PLIN2, PLIN3, PLIN4, PNPLA2, PNPLA3, 
PNPLA4, CD36, HILPDA, ACACA, FASN, 
MAP1LC3A, CEPT1, CPT2, ETNK1, PTDSS1, 
SLC25A20 
Combined survival 
analysis 
PLIN2, PLIN3, PNPLA2, CD36, HILPDA, 
MAP1LC3A, ETNK1, PTDSS1 (CEPT1, CPT2) 
or 
PLIN1, PLIN4, PNPLA3, PNPLA4, ACACA, FASN, 
SLC25A20 
Table 2.1. Gene lists for TCGA cBioPortal investigations. 
 
The “Co-occurrence and mutual exclusivity” tab was used to further investigate 
correlations in gene expression in both cohorts. The significance of each tendency 
towards co-occurrence or mutual exclusivity was assessed by the TCGA query 
function using the Fisher Exact test, p<0.05. Print screens were taken of the results 
of this test. 
The “Plots” tab was used to assess gene expression correlations in the Glioblastoma 
(TCGA, Cell 2013) cohort. The expression values were plotted for each tumour on 
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an XY scatter graph and a Spearman’s rank test was performed by the TCGA query 
function. 
The TCGA query function was used to assess the effect of multiple gene alterations 
on survival in the Brain Lower Grade Glioma (TCGA, Provisional) cohort. CEPT1 and 
CPT2 were not included in the gene list for the multiple gene alterations query as 
they were associated with predominantly down-regulation genetic alterations 
(Figures 2.1. and 3.8.A.).  Each data set was split into two groups: cases with 
alterations in query genes and cases without alterations in query genes. Cases with 
alterations in query genes were defined as any containing an up- or down-regulation 
in mRNA expression, as defined by the z-score threshold. A log-rank MC survival 
analysis was performed to assess significance. p<0.05. The process was repeated 
using the Glioblastoma (TCGA, Cell 2013) cohort. 
  
Figure 2.1. Representative oncoprint tab demonstrating mRNA up-regulation 
(red) and down-regulation (blue) alterations. Not all “no alteration” cases are 
shown here. 
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2.2. Methods used in Chapter 4  
2.2.1. Cell lines 
The T98G, U343 and U87 immortalised human GBM cell lines were obtained from 
the ATCC. The U87.1 and U87.2 cell lines were developed from the U87 cell line. 
Cells were cultured in high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 2mM glutamine (Sigma, D5796) and supplemented with 10% foetal 
bovine serum (FBS) (Hyclone, 10270). Cells were detached from culture dishes with 
a 1x phosphate buffered saline (PBS) (Hyclone, SH30258.02) wash followed by 
0.05% Trypsin (Gibco, 15400-054) incubation. 
Cells were incubated at standard culture conditions of 37oC and 5% CO2 and 
regularly tested for mycoplasma infection using the EZ-PCR Mycoplasma detection 
kit (Geneflow, 20-700). 
 
2.2.2. Short Tandem Repeat (STR) profile analysis 
Genomic DNA was extracted from the U87.1 and U87.2 cell lines using the PureLink 
Genomic DNA Mini extraction kit (ThermoFisher, K182001). The standard protocol 
included within the kit was followed: 
Cells were harvested with 0.05% Trypsin and re-suspended in 200 µL PBS. 20 µL 
protein kinase A and 20 µL RNase A were added to each sample and vortexed 
before incubation for 2 minutes at room temperature. 200 µL PureLink Genomic 
Lysis/Binding Buffer was added to each sample and vortexed to obtain a 
homogenous solution. Samples were incubated at 55oC for 10 minutes. 200 µL of 
100% ethanol was added to each lysate and vortexed for 5 minutes to obtain a 
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homogenous solution. Lysate was transferred to a PureLink spin column and 
centrifuged at 10,000 G for 1 minute. Samples were washed with 500 µL Wash 
Buffer 1 and centrifuged at 10,000 G for 1 minute. The samples were washed again 
with 500 uL Wash Buffer 2 and centrifuged at maximum speed for 3 minutes. 
Genomic DNA was eluted by adding 50 µL of PureLink Genomic Elution Buffer, 
incubating for 1 minute at room temperature and centrifuging at maximum speed for 
1 minute. Genomic DNA concentration and purity was checked with a ND-1000 
nanodrop. 
Extracted genomic DNA was sent to Eurofins, Germany to determine genetic 
characteristics through PCR-single-locus-technology. 21 independent PCR-systems 
were investigated with the Promega PowerPlex 21 PCR kit (Promega).  
 
2.2.3. mRNA extraction 
mRNA was extracted in triplicate from the U87, U87.1 and U87.2 cell lines using the 
RNeasy Mini kit (Qiagen, 74104). The standard protocol, including an on-column 
DNase digestion (Qiagen, 79254), was followed: 
Cells were lysed with 350 µL Buffer RLT, scraped and collected.  350 µL of 70% 
ethanol was added to each sample and mixed well by pipetting. Samples were 
transferred to RNeasy Mini spin columns and centrifuged for 15 seconds at 8000 G. 
350µL Buffer RW1 was added to each column and centrifuged for 15 seconds at 
8000 G. 80µL DNase 1 incubation mix (10 µL DNase 1 and 70 µL Buffer RDD) was 
added to each column and incubated at room temperature for 15 minutes. 350 µL 
Buffer RW1 was added to each column and centrifuged for 15 seconds at 8000 G. 
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500 µL Buffer RPE was added to each column and centrifuged for 15 seconds at 
8000 G. 500 µL Buffer RPE was added to each column and centrifuged for 2 minutes 
at 8000 G. 40 µL RNase-free water was added to each column and centrifuged for 1 
minute at 8000 G to elute the RNA. Extracted RNA concentration and quality was 
assessed with a ND-1000 nanodrop. 
 
2.2.4. RNA sequencing (RNAseq) 
mRNA exome paired ends sequencing was performed by Genomics Birmingham, 
run by Dr Andrew Beggs. RNA quality was very high with RNA integrity number 
scores over 9.7 (7+ considered high quality). Fastq files were provided through the 
BaseSpace portal (Illumina). 
 
2.2.5. RNAseq data analysis 
Fastq files were downloaded from BaseSpace using the BaseSpace downloader and 
uploaded to Galaxy using the FileZilla FTP transfer program. RNAseq analysis was 
performed using the Galaxy platform. All analysis used the reference genome 
“human hg38” and the annotated reference genome “gencode v25.gtf”. 
FASTQC was run on all files to assess sequencing read quality. All files were found 
to have high quality transcripts. An example quality control read out is shown in 
Figure 2.2. 
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Forward and reverse fragments for each read lane were aligned to the reference 
genome, hg38, using Hisat. This generated BAM and BAM index files. In each 
sample the 4 BAM files, one per read lane, were merged using BAMtools merge to 
generate a single BAM and BAM index file per sample for subsequent analysis. 
Integrative Genomic Viewer (IGV) was used to view the transcripts aligned to the 
reference genome. In IGV single nucleotide polymorphisms (SNPs) can be found as 
well as gene deletions and truncations.  
Gene expression was quantified using Stringtie transcript assembly and 
quantification to provide quantification of the expression of over 58,000 annotated 
genes (including protein coding genes, isoforms, microRNAs and pseudogenes). 
Gene expression was normalised using the Fragments Per Kilobase of transcript per 
Million mapped reads (FPKM) method. 
Figure 2.2. Example quality control readout of RNA sequencing data. Short and long 
transcripts were high quality (left). There was no evidence of transcript degradation into 
shorter transcript fragments (right).  
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Differences in gene expression between samples were compared using CuffDiff. The 
significance cut-off was set using an adjusted p-value (q). Differentially expressed 
genes were entered into the DAVID analysis tool and compared to known human 
biochemical pathways. 
 
2.2.6. De-lipidated serum media preparation 
FBS was incubated with 10 mg/mL activated charcoal (Sigma, C9157) for 3 hours at 
37oC. The solution was then filtered with a 2 µm filter and syringe. The filtered serum 
was used to supplement high glucose DMEM containing 2 mM glutamine with 10% 
de-lipidated FBS. 
 
2.2.7. Hypoxic incubation 
To achieve hypoxia cells were incubated in the Don Whitley H35 Hypoxystation 
which was maintained at 0.3% O2, 5% CO2, balance N2, 37
oC and 75% humidity. 
This condition is referred to as hypoxia henceforth. 
 
2.2.8. Cell treatments 
The treatment conditions used in all experiments are summarised in Table 2.2. All 
treatments were optimised with literature sources and dose response curves (data 
not shown). Control samples were treated with dimethyl sulfoxide (DMSO) where 
appropriate. 
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Drugs/Treatments Concentration Incubation time Product 
information 
De-lipidated serum 10% FBS in 
DMEM 
72 hours N/A 
Atglistatin 30 µM 8 hours Generon, 
B3021 
Bis-2-(5-phenylacetamido-
1,3,4-thiadiazol-2-yl)ethyl 
sulphide (BPTES) 
10 µM 4 hours Sigma, 
SML0601 
Orlistat 100 µM 4 hours Sigma, O4139 
Simvastatin 1 µM  24 hours Sigma, S6196 
Chloroquine 25 µM 8 hours Sigma, C6628 
3-MA 5 mM 8 hours Sigma, M9281 
siAtg5 100 nM 48 hours Dharmacon, 
L-004374-00-
0005 
Dimethyloxalylglycine 
(DMOG) 
1 mM 16 hours Sigma, D3695 
H2O2 100 µM 60 minutes Sigma, 31642 
Cisplatin 100 µM 60 minutes Sigma, 
C2210000 
Table 2.2. Cell treatments and corresponding dose and incubation period. 
 
2.2.9. Defining alterations in lipid droplet burden 
Alterations in the amount of lipid droplet contained within a cell can stem from altered 
lipid droplet number or size. However, overall alterations in the amount of lipid 
droplet within the cells have been assessed in this work, as opposed to lipid droplet 
number or diameter. Therefore, the lipid droplet burden of the cell, assessed 
qualitatively by confocal microscopy or quantitatively by flow cytometry, is referred to 
henceforth as “lipid droplet quantity” or “LDQ”. 
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2.2.10. Confocal Microscopy 
2.2.10.1. Nile red lipid droplet standard staining protocol 
Cells were plated on sterile glass coverslips and allowed to settle at 37oC, 5% CO2. 
Drug treatments or media changes were carried out for the specified time if 
applicable (Table 2.2.). In experiments investigating starvation conditions the media 
was changed to Hank’s balanced salt solution (HBSS; Sigma, 55037C). Following 
treatment, cell fixation was performed using 4% paraformaldehyde (Sigma, F1365) in 
1x PBS for 20 minutes. Wells were washed briefly 3 times with 1x PBS. Cells were 
stained with 3 µg/mL nile red (Sigma, T8787) in 1x PBS for 10 minutes in the dark. 
Wells were washed 5 times with 1x PBS. Cells were stained with 1 drop/mL DAPI 
(Molecular Probes, R37606) for 10 minutes in the dark. Wells were washed 3 times 
with 1x PBS and 1 time with dH2O. Coverslips were inverted and mounted onto 
microscopy slides using mounting media (Vectorlabs, H-1400). Bubbles were 
pressed out and the coverslip affixed with nail varnish. Slides were stored at -20oC 
until analysed. 
Confocal microscopy was carried out on a Zeiss 510 Meta-confocal at 40x 
magnification, pinhole 100µM (Microscopy and Imaging Services, University of 
Birmingham).  
Nile red is highly lipophilic and accumulates within hydrophobic regions such as cell 
membranes and lipid droplets. Due to its solvatochromic character, the excitation 
and emission wavelengths shift according to the polarity of its environment. 
Therefore, the fluorescence shifts from red in cell membranes to green in the more 
hydrophobic, less polar centre of a lipid droplet. Legend in Table 2.3. 
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Colour Dye Cellular structure 
Blue DAPI Nucleus 
Green Nile red Lipid droplet 
Red Nile red (non-droplet staining) Cellular membrane/lipid structure 
Table 2.3. Nile red confocal microscopy legend. 
 
Qualitative analysis was performed by a single observer. Staining across each slide 
was examined and 3 representative fields (containing approximately 10-20 cells) 
were selected for image capture. The green signal intensity was compared visually 
to the number of DAPI stained nuclei in each field to qualitatively assess changes in 
LDQ between slides.  
 
2.2.10.2. C16 and C11 BODIPY standard staining protocols. 
Cells were plated on sterile glass coverslips and allowed to settle at 37oC, 5% CO2 
before incubation at 21% or 0.3% O2 overnight. The media was removed and the 
cells were washed with 1x PBS. Cells were incubated with 1 µM C16 BODIPY 
(Invitrogen, D3821) in DMEM or HBSS for 30 minutes at 37oC. Cell treatments were 
carried out if applicable (Table 2.2.). Cells were washed once with 1x PBS and fixed 
with 4% paraformaldehyde in 1x PBS for 20 minutes. Cells were washed 3 times 
with 1x PBS and stained with 1 drop/mL DAPI for 10 minutes in the dark. Cells were 
mounted and affixed on microscope slides as per the nile red lipid droplet standard 
stain protocol. 
Confocal microscopy was carried out on a Zeiss 510 Meta-confocal at 40x 
magnification, pinhole 100µM (Microscopy and Imaging Services, University of 
Birmingham). 
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C11 BODIPY (Invitrogen, D3861) staining followed the same protocol as C16 
BODIPY. The fluorescence emission of this dye changes from ~590nm to ~510nm 
(red to green) following oxidation of the polyunsaturated lipid groups indicating 
oxidative damage. 
 
2.2.11. Nile red lipid droplet quantification standard flow cytometry protocol 
2.2.11.1. Sample preparation 
Cells were plated and allowed to settle at 37oC, 5% CO2 before incubation at 21% or 
0.3% O2 overnight. Drug treatments or media changes were carried out for the 
specified time if applicable (Table 2.2.). In experiments investigating starvation 
conditions the media was changed to HBSS. Following treatment, cells were washed 
once with 1x PBS and detached from the plate with 0.05% Trypsin. Trypsin activity 
was neutralised with media collected post-treatment. Cells were centrifuged at 350 G 
for 5 minutes at 4oC and the supernatant removed. Cells were washed with 1x PBS 
and centrifuged at 350 G for 5 minutes at 4oC and the supernatant removed. Cells 
were fixed with 4% paraformaldehyde in 1x PBS for 20 minutes before centrifugation 
at 350 G for 5 minutes at 4oC and removal of the supernatant. The above PBS wash 
step was repeated. Cells were stained with 1.5 µM nile red for 10 minutes before 
centrifugation at 350 G for 5 minutes at 4oC and removal of the supernatant. The 
above PBS wash step was repeated. Cells were re-suspended in 300 µL 1x PBS 
and stored at 4oC until analysed. 
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2.2.11.2. Data collection 
Flow cytometry analysis was performed on the LSR-Fortessa X-20 flow cytometer. 
Forward scatter (FSC), side scatter (SSC), FITC (530 nm wavelength) and PE (575 
nm wavelength) signal intensities were measured (laser wavelengths set according 
to manufacturer’s instructions). The FITC laser was selected to measure the green 
signal intensity, representative of lipid droplet staining. The PE laser was selected to 
measure the red signal intensity, representative of lipid droplets and membrane lipid 
staining. FITC and PE laser intensities were set so the signal intensity of the 
unstained control sample was below 102 (Figure 2.3.). 10000 events were collected 
on FACSDiva. 
 
 
 
 
 
 
2.2.11.3. Data analysis 
Data analysis was performed on the FlowJo software. FITC signal intensity was 
analysed as it provides a more accurate measurement of lipid droplet specific 
staining (247). Data was converted to FITC signal intensity histograms (Figure 2.3.). 
The signal intensity gate was set at 50% of the population in the 21% or 0.3% O2 
DMSO control and applied to all other samples (Figure 2.4.). The percentage of the 
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Figure 2.3. Example unstained control 
population histogram for flow cytometry. 
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population with a higher signal intensity than the median signal intensity of the 
control was used to measure changes in signal intensity. A percentage increase in 
this population represents an increased population FITC signal intensity, increased 
green nile red stain and therefore increased LDQ. A percentage decrease in this 
population therefore represents decreased LDQ. The percentage changes were 
graphed with GraphPad Prism 7.0. The data was analysed using unpaired t-tests; 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
 
 
 
 
 
 
 
2.2.12. High resolution magic angle spinning (HRMAS) nuclear magnetic resonance 
(NMR) spectroscopy 
2.2.12.1. Sample preparation 
Cells were plated and grown until near confluence in 21% O2. Three 15 cm
3 plates 
were required for each sample. Plates were transferred to 0.3% O2 16 hours prior to 
collection or remained at 21% O2. Cells were treated with DMSO, 30 µM atglistatin or 
25 µM chloroquine for 8 hours. Media was removed and cells were washed 3 times 
with 10 mL ice cold high quality 1x PBS (Sigma, D8537). Cells were scraped into 
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Control Sample Combined 
Figure 2.4. Gating used to generate nile red flow cytometry data. Gate set at 50% of 
the control population. The percentage change in the population with FITC signal intensity 
above this gate was measured and used for statistical analysis. In this case, LDQ is 
increased by 22%. 
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1mL ice cold high quality 1x PBS, collected into one vial per sample and centrifuged 
at full speed for 1 minute. The supernatant was removed and the remaining cell 
pellet was snap frozen in liquid nitrogen. Samples were stored at -80oC until 
analysed. 
 
2.2.12.2. Data collection 
Samples were defrosted and run on the Bruker 500 Mz spectrometer with a HRMAS 
probe. 45 µL of sample was transferred to a 50 µL rotor. 5 µL of 1 mM TMSP was 
added as a reference of chemical shift. Rotor speed was set at 4880 hz and the 
sample kept at 4oC to maintain sample integrity. A NOESY sequence was run on 
each sample (256 scans). A CPMG sequence was also run on each sample to assist 
in metabolite assignment. 
 
2.2.12.3. Data analysis 
Data was imported to Mestrenova for metabolite and lipid peak assignment. Spectra 
were phase corrected and the baseline was set using the automatic Whittaker 
Smoother method. The TMSP peak was set as the reference peak at 0 ppm. 
Metabolites were assigned using the line fitting and peak picking tools (Table 2.4.). 
The peak picking tool was adjusted to measure broader peaks when assigning lipid 
peaks (Table 2.5.). Metabolite and lipid concentrations were quantified using the 
qNMR plug-in. 
 
   
66 
 
Metabolite Chemical shift 
(PPM) 
Proton number 
Isoleucine 1.01 3 
Valine 1.04 3 
Lactate 1.33 3 
Alanine 1.47 3 
Glutamate 2.35 2 
Succinate 2.41 4 
Glutamine 2.45 2 
Glutathione 2.55 2 
Hypotaurine 2.65 2 
Aspartate 2.82 2 
Creatine 3.03 3 
Choline 3.20/1 9 
Phosphoethanolamine 3.21/3.22 2 
Phosphocholine 3.22/23 9 
Glycerophosphocholine 3.23 9 
Taurine 3.42 2 
Glycine 3.56 2 
Table 2.4. Metabolite peaks for HRMAS assignment. 
 
 
Metabolite and lipid concentrations were exported to Microsoft Excel and normalised 
to total metabolite concentration for each sample. Data was analysed in GraphPad 
Prism 7.0 using unpaired t-tests; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Total saturated and unsaturated lipid group concentrations were analysed as a 
percentage of the total lipid concentration for each sample.  
Lipid group Nomenclature Chemical shift (ppm) Proton number 
CH3 Methyl 0.9 3 
CH2 Methylene 1.3 2 
CH2CH2CO Ketene methylene 1.6 2 
CH2CH=CH Methylene 2.0 2 
CH2COO- Carboxylic methylene 2.3 2 
=CHCH2CH= Diene methylene 2.8 2 
CH= Terminal alkene 5.3 1 
Table 2.5. Lipid peaks for HRMAS assignment. 
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2.2.13. Protein knockdown 
Atg5 protein knockdown was carried out with the Smartpool ONTARGET-Plus siAtg5 
and the lipofectamine 2000 transfection reagent (Invitrogen, 11668-027) (Table 2.6.). 
A non-targeting siRNA (siNT) was transfected as a positive control. 
Cells were plated and allowed to settle at 37oC, 5% CO2 before incubation at 21% O2 
overnight. 5 µM siRNA in Optimem (Gibco, 31985-047) was mixed with 6 µL/well 
lipofectamine for 20 minutes at room temperature to form complexes. 1600 µL fresh 
media was added to each well. 400 µL of the siRNA complexes was added to each 
well in a dropwise fashion to achieve a final concentration of 100 nM. Cells were 
lysed at 24, 48 and 72 hours after transfection. 
Reagent Concentration Product number 
siAtg5 100 nM Dharmacon, L-004374-00-0005 
siNT 100 nM Dharmacon, D-001810-10-05 
Lipofectamine 6 µL/well Invitrogen, 11668-027 
Table 2.6. Summary of reagents used in siRNA transfection. 
 
2.2.14. Western blot 
Cells were lysed and scraped in 100 µL 1x laemmli buffer (reducing, denaturing: 
Sigma, S3401). Cell lysates were boiled for 10 minutes at 100oC. Lysates were 
separated by their approximate molecular weight by loading them onto a 10% 
polyacrylamide gel under reducing, denaturing conditions and subjecting them to a 
constant potential difference of 120 V. The gel was “dry” transferred to a 
nitrocellulose membrane using the Invitrogen iBlot. Membranes were blocked in 5% 
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milk (Marvel) in PBS-T (0.05% Tween) for 30 minutes. Membranes were washed 
with PBS-T for 30 minutes and incubated on a rocker with the primary antibody 
(Table 2.6.) in 5% milk in PBS-T at 4oC overnight. Antibody was removed and 
membranes were washed in PBS-T for 30 minutes. Membranes were incubated with 
the appropriate HRP-linked secondary antibody (Table 2.7.)  in 5% milk in PBS-T for 
1 hour at room temperature. Antibody was removed and membranes were washed in 
PBS-T for 30 minutes. EZ-ECL (Biological Industries, 20-500-120) substrate was 
added to membranes and blots were developed. 
 
2.2.15. Western blot densitometry 
Western blot band density was analysed to further assess protein knockdown. 
Developed blots were scanned and imported into imageJ. The density of the Atg5 
band for each sample was normalised to the density of the corresponding Actin band 
and plotted in GraphPad Prism 7.0.  
Primary/Secondary Antibody Species Concentration Product 
number 
Primary 
Anti-Atg5 Rabbit 1:500 Cell 
Signalling, 
D5F5U 
Anti-Actin Mouse 1:2000 Sigma, 
A4700 
Secondary 
Anti-Rabbit-
HRP 
Goat 1:4000 Cell 
Signalling, 
7074S 
Anti-Mouse-
HRP 
Horse 1:4000 Cell 
Signalling, 
7076S 
Table 2.7. Summary of the antibodies used for western blotting. 
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2.2.16. Growth Curves 
Cells were plated and allowed to settle at 37oC, 5% CO2 before incubation at 21% or 
0.3% O2. Cells were detached with 0.05% Trypsin, neutralised in DMEM and stained 
with trypan blue (Sigma, T8154). Cell number was assessed with duplicate cell 
counts at 24, 48, 72, 96 and 144 hours. Cell number was normalised to the 24 hour 
cell count.  Proliferation was measured as fold increase in cell number. An unpaired 
t-test was performed using the 21% O2 and 0.3% O2 cell counts at 144 hours; 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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2.3. Methods used in Chapter 5  
2.3.1. Sulforhodamine B (SRB) proliferation assay 
Cells were plated in triplicate and allowed to settle at 37oC, 5% CO2. The plates for 
hypoxic incubation were transferred to 0.3% O2. Cells were treated with 10 µM 
chloroquine or dH2O for 24 hours. This dose was selected to increase LDQ with 
minimal effect on proliferation based upon flow cytometry and dose response 
assays. Plates undergoing non-hypoxic pre-treatment were moved to 0.3% O2 and 
incubated for a further 2 hours. Cells were treated with 100 µM temozolomide 
(Sigma, T2577) or DMSO. U87, T98G and U87.2 cell lines were incubated with 
temozolomide for 24, 48 and 72 hours respectively. The dose and incubation time 
were determined by dose response assays. Cells were fixed with 20% trichloroacetic 
acid (Sigma, T6399) at 4oC for 30 minutes. Plates were washed 3 times with dH2O 
and left to dry. Fixed cells were stained with 0.4% Sulforhodamine B (SRB) (Sigma, 
T0699) at room temperature for 10 minutes. Plates were washed 4 times with 1% 
acetic acid (Sigma, 45740) and left to dry. The stain was dissolved with 50 mM Tris 
buffer pH8.8 and transferred to a 96-well plate. Plates were analysed using a 
FLUOstar OMEGA plate reader with a 495 nm absorbance scan. The triplicate 
results were averaged and the data normalised to the DMSO control for each 
experiment. The data was analysed using a one way ANOVA with a Tukey post-hoc 
test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
The atglistatin pre-treatment experiment followed this protocol with two alterations: 
Cells were treated with 30µM atglistatin instead of chloroquine. All three cell lines 
were treated with 100µM temozolomide for 48 hours. 
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2.3.2. AnnexinV/PI cell death assay 
2.3.2.1. Sample preparation 
Cells were plated and allowed to settle at 37oC, 5% CO2 before incubation at 21% or 
0.3% O2. Cells were treated with 10 µM chloroquine or dH2O for 24 hours followed 
by 100 µM temozolomide or DMSO for a further 72 hours. Dose and incubation time 
were selected as discussed in section 2.3.1. 100 µL H2O2 (30% w/w: Sigma, H1009) 
was added to the single stain and positive control samples for the final 2 hours to 
ensure cell death. Following treatment, cells were washed once with 1x PBS and 
detached from the plate with 0.05% Trypsin. Trypsin activity was neutralised with 
media collected post-treatment. Cells were incubated in media for 20 minutes before 
centrifugation at 350 G for 5 minutes and the supernatant removed. Cells were re-
suspended in 500 µl 1x AnnexinV Binding Buffer (BD, 556454) before incubation 
with 5 µL AnnexinV-FITC (BD, 556419) and 1 µL 1:1000 PI (Life Technologies, 
V13242) for 10 minutes. 
The chloroquine pre-treatment with irradiation experiment followed this protocol with 
two alterations: 
Cells were pre-treated with 10µM chloroquine for 2 hours. Cells were then irradiated 
with 40 Gy radiation (IBL437C Caesium-137 Source Irradiator) and incubated for 24 
hours before collection for analysis.  
 
2.3.2.2. Data collection 
Flow cytometry analysis was performed on the LSRFortessa X-20 flow cytometer. 
Forward scatter (FSC), side scatter (SSC), FITC (530 nm wavelength) and PE (575 
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nm wavelength) signal intensities were measured. The FITC and PE lasers were 
selected to measure the AnnexinV-FITC and PI signal intensities respectively. FITC 
and PE laser intensities were set so the signal intensity of the unstained control 
sample was below 103. Cross channel bleeding was checked through single stain 
control samples treated with AnnexinV-FITC or PI only (Figure 2.5.). Stain strength 
was assessed using a positive control sample. 10000 events were collected on 
FACSDiva. 
 
2.3.2.3. Data analysis 
Data analysis was performed on the FlowJo software. FITC signal intensity was 
plotted against PE signal intensity. AnnexinV-FITC and PI gates were set using the 
DMSO-treated control population at approximately 90% viability (Figure 2.6.). The 
viable cell population is representative of the percentage of AnnexinV-FITC and PI 
negative cells.  Increased AnnexinV-FITC staining indicates cells in the early stages 
of apoptosis. Increased AnnexinV-FITC and PI staining indicates cells in the late 
stages of apoptosis. Increased PI staining indicates cells which have finished 
apoptosis or are undergoing necrosis. The viable cell population was used to assess 
changes in cell viability between samples. The data was analysed using a one way 
ANOVA with a Tukey post-hoc test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 2.5. Example single and double stain controls for the AnnexinV-FITC/PI cell 
death assay. AnnexinV-FITC single stain control, PI single stain control, AnnexinV-FITC 
and PI double stain positive control (left to right). 
Figure 2.6. Untreated control (left) and drug treated sample (right) from AnnexinV-
FITC/PI cell death assay. The viable cell population was represented by the lower left 
quadrant (AnnexinV-FITC and PI negative) and gated at approximately 90% viability. The 
viable cell percentage was used to assess changes in cell viability between samples.  
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Chapter 3 
 
The importance of lipid droplet related genes in the 
prognosis of high grade gliomas 
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3.1. Introduction 
Despite clear differences in severity, grade 2, 3 and 4 gliomas are intrinsically linked 
and share many characteristics. Proliferation, invasion, infiltration and 
aggressiveness are common features of all three glioma types and increase 
dramatically with tumour grade (9). The process of tumour progression therefore 
presents a significant challenge in glioma treatment as tumour severity and drug 
resistance increases. 
Interestingly, distinct and characteristic genetic alterations frequently occur in 
gliomas as tumours progress through the clinical grades. IDH and TP53 mutations 
occur in 80% of grade 2 and 3 gliomas (29) and in 83% of secondary GBM (55). 
Moreover, these mutations appear to universally occur in a defined order wherein 
IDH mutations precede mutations of TP53 and subsequent GBM-associated genetic 
alterations (35,36). The frequency of these mutations in an established order 
suggests that they may be fundamentally linked to the tumour progression process. 
In contrast, primary GBM is believed to occur spontaneously at grade 4 without prior 
progression from lower grades and is associated with IDH and TP53 mutation in only 
5% of cases (55). However, the tumour progression process remains unclear as the 
biological mechanisms are yet to be explored. Mutations in IDH affect the cellular 
metabolic and epigenetic profile and can promote tumorigenic genetic instability 
(30,34) whilst TP53 mutation and loss is well-established as a tumorigenic alteration 
(41,42). Paradoxically, IDH mutant tumours are also associated with an improved 
prognosis, possibly attributable to increased therapeutic sensitivity (37). 
Nevertheless, hypotheses regarding how these genetic alterations may influence a 
route to glioma tumour progression are based predominantly upon a general 
increased predisposition to mutation. Moreover, the spontaneous occurrence of 
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primary GBM at grade 4 suggests that there are other important aspects of glioma 
biology which produce high grade gliomas. Therefore, it is not unreasonable to 
hypothesise that these areas of glioma biology also impact tumour progression and 
produce high grade gliomas.  
Lipid droplet metabolism represents an important component in the metabolism of 
many types of cancer (248) including gliomas (123,249) and influences many 
aspects of tumorigenesis. Moreover, lipid droplet accumulation is increased with 
clinical grade (94,240) and indicates prognosis (94,241) suggesting that the 
importance of lipid droplets alters with increased tumour grade. As such, lipid 
droplets and their associated metabolic pathways may be altered in response to 
tumour progression or may even influence the tumour progression process. In this 
case representative genes would be expressed differentially according to tumour 
grade and may represent prognostic biomarkers. Lipid droplet-associated metabolic 
pathways such as exogenous lipid uptake (123,152) and autophagy 
(152,184,185,188) have been suggested to be important in many cancers and, if 
associated with lipid droplets across the clinical grades, may indicate aspects of the 
underlying biological metabolism of tumour progression.  
In this chapter we investigate the importance of genes that control and modulate the 
metabolism of lipid droplets and their associated metabolic pathways with regards to 
survival and tumour progression.   
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3.2. Results 
3.2.1. The selection of genes for investigation 
A list of genes representative of pathways such as; autophagy, lipase-mediated 
degradation, exogenous lipid uptake and de novo fatty acid synthesis which have 
known effects on lipid droplet metabolism in other cancers and cell types was 
created (Table 3.1.).  Similarly, lipid droplet-associated proteins were selected as 
they have clear importance in lipid droplet biology whilst lipid utilising pathways were 
selected for possible post-lipid droplet roles.  Many gene paralogs were also 
included to assess the effect of similar pathways with the expectation many would be 
later excluded. This list was not exhaustive and many other genes could have been 
included, but the aim was to create a clear and structured gene list for improved 
clarity in our analysis.  
 
Biological 
Process 
Gene Name Function 
Lipid 
droplet-
associated 
proteins 
Plin1 Perilipin 1 
Lipid droplet-associated 
protein 
Plin2 Adipophillin 
Lipid droplet-associated 
protein 
Plin3 TIP47 
Lipid droplet-associated 
protein 
Plin4 Perilipin 4 
Lipid droplet-associated 
protein 
HILPDA 
Hypoxia Inducible Lipid 
Droplet-Associated 
Hypoxia-associated lipid 
droplet protein 
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Lipases 
PNPLA1 
Patatin-Like Phospholipase 
Domain-Containing Protein 1 
Uncharacterised 
PNPLA2 Adipose triglyceride lipase 
Removal of the first fatty 
acid from triacylglycerols 
PNPLA3 Adiponutrin Triacylglycerol lipase 
PNPLA4 
Patatin-Like Phospholipase 
Domain-Containing Protein 4 
Triacylglycerol lipase 
PNPLA5 
Patatin-Like Phospholipase 
Domain-Containing Protein 5 
Inhibits transacylation 
PNPLA6 Neuropathy target esterase 
Phospholipase responsible 
for the conversion of 
phosphatidylcholine to 
glycerophosphocholine 
PNPLA7 
Patatin-Like Phospholipase 
Domain-Containing Protein 7 
Uncharacterised 
PNPLA8 
Intracellular Membrane-
Associated Calcium-
Independent Phospholipase 
A2 Gamma 
Phospholipase that cleaves 
fatty acids from membrane 
phospholipids 
LIPE Hormone-sensitive lipase 
Removal of the second 
fatty acid from 
triacylglycerol 
LPL Lipoprotein lipase 
Lipoprotein and 
triacylglycerol degradation 
Lipid 
uptake 
CD36 
CD36 (fatty acid 
translocase) 
Exogenous lipid uptake 
transporter 
Autophagy 
MAP1LC3
A, B 
Light-chain 3 autophagy 
protein 
Autophagy vital proteins 
ATG2A, 
2B, 3, 4A, 
4B, 4C, 
4D, 5, 7, 
9A, 9B, 10, 
12, 13, 15, 
Autophagy proteins Autophagy vital proteins 
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16L1, 
16L2 
De novo lipid 
synthesis 
ACACA Acetyl-CoA carboxylase 
Converts acetyl CoA to 
malonyl CoA. Rate limiting 
step in fatty acid synthesis 
FASN Fatty acid synthase Vital to fatty acid synthesis 
GLS Glutaminase 
Converts glutamine to 
glutamate 
ACSL1, 3, 
4, 5, 6 
Long-chain fatty-acid-
coenzyme A ligase family 
Important to lipid 
biosynthesis 
ACSS2 
Acetyl-Coenzyme A 
synthetase 2 
Production of acetyl CoA 
from acetate 
DGAT1 
Diacylglycerol O-
Acyltransferase 1 
Conversion of 
diacylglycerol to 
triacylglycerol 
Phospholipid 
production 
CEPT1 
Choline/Ethanolamine 
Phosphotransferase 1 
Production of 
phosphatidylcholine and 
phosphatidylethanolamine 
CHPT1 
Cholinephosphotransferase 
1 
Production of 
phosphatidylcholine 
ETNK1 Ethanolamine kinase 1 
Phosphatidylethanolamine 
synthesis 
PTDSS1, 
2 
Phosphatidylserine 
synthase 
Synthesis of 
phosphatidylserine 
CHKA, B 
Choline 
kinase/ethanolamine kinase 
Phosphatidylcholine and 
phosphatidylethanolamine 
synthesis 
Mitochondrial 
fatty acid 
transport 
CPT1A, B 
Carnitine 
palmitoyltransferase 1A and 
B 
Transport of fatty acids 
across outer mitochondrial 
membrane 
CPT2 
Carnitine 
palmitoyltransferase 2 
Transport of fatty acids 
across the inner 
mitochondrial membrane 
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CRAT Carnitine Acetyl transferase 
Catalyses the addition of 
carnitine to fatty acids for 
transport into mitochondria 
SLC25A20 
Carnitine/Acylcarnitine 
Transolcase 
Mediation of transport of 
acylcarnitines into the 
mitochondrial matrix 
Cholesterol 
metabolism 
LIPA Sterol esterase 
Breakdown of cholesteryl 
esters 
LDLR 
Low density lipoprotein 
lipase receptor 
Uptake of cholesterol 
Table 3.1. Genes selected for investigation in initial survival analysis. Gene 
names are matched with the encoded protein, the protein function and the associated 
biological process. 
 
3.2.2. Expression of lipid droplet-associated proteins and genes in key metabolic 
pathways is associated with survival in grade 2 and 3 gliomas 
Using the selected genes we sought to investigate the effect of high or low gene 
expression on survival in the combined grade 2 and 3 glioma cohort using Kaplan-
Meier survival analysis. The genes could be separated into three groups:  those for 
which high expression correlated with poor survival, those for which high expression 
correlated with good survival and those where there was no association with survival 
(Figure 3.1.A, 3.1.B and 3.1.C respectively, Table 3.2.). The first group consisted 
predominantly of lipid droplet-associated proteins, autophagy and phospholipid 
synthesis genes. In contrast, the second group consisted of predominantly de novo 
fatty acid synthesis genes. The genes composing these two groups were selected 
for further investigation due to significant separation of survival curves. However, 
there were several exclusions: the ACSL and ATG genes were excluded from further 
investigation despite significant survival separation due to conflicting results from the 
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different gene paralogs (data not shown). In both cases, an alternative gene was 
used to represent each pathway; de novo fatty acid synthesis could be represented 
by FASN and ACACA whereas autophagy could be represented by MAP1LC3A. 
These genes better represent the metabolic pathways and avoid the confounding 
variables introduced by the gene paralogues, wherein each paralogue can have 
multiple associations with other pathways. The majority of genes with no significant 
difference between the high and low gene expression curves were excluded from 
this list with the exception of CD36, PLIN4 and CPT2. CD36 remains of interest as 
high gene expression indicated both poor and good survival over time (Figure 3.1.C) 
whereas PLIN4 was included because of a clear role in lipid droplet biology. CPT2 
was included as the p-value approached significance (Table 3.2.). The final list of 
genes for further investigation is reported in Table 3.2. The separation of significantly 
different survival curves according to gene expression indicates that many of these 
pathways may be important aspects of grade 2 and 3 glioma biology. 
We further investigated gene expression across several histological classifications. 
We observed no association between histological classification, such as astrocytoma 
or oligoastrocytoma, and survival association in our gene set (data not shown) 
indicating that these pathways are important in grade 2 and 3 tumours regardless of 
glioma sub-classification. 
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A 
B 
p= 0.0001 p= 0.0002 
p= 0.0481 p= 0.0061 
p= 0.0262 p= 0.0451 
p= 0.0021 p= <0.0001 
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C 
p= 0.5588 p= 0.6500 
p= 0.7244 p= 0.1914 
Figure 3.1. Expression of lipid droplet-associated genes was associated with survival 
in grade 2 and 3 gliomas. Representative Kaplan-Meier survival curves of the combined 
grade 2 and 3 glioma cohort. n=527. A) Representative graphs of genes where high gene 
expression was associated with worse survival. PLIN2 (lipid droplet-associated protein), 
HILPDA (hypoxia associated lipid droplet-associated protein) PNPLA2 (adipose triglyceride 
lipase [ATGL]), MAP1LC3A (autophagy vital protein). B) Representative graphs of genes 
where high gene expression was associated with better survival. PLIN1 (lipid droplet-
associated protein), PNPLA3 (lipase), ACACA (acetyl-CoA carboxylase), FASN (fatty acid 
synthase). C) Representative graphs of genes where gene expression was not associated 
with survival. PLIN1 (lipid droplet-associated protein), CD36 (fatty acid uptake transporter), 
LIPE (hormone sensitive lipase), GLS (glutaminase). Log-rank (Mantel-Cox) and Gehan-
Breslow-Wilcoxon statistical tests were performed in all cases; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Gene MC p-value GBW p-value 
High gene expression was associated with poor survival 
PLIN2 0.0001 <0.0001 
PLIN3 0.0126 0.0203 
PNPLA2 0.0481 0.0683 
PNPLA4 0.0002 <0.0001 
HILPDA 0.0002 <0.0001 
MAP1LC3A 0.0061 0.0012 
CEPT1 <0.0001 <0.0001 
ETNK1 0.0242 0.2992 
PTDSS1 0.0278 0.0017 
SLC25A20 0.003 0.0001 
High gene expression was associated with good survival 
PLIN1 0.0262 0.0022 
PNPLA3 0.0451 0.1227 
ACACA 0.0021 0.0049 
FASN <0.0001 <0.0001 
Survival was independent of gene expression 
PLIN4 0.5588 0.3979 
CD36 0.6500 0.8824 
CPT2 0.059 0.1709 
Table 3.2. Gene expression correlates with survival in grade 2 and 3 gliomas. 
Summary of data in Figure 3.1. and Appendix 7.4. 
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3.2.3. The prognostic value of gene expression varies between grade 2 and grade 3 
gliomas 
Tumour progression through clinical grades reflects the altered gene expression and 
metabolic pathway activity of the cell in response to new challenges. We further 
investigated the separation of survival curves by gene expression at grade 2 and 3 
separately using the gene list established in section 3.2.2. There was a significant 
difference between the survival curves according to median PLIN3 expression in 
grade 2 tumours only (Figure 3.2.A, Table 3.3.), whereas a significant difference 
between the survival curves was observed in grade 3 tumours in several genes 
representing multiple pathways (Figure 3.2.B, Table 3.3.). In contrast, there was a 
significant difference between the survival curves separated by median CEPT1 and 
ACACA expression in both the individual grade 2 and grade 3 tumour cohorts 
(Figure3.2.C, Table 3.3.). Survival curves could not be separated in either grade 2 or 
3 tumours for several genes which had significantly different survival curves 
according to median gene expression in the combined grade 2 and 3 cohort (Figure 
3.2.D, Table 3.3.). However, the separation of survival curves according to high and 
low expression of PNPLA2, CPT2 and ETNK1 almost reached significance (Table 
3.3.) whilst PLIN4 and CD36 expression did not separate survival curves in the 
original combined grade 2 and 3 cohort (Figure 3.1.C). As expected, the indication of 
poor or good survival according to high gene expression frequently mirrored the 
prognostic indications observed in the combined grade 2 and 3 glioma cohort. The 
significantly different survival curves at each clinical grade indicate that the 
importance of these genes is altered across the stages of tumour development, 
implying different roles throughout tumour progression.  
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A 
B 
p= 0.0095 p= 0.3348 
p= 0.0074 p= 0.0469 
p= 0.7484 p= 0.0061 
p= 0.3564 p= <0.0001 
C 
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D 
p= 0.1347 p= 0.8458 
p= 0.5383 p= 0.8209 
Figure 3.2. The association of gene expression with survival is grade dependent. 
Representative Kaplan-Meier survival curves of the combined grade 2 and 3 glioma cohort 
split into a grade 2 and a grade 3 glioma cohort. Grade 2 n=256, Grade 3 n=270. A) 
Representative graphs of a gene where survival curves were significantly separated 
according to median gene expression in grade 2 tumours. PLIN3 (lipid droplet-associated 
protein). B) Representative graphs of genes where survival curves were significantly 
separated according to median gene expression in grade 3 tumours. MAP1LC3A 
(autophagy vital protein), FASN (fatty acid synthase). C) Representative graphs of genes 
where survival curves were significantly separated according to median gene expression in 
grade 2 and 3 tumours. ACACA (acetyl-CoA carboxylase).  D) Representative graphs of 
genes which did not separate survival curves according to median gene expression in either 
tumour grade. PLIN4 (lipid droplet-associated protein), CD36 (fatty acid uptake transporter). 
Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon statistical tests were performed in all 
cases; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Gene 
Grade 2 Grade 3 
MC p-value GBW p-value MC p-value GBW p-value 
Grade 2 Separation 
PLIN3 0.0095 0.0667 0.3348 0.1444 
Grade 3 Separation 
PLIN1 0.1754 0.3772 0.0035 0.0015 
PLIN2 0.3027 0.4237 0.0163 0.0039 
PNPLA4 0.2556 0.2229 0.0001 0.0004 
FASN 0.3564 0.0955 <0.0001 0.0001 
MAP1LC3A 0.7484 0.9335 0.0061 0.0024 
PTDSS1 0.7460 0.4336 0.0350 0.0154 
SLC25A20 0.0819 0.1154 0.0036 0.0002 
Grade 2 and 3 Separation 
CEPT1 0.0216 0.1197 0.0003 0.0026 
ACACA 0.0074 0.0248 0.0469 0.0760 
No Grade Separation 
PLIN4 0.1347 0.0369 0.8458 0.9741 
PNPLA2+ 0.0608 0.0996 0.4220 0.2324 
PNPLA3 0.1214 0.3364 0.6870 0.5776 
CD36 0.5383 0.1009 0.8209 0.7139 
HILPDA 0.3069 0.1795 0.1632 0.0920 
CPT2+ 0.0502 0.2453 0.7174 0.5424 
ETNK1+ 0.3861 0.8695 0.0521 0.4209 
Table 3.3. The prognostic value of gene expression is altered across tumour 
grades. Summary of data in Figure 3.2. and Appendix 7.5. + gene expression may 
associate with survival (p-value approaching significance) 
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3.2.4. Gene expression is not a prognostic marker for the majority of genes in grade 
4 gliomas  
As gene expression was a prognostic marker in grade 2 and 3 tumours, we sought to 
investigate the effect of gene expression on survival in the glioblastoma grade 4 
cohort. Poor survival was observed in tumours with a high expression of MAP1LC3A 
or SLC25A20 only (Figure 3.3, Table 3.4). Although PNPLA2 and CEPT1 
approached significance, the survival curves are too steep, due to the low survival 
time of glioblastoma, and no separation was observed. This suggests that either 
expression of these genes is no longer important at grade 4 or that expression is 
similar in all glioblastoma tumours. 
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A 
B 
p= 0.0125 p= 0.0308 
p= 0.4669 p= 0.3275 
p= 0.6972 p= 0.8160 
p= 0.0936 p= 0.0715 
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Figure 3.3. Gene expression does not associate with survival in grade 4 gliomas for 
the majority of genes. Representative Kaplan-Meier survival curves of the glioblastoma 
grade 4 cohort. n=151. A) Representative graphs of genes which separated survival curves 
by median gene expression in grade 4 tumours. MAP1LC3A (autophagy vital protein), 
SLC25A20 (mitochondrial fatty acid transporter). B) Representative graphs of genes which 
did not separate survival curves by median gene expression in grade 4 tumours. PLIN2 (lipid 
droplet-associated protein), HILPDA (hypoxia associated lipid droplet-associated protein), 
ACACA (acetyl-CoA carboxylase), FASN (fatty acid synthase), PNPLA2 (adipose triglyceride 
lipase [ATGL]), CEPT1 (phosphatidylcholine/phosphatidylethanolamine synthesis). Log-rank 
(Mantel-Cox) and Gehan-Breslow-Wilcoxon statistical tests were performed in all cases; 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Gene MC p-value GBW p-value 
Expression is indicative of survival 
MAP1LC3A 0.0125 0.0123 
SLC25A20 0.0308 0.0108 
Survival is independent of expression 
PLIN1 0.4058 0.1408 
PLIN2 0.4669 0.1826 
PLIN3 0.5326 0.2168 
PLIN4 0.1123 0.1067 
PNPLA2 0.0936 0.0667 
PNPLA3 0.8586 0.9001 
PNPLA4 0.1987 0.2737 
CD36 0.9108 0.8175 
HILPDA 0.3275 0.2430 
ACACA 0.6972 0.3787 
FASN 0.8160 0.6188 
CEPT1 0.0715 0.1807 
CPT2 0.9655 0.8749 
ETNK1 0.1396 0.1410 
PTDSS1 0.8689 >0.9999 
Table 3.4. Gene expression does not associate with survival at grade 4 for 
the majority of gliomas. Summary of data in Figure 3.3. and Appendix 7.6. 
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3.2.5. Gene expression alters with clinical grade indicating the importance of these 
pathways in grade 4 glioma biology 
The lack of prognostic significance in grade 4 tumours suggests that expression of 
many of these genes could reach an “end-point” in grade 4 tumours. To assess this 
we compared gene expression across grade 2, 3 and 4 gliomas. Expression of 
genes representing several pathways such as autophagy, ATGL-mediated lipolysis, 
lipid uptake and phospholipid synthesis was increased at grade 3 and 4 or grade 4 
alone (Figure 3.4.A. and 3.4.B, Table 3.5.). Interestingly, we observed above that 
high expression of many of these genes was associated with poor survival in grade 
2, 3 or 4 tumours. In contrast, the expression of several de novo fatty acid synthesis 
genes and the lipid droplet-associated protein genes PLIN1 and PLIN4 was 
decreased in grade 3, grade 4 or both grade 3 and 4 tumours (Figures 3.4.A. and 
3.4.B, Table 3.5.). Interestingly, for the majority of genes, expression was most 
different at grade 4 whereas expression was frequently similar at grade 2 and 3. This 
matches the clinical presentation of gliomas and indicates clearly that expression of 
these genes remains an important factor in grade 4 tumours.  
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C 
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Figure 3.4. Gene expression alters with clinical grade. Representative Boxplots showing 
the range of gene expression in grade 2, 3 and 4 gliomas. Data produced from the combined 
grade 2 and 3 glioma cohort and grade 4 glioma cohorts. Grade 2 n=256, Grade 3 n=270, 
Grade 4 n=151. A) Representative Boxplots of genes for which gene expression was 
increased at higher clinical grades. PLIN2 (lipid droplet-associated protein), HILPDA 
(hypoxia associated lipid droplet-associated protein), PTDSS1 (phosphatidylserine 
synthesis). B) Representative Boxplots of genes for which gene expression was increased in 
grade 4 tumours only. PLIN3 (lipid droplet-associated protein), CD36 (fatty acid uptake 
transporter), MAP1LC3A (autophagy vital protein). C) Representative Boxplots of genes for 
which gene expression was decreased at grade 3 and 4. PLIN1 (lipid droplet-associated 
protein), FASN (fatty acid synthase). D) Representative Boxplots of genes for which gene 
expression was decreased in grade 3 or 4 only. ROUT outlier removal was performed for 
each gene to remove definitive outliers (Q=0.1%). Resulting data sets were analysed with 
using a Kruskal-Wallis statistical test with a Dunn’s post-hoc correction; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Gene expression increased at grade 
3 and 4 
Gene expression decreased at grade 
3 and 4 
PLIN2 PLIN1 
HILPDA FASN 
PTDSS1 Gene expression only decreased in 
grade 4 
Gene expression only increased in 
grade 4 
PLIN4 
PLIN3 PNPLA3 
PNPLA2 Gene expression only decreased in 
grade 3 
PNPLA4 ACACA 
CD36  
MAP1LC3A  
CEPT1  
CPT2  
ETNK1  
SLC25A20  
Table 3.5. Gene expression alters across clinical grades. Summary of data in 
figure 3.4. and Appendix 7.7. 
 
 
 
 
 
   
97 
 
3.2.6. “Grade 3 like” gene expression in grade 2 gliomas characterises a poor 
prognostic group of tumours suggesting a role in tumour progression 
If alterations in gene expression across clinical grades can indicate worse survival 
due to tumour progression then it may be possible to detect lower grade tumours 
with a higher probability of progression. We sought to investigate this by defining 
high and low gene expression in the grade 2 cohort with the grade 3 mean gene 
expression. High or low gene expression was determined to be “grade 3 like” using 
our previous survival analysis and gene expression data (Section 3.2.1 to 3.2.5). 
Genes such as PLIN3 and PNPLA2 have indicated an association between high 
expression and poor survival and were increased in higher clinical grades. 
Therefore, in these cases grade 2 tumours with higher gene expression than the 
grade 3 mean were determined to be “grade 3 like” and therefore associated with the 
lower survival and higher probability of tumour progression observed with grade 3 
tumours. Conversely, genes such as ACACA and FASN previously indicated an 
association between high expression and good survival and had decreased 
expression in higher grade tumours. Therefore, tumours with expression of these 
genes below the grade 3 mean were determined to be “grade 3 like”. “Grade 3 like” 
gene expression separated significantly different survival curves in several genes 
suggesting poor prognosis grade 2 tumours can be predicted (Figure 3.5.A, Table 
3.6.). Moreover, in the case of PLIN2, HILPDA and MAP1LC3A, the small number of 
“grade 3 like” tumours indicated that gene expression resembles grade 3 tumours in 
very few grade 2 tumours, providing evidence regarding a role for these genes in 
later tumour grades (Figure 3.5.B). Therefore, gene expression can indicate a poor 
survival set of grade 2 tumours based upon their similarity to a higher clinical grade. 
Indeed, these data draw interesting parallels with the changes in IDH1 and TP53 
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mutation observed during tumour progression. In summary, grade 2 tumours with a 
worse prognosis have an increased chance of progression and recurrence and 
therefore, combined with our previous data, this suggests that these genes may alter 
across clinical grades and that understanding of these alterations may allow the 
prediction of tumour progression.  
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Figure 3.5. “Grade 3 like” expression of several genes is associated with poor 
survival in grade 2 gliomas. Representative Kaplan-Meier survival curves of the grade 2 
glioma cohort. High/Low gene expression was determined by grade 3 mean gene 
expression. n=256. A) Representative graphs of genes which separated survival curves 
according to grade 3 mean gene expression. PLIN3 (lipid droplet-associated protein), 
PNPLA2 (adipose triglyceride lipase [ATGL]), PTDSS1 (phosphatidylserine synthesis), 
ACACA (acetyl-CoA carboxylase). B) Representative graphs of genes which did not 
separate survival curves according to grade 3 mean gene expression. PLIN2 (lipid droplet-
associated protein), MAP1LC3A (autophagy vital protein), HILPDA (hypoxia associated lipid 
droplet-associated protein), FASN (fatty acid synthase). Log-rank (Mantel-Cox) and Gehan-
Breslow-Wilcoxon statistical tests were performed in all cases; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Gene MC p-value GBW p-value 
“Grade 3 like” gene expression is associated with survival in grade 2 
tumours 
PLIN3 0.0056 0.0483 
PLIN4 0.0013 0.0064 
PNPLA2 0.0455 0.0164 
PNPLA4 0.0240 0.0529 
ACACA 0.0185 0.0182 
CPT2 0.0109 0.0519 
PTDSS1 0.0120 0.0008 
“Grade 3 like” gene expression is not associated with survival in grade 2 
tumours 
PLIN1 0.3013 0.3696 
PLIN2 0.6748 0.4051 
PNPLA3 0.0512 0.2389 
CD36 0.4188 0.9142 
HILPDA 0.3748 0.2569 
FASN 0.3870 0.0807 
MAP1LC3A 0.4340 0.3621 
CEPT1 0.1633 0.3087 
ETNK1 0.1507 0.2667 
SLC25A20 0.1180 0.0603 
Table 3.6. “Grade 3 like” expression of several genes was associated with 
poor survival. Summary of data in Figure 3.5. and Appendix 7.8. 
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3.2.7. IDH1 mutation is associated with expression of selected genes 
IDH1 mutations are known to result in alterations in glioma metabolism and are 
linked to tumorigenesis and we sought to investigate an association with the 
expression of genes in our selected gene set. Several of the genes we investigated 
were noted to have increased expression in either the IDH wildtype (WT) or mutant 
(MUT) tumours (Figure 3.6, Table 3.7.). Many of the genes we have associated with 
poor survival in our glioma cohorts had increased gene expression in IDH1 WT 
tumours (Figure 3.6.A), also known to have poor survival (250,251). In contrast, only 
the genes associated with de novo fatty acid synthesis had increased expression in 
the IDH1 MUT tumours (Figure 3.6.B). Interestingly, IDH1 MUT tumours are known 
to have a better survival (250,251) and we observed the tumours with high ACACA 
and FASN expression tended to result in better overall survival. Notably, few 
tumours in the combined grade 2 and 3 glioma cohort had a known IDH1 mutational 
status and this may limit the strength of these findings. Nevertheless, this data raises 
the possibility of an interesting association between lipid droplet-associated 
pathways and IDH1 mutational status as independent markers of tumour severity 
and patient survival. 
 
 
 
 
 
 
   
103 
 
 
A 
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C 
Figure 3.6. IDH1 mutational status is associated with the expression of selected 
genes. Representative Boxplots comparing the gene expression of IDH1 wild-type (WT) and 
mutant (MUT) tumours in the combined grade 2 and 3 glioma cohort. Known IDH mutational 
status was required for inclusion. IDH1 WT n=34, IDH1 MUT n=91. A) Representative 
Boxplots of genes with increased gene expression in IDH1 WT tumours. PLIN2 (lipid 
droplet-associated protein), MAP1LC3A (autophagy vital protein), CEPT1 
(phosphatidylcholine/phosphatidylethanolamine synthesis). B) Representative Boxplots of 
genes with increased gene expression in IDH1 MUT tumours. ACACA (acetyl-CoA 
carboxylase), FASN (fatty acid synthase). C) Representative Boxplots of genes with no 
significant difference in IDH1 WT or MUT tumour gene expression. PLIN1 (lipid droplet-
associated protein), CD36 (fatty acid uptake transporter), ETNK1 
(phosphatidylethanolamine synthesis). Unpaired two-tailed t-test statistical tests were 
performed in all cases; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Gene p-value 
Higher gene expression in IDH1 WT tumours 
PLIN2 0.0005 
PLIN3 0.0064 
PLIN4 0.0236 
PNPLA2 0.0090 
PNPLA4 <0.0001 
HILPDA 0.0060 
MAP1LC3A <0.0001 
CEPT1 <0.0001 
CPT2 0.0365 
PTDSS1 0.0003 
SLC25A20 <0.0001 
Higher gene expression in IDH1 MUT tumours 
ACACA 0.0007 
FASN 0.0001 
Gene expression is independent of IDH1 mutational status 
PLIN1 0.2968 
PNPLA3 0.3094 
CD36 0.1688 
ETNK1 0.9849 
Table 3.7. Expression of several genes associates with IDH1 mutational 
status. Summary of data in Figure 3.6. and Appendix 7.9. 
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3.2.8. Significant correlations are found between genes with prognostic indications 
We sought to explore whether the genes investigated in the previous sections are 
independently or co-ordinately expressed. Specifically we investigated whether 
genes are independent biomarkers as a prelude to determining gene combinations 
as prognostic markers. We also explored whether genes of prognostic value define 
specific tumour sub-groups or rather are altered continuously throughout tumour 
progression. Spearman’s rank correlation analysis was used to highlight the 
correlation between the expression of many genes (Figure 3.7.A.). This was 
visualised using a heat map (Figure 3.7.B.) which displayed significant correlations 
between genes associated with better survival or genes associated with worse 
survival. Negative correlations were observed in gene expression between genes 
associated with different survival outcomes. This indicates that these genes do not 
act as independent biomarkers and suggests that the represented pathways are 
linked by a shared attribute such as an association with lipid droplet metabolism. 
Moreover, the tumours were not observed to cluster by cluster analysis indicating 
that these tumours do not form specific sub-groups defined by the expression of 
these genes (Figure 3.7.C.). Many significant correlations observed in Figure 3.7.B. 
were also found to be significant using the TCGA cBioPortal query function (Figure 
3.7.D.), further supporting the gene correlations. Notably, alterations in CEPT1 and 
CPT2 expression co-occurred with several genes; however, as CEPT1 and CPT2 
were predominantly detected as mRNA down-regulation, this is in fact mutual 
exclusivity. The TCGA cBioPortal query function was also used to assess these 
correlations in the grade 4 glioblastoma cohort (Figure 3.7.E.). Although far fewer 
correlations were present in this data set, PLIN2 and HILPDA alterations and 
ACACA and FASN alterations were observed to co-occur indicating their importance. 
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Therefore, gene expression appears to alter across grade 2 and 3 tumours in a 
continuous manner as opposed to defining separate tumour sub-groups and further 
suggests an association with tumour progression 
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Figure 3.7. The expression of prognostic genes correlates but tumours do not form 
clusters by gene expression. A) Representative correlation scatter plots of gene 
expression in the combined grade 2 and 3 glioma cohort. Graphs represent positive, 
negative and no correlation (left to right). Spearman’s correlation analysis was used to 
assess correlation strength [r]. B) A heat map of gene expression correlation shows 
correlations between genes predictive of survival. Genes predictive of poor survival: PLIN2 
to PTDSS1. Genes predictive of good survival: PLIN1 to FASN. Green to red colour change 
represents positive to negative correlations [r]. X icons mark significant correlations; A 
Bonferroni correction was applied to generate adjusted p-value p<0.00037, n=135. r-values 
and p-values can be found in Appendix 7.2. C) Cluster analysis of gene expression 
indicated that these genes do not form distinct groups. Gene expression normalised to 
percentage of the maximum gene expression for each gene. D) Correlation analysis 
performed on the combined grade 2 and 3 glioma cohort using the TCGA cBioPortal query 
function supported many of the correlations identified in the above heat map (Figure 3.7.B). 
p<0.05. E) Correlation scatter plots of gene expression in the grade 4 glioblastoma cohort 
using the TCGA cBioPortal query function supported some correlations observed in the 
combined grade 2 and 3 glioma cohort. PLIN2 and HILPDA (left), ACACA and FASN (right). 
E 
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3.2.9. Combined gene sets show higher levels of prognostic prediction in grade 4 
gliomas 
As previously observed it is difficult to associate gene expression with survival in 
grade 4 tumours. We therefore sought to investigate the expression of combinations 
of genes as prognostic markers in these tumours instead. Genes were separated 
into two gene sets: those associated with poor survival and increased expression in 
higher grade tumours and those associated with good survival and decreased 
expression in higher grade tumours. In contrast, with the rest of the gene set, CEPT1 
and CPT2 mRNA was predominantly down-regulated and were therefore excluded 
from this analysis (Figure 3.8.A). These two gene sets separated significantly 
different survival curves in the combined grade 2 and 3 glioma cohort. Tumours with 
mRNA up-regulation of genes in the poor survival gene set were associated with a 
significantly worse survival compared to those without (Figure 3.8.A). Interestingly, 
mRNA up-regulation of this poor survival gene set was also able to separate survival 
curves in the grade 4 glioblastoma cohort (Figure 3.8.B) implicating these genes as 
biomarkers of poor prognosis. Similarly, mRNA up-regulation of the good survival 
gene set also separated survival curves in the grade 4 glioblastoma cohort (Figure 
3.8.C.) suggesting these genes may be biomarkers of good prognosis. However, this 
separation of the survival curves in grade 4 tumours was not significant due to the 
low number of cases detected with mRNA up-regulation compared to the control 
group. Nevertheless, it has always been difficult to separate survival curves at grade 
4 and therefore it is encouraging that the p-values are close to significance. Despite 
difficulties separating survival curves in grade 4 tumours with univariate analysis, we 
observe here that combinations of correlated genes can improve survival curve 
separation and prognostic prediction. 
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Figure 3.8. Analysis of combined gene alterations can improve prognostic prediction. 
A) Representative Kaplan-Meier survival curves of the combined grade 2 and 3 glioma 
cohort. The combined analysis of genes individually predictive of a worse survival also 
associated mRNA upregulation with poor survival in a multivariate analysis. n=527. B) 
Representative Kaplan-Meier survival curves of the grade 4 glioblastoma cohort. 
Expression of genes associated with poor prognosis in grade 2 and 3 tumours had 
improved prognostic value in grade 4 tumours through multivariate analysis and associated 
with poor survival. The p-value did not reach significance due to the small number of 
tumours with mRNA upregulation alterations. n=151. C) Representative Kaplan-Meier 
survival curves of the grade 4 glioblastoma cohort. Expression of genes associated with 
good prognosis in grade 2 and 3 tumours had improved prognostic value in grade 4 
tumours through multivariate analysis and associated with good survival. The p-value did 
not reach significance due to the small number of tumours with mRNA upregulation 
alterations. n=151. Genes analysed: A) and B); PLIN2, PLIN3, PNPLA2, CD36, HILPDA, 
MAP1LC3A, ETNK1, PTDSS1. CEPT1 and CPT2 were excluded from this analysis as the 
query function recognised predominantly mRNA down-regulation alterations. C); PLIN1, 
PLIN4, PNPLA3, PNPLA4, ACACA, FASN, SLC25A20. Survival curve analysis was 
performed in all cases using the TCGA cBioPortal query function; statistical analysis 
performed using the log-rank test. 
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3.3. Discussion 
3.3.1. Introduction 
Lipid droplets are an important area of tumour metabolism in many cancers, 
including gliomas, where they are clinically associated with poor survival and higher 
tumour grade (94,240,241). However, despite characterisation of lipid droplet 
metabolism in other tumours, the glioma-specific lipid droplet metabolic pathways 
remain poorly characterised. Through survival and correlation analysis of clinical 
tumour data, we identified possible pathways involved in glioma lipid droplet 
metabolism which could be biologically investigated. Moreover, tumour progression 
presents a major challenge in glioma management and we therefore investigated 
changes in gene expression across clinical grades, uncovering possible associations 
with the tumour progression pathway. 
 
3.3.2. Gene expression of key metabolic pathways and lipid droplet-associated 
proteins is associated with survival in the combined grade 2 and 3 glioma cohort 
The separation of the gene list into three groups indicated a number of genes with 
possible effects on survival in grade 2 and 3 gliomas and provided an initial 
indication of which genes may be pro- or anti-survival (Figure 3.1.). The association 
of the lipid droplet-associated proteins PLIN2 and PLIN3 with poor survival tumours 
suggests that increased lipid droplet presence is a negative indicator of survival. 
Indeed, this is supported by Wilson et al. (241) who observed that increased 
presence of lipid droplets was a negative indicator of survival in vivo. Hypoxia is also 
an established marker of poor prognosis (252,253) and is known to increase lipid 
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droplet accumulation (123). Therefore, the association of HILPDA with poor survival 
tumours further suggests that increased lipid droplet presence in conjunction with 
hypoxia is an indicator of poor survival.  Interestingly, autophagy and the lipase 
ATGL were also associated with poor prognosis and both have established roles in 
lipid droplet metabolism (179,194). Although autophagy also has pro- and anti-
survival effects (170,171) which may obscure its contribution to survival in grade 2 
and 3 gliomas, it has a well-established role in lipid droplet breakdown in many cell 
types (152,179,184,185,188). Similarly, several genes involved in phospholipid 
synthesis, a possible fate for lipid droplet derived lipids, were also associated with 
poor survival suggesting an association between lipid droplets and membrane 
synthesis in gliomas. However, these enzymes are also vital to proliferation and the 
impact of increased expression may be independent of lipid droplets. 
In contrast, high expression of several genes linked to lipid droplet metabolism was 
associated with good survival in grade 2 and 3 gliomas (Figure 3.1.). High 
expression of the lipid droplet-associated protein PLIN1 was associated with tumours 
with a better survival and, in contrast with PLIN2 and PLIN3, is thought to promote 
lipid droplet breakdown by cytoplasmic lipases (115). Moreover, de novo fatty acid 
synthesis is known be involved in lipid droplet metabolism (136,164) and be 
associated with poor survival (156,157) in other tumours, yet expression of ACACA 
and FASN, which are vital in de novo fatty acid synthesis, was associated with a 
better survival in grade 2 and 3 gliomas. Similarly, expression of PNPLA3, which 
encodes an alternative lipase (254), was also associated with good survival. This 
suggests that different metabolic pathways, for example a preference for autophagy 
and ATGL as opposed to de novo lipogenesis, may influence the tumour phenotype 
and prognosis. Indeed, the importance of the expression of these genes in glioma 
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biology and survival endorses the further investigation of the represented pathways 
in lipid droplet metabolism using biological models. 
Notably, several genes representing other important metabolic pathways were not 
associated with survival in grade 2 or 3 gliomas (Figure 3.1.) including the 
metabolism of cholesterol, a known component of lipid droplets (255). Genes 
encoding lipases responsible for the subsequent steps of lipolysis post-ATGL were 
also not associated with survival further highlighting PNPLA2 specifically as a gene 
of interest. The majority of genes in this final group, with the exception of a CD36, 
PLIN4 and CPT2, were excluded from the analysis to focus on genes with more 
significant associations to glioma survival. CD36 expression was associated with 
both poor and good survival dependent upon survival time indicating prognostic 
prediction may be altered in long term survivors. This is of particular interest as 
patient survival was monitored for up to 16.5 years, far longer than standard glioma 
studies in which CD36 would have been associated with poor survival. Moreover, 
uptake of exogenous serum lipids is an important pathway in lipid droplet metabolism 
in many cancers (123,152), justifying its inclusion for further analysis. In summary 
the survival analysis of grade 2 and 3 gliomas generated an edited list of genes, 
representative of several metabolic pathways, which may impact glioma lipid droplet 
metabolism and survival. 
 
3.3.3. The prognostic value of gene expression varies between grade 2 and 3 
gliomas 
As tumours progress from grade 2 to 3 the requirements for continued growth and 
survival change and therefore gene expression is altered correspondingly. In the 
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separated grade 2 and 3 cohorts several genes were associated with survival 
(Figure 3.2.) and mirrored the prognostic prediction observed in the combined data 
set. However, expression of several genes such as PNPLA3 and HILPDA was not 
associated with survival in grade 2 or 3 tumours, despite prior association with 
survival in the combined grade 2 and 3 cohort. This suggests key differences in the 
biological importance of gene expression between grades 2 and 3. Nevertheless, the 
increased number of tumours in the combined cohort provides further statistical 
power in the significant separation of survival curves. 
The altered expression of numerous genes between grade 2 and 3 tumours 
suggests the expression of these pathways may be altered in response to the 
different metabolic and survival requirements of each clinical grade. Moreover, it is 
possible that altered expression of these pathways at each clinical grade may 
influence the tumour progression process, rather than be a response to tumour 
progression. Nevertheless, lipid droplets have been associated with multiple tumour 
grades (94,240,241) suggesting that, although expression of each gene and pathway 
may change, lipid droplet metabolism remains fundamental in glioma biology.  
 
3.3.4. Gene expression cannot separate significantly different survival curves in 
grade 4 gliomas for the majority of the investigated genes  
In contrast to grade 2 and 3 tumours, gene expression within the defined gene set 
provided significant biomarkers of survival at grade 4 in very few genes (Figure 3.3.). 
Separation of survival curves is particularly uncommon in grade 4 gliomas due to 
their steep nature, emphasising the importance of any distinguishing genes. Notably, 
MAP1LC3A is a vital protein in autophagy, which is frequently investigated in GBM 
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(172), and was associated with poor survival at grade 3 and 4 implying increased 
importance in higher grade tumours. Similarly, expression of the phospholipid 
synthesis gene CEPT1 was significantly associated with survival in grade 2 and 3 
tumours and neared significance in grade 4 tumours. Phospholipid synthesis is an 
important component of proliferation and expression of these genes can be expected 
to impact glioma biology across tumour grades. 
However, expression was not associated with survival in the majority of investigated 
genes in grade 4 tumours despite previous association with survival in grade 2 and 3 
tumours. This could be due to these genes having decreased importance in grade 4 
tumours, due to significant metabolic alterations, or differences between the 
combined grade 2 and 3 tumour cohort and the grade 4 tumour cohort. The grade 4 
cohort was comprised predominantly of primary GBMs whereas grade 2 and 3 
tumours are believed to precede secondary GBM and share several key mutations 
and characteristics. This important variable between the two cohorts could influence 
whether gene expression is associated with survival across all three grades. 
Alternatively, the loss of prognostic indication from gene expression at grade 4 could 
provide further evidence regarding an association of gene expression with tumour 
progression. GBM is the final stage of tumour progression and therefore gene 
expression would no longer separate survival curves by the probability of 
progression. If these genes become statistically less significant in survival in grade 4 
tumours or represent the difference between primary and secondary GBM then gene 
expression should not alter sequentially between grade 2, 3 and 4 tumours. In 
contrast, if these genes are associated with the tumour progression process then 
expression should be further altered in grade 4 tumours. 
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3.3.5. Gene expression alters with clinical grade indicating the importance of these 
pathways in grade 4 glioma biology despite not being associated with survival 
In many cases gene expression was altered sequentially across tumour grades with 
the greatest difference frequently observed at grade 4 (Figure 3.4.), matching the 
clinical presentation of grade 4 tumours. As discussed in section 3.3.4, this provides 
evidence that these genes continue to be important at grade 4 and may be 
associated with glioma progression from low to high grade. Interestingly, when 
combined with the survival data, genes associated with poor survival had an 
increased expression in higher grade tumours with an inverse relationship observed 
in genes associated with good survival. For example high expression of the 
autophagy gene MAP1LC3A was associated with poor survival in grade 3 and 4 
tumours and expression was significantly increased in grade 4 tumours. Therefore, 
tumours with high MAP1LC3A expression resemble higher grade tumours in aspects 
of molecular phenotype, perhaps suggestive of a more severe phenotype with worse 
prognosis. Conversely, high expression of the de novo fatty acid synthesis enzyme 
FASN was associated with good survival in grade 2 and 3 tumours and had 
decreased expression in higher grade tumours. This suggests that tumours with high 
FASN expression maintain aspects of a lower grade phenotype with a better 
prognosis. Alterations in the expression of these genes may be associated with the 
process of tumour progression as cells adapt to the increased metabolic demand, 
microenvironment and altered phenotypes of higher clinical grades.  Moreover, gene 
expression may indicate tumour aggressiveness within each grade and therefore 
understanding the pattern of gene expression may predict tumour severity or the 
probability of tumour progression. 
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3.3.6. Expression of genes known to be involved in lipid droplet metabolism is 
important in gliomas across clinical grades and is associated with survival in grade 2 
and 3 gliomas  
Importantly the genes investigated represent key metabolic pathways and proteins 
that could represent essential changes in tumour biology, influencing the tumour 
phenotype. Several genes representing lipid droplet proteins, autophagy proteins, 
ATGL, phospholipid synthesis enzymes and mitochondrial lipid uptake transporters 
were associated with poor survival and higher grade tumours (Figures 3.1. to 3.4.). 
Indeed, in a study using immunohistochemistry, Kohe et al. (240) noted that the lipid 
droplet-associated protein adipophilin, encoded by PLIN2, was increased in higher 
grade gliomas. We have also demonstrated an association between genes encoding 
the lipid droplet-associated protein perilipin 1, the PNPLA3 lipase and key de novo 
fatty acid synthesis enzymes with lower grade tumours and good survival (Figures 
3.1. to 3.4.). Therefore, we suggest that tumour lipid metabolism is altered as 
tumours progress from grade 2 to 4 and that gene expression may indicate 
prognosis and tumour progression. Increased de novo fatty acid synthesis may 
therefore indicate a lower grade tumour phenotype or that increased activity of this 
pathway has tumour suppressive activity in high grade gliomas. In contrast, 
increased lipid droplet presence, autophagy and ATGL activity may indicate an 
increased probability of progression and a higher grade tumour phenotype. 
Therefore, the metabolic pathways that predominate may drive progression and 
aggressiveness across the glioma grades and indicate important metabolic 
requirements for high grade glioma. Moreover, these genes were selected in relation 
to lipid droplet metabolism and may indicate the glioma-specific lipid droplet 
metabolic pathways, requiring further biological investigation.  
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3.3.7. “Grade 3 like” gene expression in grade 2 gliomas characterises a poor 
prognostic group suggesting an association with tumour progression 
The role of the investigated genes across tumour grades also presents an 
opportunity to better understand the process of tumour progression from lower 
clinical grades. Therapy efficacy is significantly improved in low tumour grades and 
the aggressiveness of treatment regimens can be altered depending upon the 
chance of progression making this a valuable clinical tool. We therefore aimed to use 
these genes to predict “grade 3 like” tumours in the grade 2 cohort with a worse 
prognosis and therefore a higher chance of progression (Figure 3.5.). The increased 
expression of genes representing pathways, such as lipid droplets and ATGL in 
“grade 3 like” tumours associated with poor survival and correlated with the previous 
survival analysis. Conversely, expression of genes representing pathways such as 
de novo fatty acid synthesis was low in the “grade 3 like” tumours and was 
associated with poor survival, further correlating with the previous survival analysis. 
Therefore, the poor survival, higher grade phenotype of a “grade 3 like” gene 
expression profile in grade 2 tumours is characterised by increased expression of 
genes representing lipid droplets and ATGL and decreased expression of genes 
representing de novo fatty acid synthesis. Moreover, poor survival tumours have a 
higher probability of progression and therefore the expression profile of “grade 3 like” 
tumours combined with our previous survival analysis suggests an association with 
tumour progression. 
As expected, not all genes predict a “grade 3 like” survival phenotype. However, 
several of these genes predominantly associate with survival in grade 3 and 4 
tumours suggesting that these may be a later event in the process of tumour 
progression and emphasising the importance of appropriate gene selection. Indeed, 
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the separation of survival curves using PLIN2, HILPDA and MAP1LC3A expression 
was limited by the small number of tumours with “grade 3 like” expression indicating 
a large difference in gene expression between grade 2 and 3 tumours. Further 
prediction of grade 3 tumours with a “grade 4 like” phenotype could indicate the 
importance of this gene set in each tumour grade and the overall biological 
significance of alterations in expression. However, prediction of progression from 
grade 3 to 4 was impractical due to the large difference between grade 3 and 4 gene 
expression observed in many genes. 
Moreover, these data represent the gene expression of different tumours across 
clinical grades. Assessing follow-up data from each tumour as gene expression is 
altered during progression to higher grades could clarify the difference between 
grade-specific phenotypes and the process of tumour progression. However, these 
data are difficult to obtain and may be skewed by the effects of increasingly 
aggressive therapies used in higher grade tumours. We therefore suggest that 
selected gene expression can offer useful insight into the progression of tumours 
between tumour grades. 
Although this investigation is limited to gene expression, the pathways represented 
by these tumours provide an indication of the core tumour biology and may influence 
the tumour progression process. The biological changes underlying the altered gene 
expression remain to be understood. However, through this we may better predict 
patient survival and tumour progression and adapt treatment regimens appropriately. 
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3.3.8. IDH1 mutation is linked to expression of selected genes 
Mutations in genes such as IDH1 and TP53 have become established biomarkers in 
several glioma sub-groups (9). Although no association between gene expression 
and TP53 mutation was observed in this study, the prognostic indication of genes 
such as PLIN2, MAP1LC3A, ACACA and FASN correlated with the prognostic 
indication and mutational status of IDH1 (Figure 3.6.). IDH1 mutation can 
significantly alter cell metabolism, although a mechanistic link to lipid droplets is not 
known. Notably, several genes with significant prognostic value in our survival 
analysis remain unaffected by IDH1 mutational status suggesting that other factors 
are involved. Indeed, the interlinked nature of cellular metabolism may mean that the 
impact of changes in a given metabolic pathway affect the activity of other metabolic 
pathways, such as those represented by these genes. Therefore, the association of 
several of these genes with IDH1 mutational status requires further investigation but 
may not indicate a mechanistic link to lipid droplets. 
Interestingly, this association with IDH1 mutational status further supports the 
importance of these genes across all glioma grades. As discussed in Section 3.3.4, it 
could be suggested that gene expression did not associate with survival in grade 4 
tumours as this cohort is comprised predominantly of primary GBM tumours whereas 
grade 2 and 3 gliomas are more associated with secondary GBM. However, in this 
case, gene expression would be associated with IDH1 mutant tumours whereas 
expression of many genes was instead associated with IDH1 wildtype tumours 
suggesting that these genes are relevant to all GBMs. 
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3.3.9. Significant correlations are found between genes with prognostic indications 
The ability to predict survival and tumour progression at different tumour grades 
presents an important clinical opportunity, but requires further investigation. Genes 
can act independently as individual biomarkers or be interlinked and correlated. They 
can also define delineated groups of tumours containing characteristic genetic 
alterations synergistically affecting tumorigenesis and tumour progression. The 
positive correlation of genes associated with similar prognostic indications and the 
negative correlation between these two groups suggests these genes are not 
independent biomarkers and are, instead, interlinked by a shared attribute (Figure 
3.7.). Indeed, these genes were selected due to possible associations with lipid 
droplet metabolism and correlate with lipid droplet-associated proteins. Whilst the 
involvement of the pathways represented by these genes in lipid droplet metabolism 
could be tested with pathway analysis software, investigation using biological models 
would provide more definitive proof. 
Many cancer types can be classified into clear groups and sub-groups defined by the 
expression of characteristic genes and mutations and often present a specific 
phenotype such as decreased survival. However, these gliomas could not be 
classified into sub-groups defined by expression of these genes, as observed in the 
cluster analysis (Figure 3.7.). Therefore, we suggest that alterations in these genes 
represent an important part of glioma biology in all cases and that expression is 
altered in a continuous process as tumours grow and progress. Moreover, through 
proper understanding of these alterations, gene expression may predict the tumour 
severity and progression at a given time point. 
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The gene expression correlations were supported using the TCGA cBioPortal query 
function which further highlighted several important genetic alterations (Figure 3.7.). 
Alterations in PLIN2 co-occurred with alterations in PLIN3, HILPDA and CD36 
supporting the importance of lipid droplet-associated proteins and linking them to 
fatty acid uptake. Similarly, the co-occurrence of mRNA alterations in ACACA and 
FASN suggests their importance in gliomas is due to the activity of the de novo fatty 
acid synthesis pathway. Additionally the co-occurrence of MAP1LC3A and PTDSS1 
links autophagy with membrane production, although the reason for the co-
occurrence of alterations in PLIN1, PLIN4, PNPLA4 and SLC25A20 is currently 
unclear. 
Although this multivariate analysis did not support all significant alterations observed 
through the Spearman’s rank analysis, the TCGA cBioPortal query function is more 
conservative. An mRNA z-score cut-off was used to determine tumours with mRNA 
upregulation as opposed to consideration of the whole tumour population with 
Spearman’s rank correlation analysis. Therefore, correlations observed through both 
methodologies have increased validity. 
Notably, associations in gene expression correlate with the prognostic indications of 
the univariate survival analysis and several of these correlations were also observed 
in the grade 4 tumour cohort (Figure 3.7.), further supporting the validity of these 
findings and the importance of these pathways in glioma biology. Therefore, the 
expression of genes with prognostic importance in grade 2, 3 and 4 gliomas may 
represent important and interlinked stages in adaptation through tumour progression 
and could represent a diagnostic opportunity.  
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3.3.10. Combined gene sets show higher levels of prognostic prediction in grade 4 
gliomas 
Despite no separation of survival curves for many genes in grade 4 tumours through 
univariate analysis, the correlated gene sets improved prognostic prediction (Figure 
3.8.). Although the survival curves did not significantly separate, this may be due to 
the low number of cases classified as having mRNA up-regulation by the mRNA z-
score cut-off. However, a lower cut-off could not be used as this identified an 
increased number of contradictory mRNA down-regulation alterations. Therefore, 
these gene sets require further testing on alternative data sets. The separation of 
survival curves remains difficult in grade 4 gliomas and, whilst multivariate 
expression of these genes is unlikely to offer a clinical prognostic tool or alter the 
current glioblastoma treatment regimens, it further advocates investigation into the 
biological significance of these pathways. 
 
3.3.11. Summary 
We have defined a list of genes associated with survival in grade 2, 3 and 4 gliomas. 
The prognostic value of these genes varies between tumour grades and indicates 
that gene expression may be altered in response to higher clinical grade and tumour 
aggressiveness. Moreover, we suggest that gene expression is important in tumour 
progression and can predict poor survival “grade 3 like” tumours in a grade 2 tumour 
cohort. The correlation of gene expression in genes with similar prognostic 
indications suggests that altered gene expression is not limited to a tumour sub-
group but occurs across all gliomas throughout progression. Indeed, the represented 
pathways can improve prognostic prediction in grade 4 tumours. We further suggest 
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that the pathways, represented by gene expression, are involved in or altered by the 
tumour progression process and that we may predict progression through 
understanding the changing involvement of these pathways in gliomas across the 
tumour grades. Although this hypothesis is limited as it does not follow-up gene 
expression after tumour progression, the consistent association of gene expression 
with survival and tumour grade suggests a possible role in tumours undergoing 
progression. Therefore, whilst this area requires greater investigation, the possibility 
of progression prediction represents an interesting clinical opportunity. 
Expression of specific genes was associated with indicators of poor or good 
prognosis repeatedly throughout univariate and multivariate analysis. Genes 
representing adipophillin, TIP47, ATGL, autophagy and phospholipid synthesis were 
consistently associated with poor survival, high grade and progression indicating that 
these proteins are important in glioma tumour biology and constitute possible 
therapeutic targets. In contrast, genes representing perilipin 1, the PNPLA3 lipase 
and de novo fatty acid synthesis enzymes were associated with good survival, low 
tumour grade and less progressive tumours indicating a possible shift in metabolism 
as tumours progress. The correlations between these pathways may suggest a 
common feature such as a unifying area of metabolism. Indeed, these pathways are 
known to be important in lipid droplet metabolism (136,152,179,184-188,197) in 
many other cancers and lipid droplets have clear importance in glioma biology 
across tumour grades (240). However, lipid droplet metabolism remains poorly 
understood in gliomas and therefore these pathways and proteins form the basis for 
further biological investigation. 
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Chapter 4 
 
Metabolic pathways in GBM lipid droplet 
metabolism 
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4.1. Introduction 
Lipid droplets are important aspects in many cancers and increased levels are 
associated with clinical features such as poor survival and clinical grade 
(94,240,241). However, the underlying metabolic pathways in gliomas remain poorly 
understood. In many cancers, lipid droplet production occurs through increased 
uptake of exogenous lipids, de novo fatty acid synthesis or a combination of both 
pathways (123,136,152) whilst lipid droplet breakdown occurs through the combined 
or independent action of autophagy or cytoplasmic lipases (152,184-188,197). 
Increased lipid droplet uptake has been suggested to affect hypoxic lipid droplet 
production in gliomas (123), although the roles of de novo fatty acid synthesis, 
autophagy and cytoplasmic lipases in glioma lipid droplet metabolism are yet to be 
fully explored. In Chapter 3 we demonstrated that expression of exogenous lipid 
uptake, autophagy and cytoplasmic lipase genes was associated with poor 
prognosis and was an important aspect of glioma biology at higher clinical grades. 
Given this evidence, it is important to investigate the roles of lipid droplets in the 
biology of gliomas and try to establish mechanistic links between these intracellular 
organelles and the malignant phenotypes observed in GBM.  
Choice of cell model is, as always, important, as most cell lines represent grade 4 
tumours due to the difficulty in growing cells derived from lower grade tumours. Cell 
lines from GBM are therefore used for the majority of studies into glioma biology, and 
are used in this investigation. 
In this chapter we investigate lipid droplet metabolism using GBM cell lines. Through 
confocal microscopy, flow cytometry and NMR-based methods we explore the 
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metabolic pathways involved in lipid droplet production and breakdown and indicate 
possible applications for lipid droplets in GBM.  
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4.2. Results 
4.2.1. Uptake of exogenous serum lipids is important in normoxic lipid droplet 
production. 
Exogenous serum provides an abundant source of lipids and fatty acids which can 
be imported via membrane transport proteins (146,147).  Activated charcoal was 
used to produce a de-lipidated serum to culture cells in the absence of this lipid 
source. The LDQ of cells grown in standard or de-lipidated serum was assessed 
over 5 GBM cell lines using confocal microscopy and flow cytometry. Qualitative 
analysis of confocal microscopy images revealed that incubation in de-lipidated 
serum decreased LDQ in the T98G and U87.1 cell lines (Figure 4.1.A.). This was 
supported by a negative percentage shift in the population FITC signal intensity in all 
5 cell lines when incubated in de-lipidated serum (Figure 4.1.B). Therefore, lipid 
droplet production is decreased in the absence of the exogenous serum lipid pool. 
Moreover, exogenous C16 BODIPY, an extracellular fatty acid, was observed within 
lipid droplets (Figure 4.1.C.). This demonstrated the presence of an exogenously 
supplied fatty acid in lipid droplets and further supports exogenous serum lipids as 
an important source in lipid droplet production. 
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4.2.2. ATGL may impact lipid droplet production through cell membrane unsaturated 
fatty acid release. 
ATGL is the rate-limiting lipase in the hydrolysis of fatty acids from TAGs (189) and 
has been previously implicated in lipid droplet metabolism in other cell types 
(174,194). Confocal microscopy and flow cytometry were used to investigate the 
effect of the competitive and selective ATGL inhibitor atglistatin on LDQ across the 5 
cell lines. Following atglistatin treatment LDQ was observed to be decreased in the 
U87 and U87.2 cell lines (Figure 4.2.A). This was further supported in all 5 cell lines 
by a negative percentage shift in the FITC signal intensity following atglistatin 
treatment (Figure 4.2.C.), suggesting a common role for ATGL in lipid droplet 
production. Moreover, the atglistatin-induced decrease in LDQ was enhanced in 
HBSS as observed with confocal microscopy and flow cytometry (Figure 4.2.B. and 
4.2.D. respectively) reflecting flexibility in the activity of ATGL in response to 
metabolic need.  
  
Figure 4.1. Uptake of exogenous serum lipids is important in lipid droplet production 
in normoxia. A) Confocal microscopy of nile red stained T98G and U87.1 cells incubated in 
DMEM or de-lipidated serum media in normoxia for 72 hours. Incubation in de-lipidated 
serum decreased LDQ. B) LDQ was decreased in cells incubated in de-lipidated serum, as 
observed by flow cytometry, in all five cell lines. Data shown as mean ±SEM, representative 
of several independent experiments (U343, U87, U87.2 n=3; T98G, U87.1 n=4), analysed 
with an unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. C) Confocal 
microscopy images of T98G and U87 cells incubated with C16 BODIPY for 30 minutes prior 
to 8 hours HBSS incubation. C16 BODIPY was observed within lipid droplets. 
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ATGL is known to localise at the cell membrane as well as lipid droplets (189) and 
associate with proteins important to lipid droplet production such as FABPs (192). 
Therefore, a role in the release of fatty acids from the cell membrane for transport to 
Figure 4.2. ATGL plays a role in lipid droplet production in fed and starvation 
conditions. A) Confocal microscopy of nile red stained U87 and U87.2 cells incubated with 
DMSO or atglistatin for 8 hours in DMEM. Atglistatin treatment decreased LDQ. B) Confocal 
microscopy of nile red stained U87 and U87.2 cells incubated with DMSO or atglistatin for 8 
hours in HBSS. Atglistatin treatment in HBSS enhanced the observed decrease in LDQ. C) 
and D) Flow cytometry quantification of the decrease in LDQ observed with atglistatin 
treatment in DMEM (C) and HBSS (D) across all five nile red stained cell lines with the 
exception of T98G in HBSS. Data shown as mean ±SEM, representative of several 
independent experiments (T98G n=3; U343, U87.1 n=4; U87, U87.2 n=5), analysed with an 
unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
C 
D 
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lipid droplets was investigated using fluorescent labelled fatty acids and NMR 
HRMAS. Atglistatin treated cells had an increased accumulation of the C16 BODIPY 
saturated fatty acid in their membranes in both normoxia and hypoxia compared to 
DMSO controls (Figure 4.3.A.), implicating ATGL in the metabolism of saturated 
lipids at the cell membrane. No change in membrane staining was detected with the 
C11 BODIPY unsaturated fatty acid; however, observation of this effect is limited by 
the lower stain intensity of C11 BODIPY and the oxidation-induced colour change 
observed in hypoxia (Figure 4.3.B.). Notably, the concentration of unsaturated fatty 
acid groups in lipid droplets was decreased in atglistatin treated cells when assessed 
by HRMAS NMR (Figure 4.3.C.). This was accompanied by a slight increase in the 
concentration of saturated lipid groups (Figure 4.3.D). This trend suggests ATGL 
activity can alter the concentration of unsaturated lipids in lipid droplets. However, 
statistical significance was not achieved, most likely due to challenges in accurately 
quantifying the lipid peaks, which were at low levels. The proportion of saturated and 
unsaturated lipid groups in lipid droplets represented as a percentage of total lipid 
concentration indicated that unsaturated lipid groups decreased in lipid droplets 
following atglistatin treatment in the U87 cell line (Figure 4.3.E.). The decreased 
unsaturated lipid group concentration in the atglistatin treated samples was mainly 
due to the decreased CH2CH=CH concentration as shown in the example HRMAS 
spectra (Figure 4.3.F.). Taken together, this data further supports a role for ATGL in 
altering the concentration of unsaturated lipids in lipid droplets, potentially through 
the release of unsaturated fatty acids from the cell membrane. 
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Figure 4.3. ATGL may be important in the release of fatty acids, particularly 
unsaturated fatty acids, from the membrane for transport to lipid droplets. A) Confocal 
microscopy images of U87 cells incubated with C16 BODIPY prior to 30 minute atglistatin 
treatment in HBSS. Atglistatin treated cells had an increased accumulation of C16 BODIPY 
in their membranes in both oxygen concentrations compared to the DMSO-treated controls. 
B) Confocal microscopy images of U87 cells incubated with C11 BODIPY prior to 60 minute 
atglistatin treatment in HBSS. There was no visible difference in C11 BODIPY membrane 
accumulation with atglistatin treatment in normoxia. The lipid oxidation-induced colour 
change observed in hypoxic atglistatin-treated cells further hindered visualisation of 
potential lipid accumulation. C) and D) Total unsaturated (C) and saturated (D) mobile lipid 
groups in U87 and U87.2 cells treated with DMSO or atglistatin for 8 hours, as measured by 
HRMAS NMR. Atglistatin decreased the quantity of unsaturated fatty acid groups and 
increased the saturated fatty acid groups in both U87 and U87.2 cells. Due to high 
variability in HRMAS lipid peak assignment, significance could not be reached within this 
sample size (n=3); n.s. p>0.05. Lipid group concentrations were normalised to the total 
metabolite concentration of each sample. E) Representation of saturated and unsaturated 
lipid group concentrations as a proportion of total lipid group concentration in U87 and 
U87.2 cells. Atglistatin treatment decreased the proportion of total lipid which is unsaturated 
in the U87 cell line but not the U87.2 cell line. F) Representative HRMAS spectra 
demonstrating the decreased CH2CH=CH unsaturated lipid group peak size in the 
atglistatin (bottom) treated cells compared to DMSO (top) treated cells. Spectra includes 
only the 1.5 – 2.3 ppm region of the spectra. 
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4.2.3. De novo fatty acid synthesis may impact lipid droplet production; however, 
pharmacological inhibition may induce cell stress, confounding the effect. 
De novo synthesis of fatty acids can provide a dynamic source for the production of 
lipid droplets (136,164,165). The importance of de novo fatty acid synthesis in lipid 
droplet production was investigated with BPTES, a selective GLS1 inhibitor, and 
orlistat, a non-selective FASN inhibitor. Analysis of confocal microscopy images 
suggested that there was no effect from either drug on LDQ (Figure 4.4.A.), although 
changes were observed when assessed using flow cytometry (Figure 4.4.B.).  
BPTES treatment decreased the FITC signal intensity in the U87 cell line suggesting 
glutamine may be a pre-cursor for lipid droplet production. However, BPTES 
treatment increased the FITC signal intensity in the T98G cell line emphasising the 
effect of cellular stress upon LDQ. As this was only observed in one cell line, this 
suggests that the glutamine contribution to lipid droplets may be dependent on the 
genetic background. Orlistat treatment increased the FITC signal intensity observed 
in both cell lines. However, orlistat has previously been suggested to have off-target 
effects, suggesting that this effect could be induced through a non-FASN 
mechanism.  
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Figure 4.4. Pharmacological targeting of de novo fatty acid synthesis has an unclear 
impact on lipid droplets and may induce cell stress. A) Confocal microscopy images of 
nile red stained U87.1 cells incubated with DMSO, BPTES or orlistat for 4 hours in 
normoxia. BPTES and orlistat had no effect on LDQ. B) Flow cytometry quantification of the 
decreased LDQ following BPTES treatment in the U87 cell line. In contrast, orlistat treatment 
increased LDQ. Both drug treatments increased LDQ in the T98G cell line. Data shown as 
mean ±SEM, representative of several independent experiments (T98G, U87 n=3), analysed 
with an unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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4.2.4. Inhibition of cholesterol synthesis did not have a major effect on LDQ by 
confocal microscopy. 
Cholesterol is an important component of lipid droplets (255) and therefore the effect 
of simvastatin, a HMG-CoA reductase inhibitor, on LDQ was investigated. Analysis 
of confocal microscopy images indicated that inhibition of cholesterol synthesis may 
increase LDQ in the T98G, U87 and U87.1 cell lines, although this effect was very 
small and variable (Figure 4.5.). These data suggest that there is not a major role for 
cholesterol synthesis in lipid droplet metabolism in our system. Therefore, this was 
not further investigated with flow cytometry. 
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Figure 4.5. Cholesterol synthesis does not have a major role in lipid droplet 
metabolism. Confocal microscopy images of nile red stained T98G, U87, U87.1 and U87.2 
cells incubated with DMSO or simvastatin for 24 hours in normoxia. Simvastatin treatment 
increased LDQ in the T98G, U87 and U87.1 cell lines. There is no clear effect in the U87.2 
cell line. 
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4.2.5. Lipid droplets are broken down by lipid droplet-specific autophagy. 
Autophagy is an important mechanism by which cellular components, including lipid 
droplets, can be broken down (178,179). LDQ was assessed following autophagy 
inhibition across 5 cell lines using confocal microscopy and flow cytometry. An 
increase in LDQ was observed through analysis of confocal images of cells treated 
with chloroquine, a late stage autophagy inhibitor (Figure 4.6.A.). This was supported 
by flow cytometry wherein chloroquine treatment increased the FITC signal intensity, 
representing increased LDQ, in all 5 cell lines (Figure 4.6.B.). This suggests that 
autophagy inhibition prevents lipid droplet breakdown and causes lipid droplet 
accumulation. An early stage autophagy inhibitor, 3-methyladenine (3-MA), also 
increased LDQ, observed through both confocal microscopy and flow cytometry 
(Figures 4.6.C. and 4.6.D.). Moreover, 3-MA increased the accumulation of C16 
BODIPY within lipid droplets in the T98G and U87 cell lines, as assessed through 
confocal microscopy, further implicating autophagy in lipid droplet breakdown (Figure 
4.7.A.). The role of off-target drug effects and cell-stress induced lipid droplet 
alterations were tested using targeted siRNA knockdown of the vital autophagy 
protein Atg5. siAtg5 increased LDQ compared to the non-targeted control in both the 
U87 and U87.2 cell lines confirming that autophagy inhibition is responsible for the 
accumulation of lipid droplets (Figure 4.7.B.). Knockdown of the Atg5 protein was 
confirmed via western blot (Figure 4.7.C.), further analysed with densitometry (Figure 
4.7.D.). This indicated 48 hours as the optimal incubation period for protein 
knockdown.  
 
   
142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A 
B 
C 
DMSO Chloroquine 
U87 
U87.2 
   
143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Autophagy inhibition prevents lipid droplet breakdown and causes 
accumulation. A) Confocal microscopy of nile red stained U87 and U87.2 cells incubated 
with DMSO or chloroquine for 8 hours in DMEM. Chloroquine treatment increased LDQ. B) 
and C) Flow cytometry quantification of the increased LDQ observed with chloroquine 
treatment in DMEM (B) and 3-MA treatment in HBSS (C) across all five nile red stained cell 
lines. Data shown as mean ±SEM, representative of several independent experiments 
(U343 n=3; U87.2 n=4; T98G, U87, U87.1 n=5), analysed with an unpaired t-test; *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. D) Confocal microscopy of nile red stained U87 and 
U87.2 cells incubated with DMSO or 3-MA for 8 hours in HBSS. 3-MA treatment in HBSS 
increased LDQ, supporting Figure 4.6.C. 
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Figure 4.7. Autophagy is important in the metabolic regulation of lipid droplets. A) 
Confocal microscopy of T98G and U87 cells incubated with C16 BODIPY prior to 8 hour 
treatment with 3-MA in either DMEM or HBSS. 3-MA treatment increased LDQ and the 
accumulation of C16 BODIPY within them. B) Flow cytometry of nile red stained U87 and 
U87.2 cell lines treated with siN.T. and siAtg5 for 48 hours. siAtg5 increased LDQ in both 
cell lines compared to the non-targeting control. Data shown as mean ±SEM, representative 
of several independent experiments (U87 n=2; U87.2 n=4), analysed with an unpaired t-test; 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. C) Protein knockdown was confirmed with 
western blot. U87 and U87.2 cells treated with siN.T. or siAtg5 for 24, 48 and 72 hours. D) 
Densitometry analysis of western blot (C) confirmed knockdown (%) of Atg5 protein. 
Normalised to siN.T. control. Raw densitometry data in Appendix 7.12. 
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4.2.6. LDQ is increased in hypoxia and in response to HIF1α stabilisation. 
Hypoxia induces global changes in cellular metabolism (256) and is known to 
increase lipid droplet accumulation (123). Indeed, LDQ was increased in hypoxic 
conditions in the T98G, U87, U87.1 and U87.2 cell lines, as observed by confocal 
microscopy (Figure 4.8.A.). This was supported by a positive shift in the FITC signal 
intensity of cells incubated at 0.3% O2 as measured by flow cytometry in all 5 cell 
lines (Figure 4.8.B.). Hypoxic incubation also increased the total lipid concentration 
detected by HRMAS NMR in the U87 and U87.2 cell lines (Figure 4.8.C.). 
Low oxygen concentrations result in the stabilisation of the HIF protein which is 
responsible for many of the downstream effects of hypoxia (256). DMOG, an alpha-
ketoglutarate-like inhibitor of the prolyl hydroxylase enzymes, stabilises HIF1α 
regardless of oxygen concentration, allowing the HIF1α-specific effects of hypoxia to 
be mimicked in normoxic conditions (257). LDQ in the U87 and U87.2 cell lines was 
observed to be increased in DMOG treated cells in normoxic and hypoxic conditions 
compared to DMSO controls (Figure 4.9.A.). Flow cytometry supported the evidence 
suggesting that DMOG induced an increase in LDQ in normoxic and hypoxic 
conditions (Figure 4.9.B.). Indeed, normoxic DMOG treatment increased the FITC 
signal intensity more than hypoxia alone, a result likely attributable to the increased 
stabilisation of HIF1α by DMOG (257). This is supported by other studies showing 
that the hypoxia induces an increased LDQ through HIF1α (123). 
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Figure 4.8. Hypoxia increased LDQ. A) Confocal microscopy of nile red stained T98G, 
U87, U87.1 and U87.2 cells incubated in 21% or 0.3% O2 for 16 hours. Hypoxia increased 
LDQ within the four cell lines. B) Flow cytometric quantification of the increased LDQ 
observed with hypoxic incubation across all five nile red stained cell lines. Data shown as 
mean ±SEM, representative of several independent experiments (U87.2 n=4; T98G, U87, 
U87.1 n=5; U343 n=6), analysed with an unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. C) Relative total lipid concentration in U87 and U87.2 cells incubated in 21% 
or 0.3% O2 for 24 hours as measured by HRMAS NMR. The relative total lipid concentration 
was increased in hypoxia in both cell lines. Data shown as mean ±SEM, representative of 
three independent experiments analysed with an unpaired t-test; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. Total lipid concentrations were normalised to the total metabolite 
concentration of each sample. 
   
149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
21% O
2
 
DMSO 
0.3% 
O  
DMOG 
U87 
DMSO DMOG 
U87.2 
21% O
2
 
0.3% 
O  
   
150 
 
 
 
 
 
 
 
 
 
B 
U87 U87.2 
Figure 4.9. HIF-1a stabilisation can increase LDQ at 21% and 0.3% O2. A) Confocal 
microscopy of nile red stained U87 and U87.2 cells incubated in 21% or 0.3% O2 for 16 
hours with DMSO or DMOG. DMOG treatment increased LDQ further than hypoxia alone in 
both cell lines. B) Flow cytometric quantification of the DMOG-induced increase in LDQ 
observed in both the U87 and U87.2 cell lines. Data shown as mean ±SEM, representative of 
several independent experiments (n=5), analysed with an unpaired t-test; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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4.2.7. The uptake of exogenous serum lipids is important in lipid droplet production in 
hypoxia as well as normoxia. 
The exogenous lipid pool was an important factor in lipid droplet production in 
normoxia and was therefore investigated further in hypoxia. Confocal microscopy 
images of cells grown in de-lipidated serum media in hypoxia indicated that removal 
of the exogenous lipid droplet pool decreased LDQ (Figure 4.10.A). Concurrently 
growth in de-lipidated serum in hypoxia decreased the FITC signal intensity in the 
U343 and U87 cell lines, as assessed by flow cytometry (Figure 4.10.B.). This further 
supports the use of the exogenous lipid pool to produce lipid droplets. The T98G, 
U87.1 and U87.2 cell lines did not reach significance, but all three cell lines 
demonstrate a trend toward decreased LDQ when grown in de-lipidated serum 
media. This suggests that compensation from other mechanisms may also be 
important in hypoxic lipid droplet production in these cell lines. Moreover, hypoxia 
increased the uptake of C16 BODIPY in the T98G and U87 cell lines whilst C11 
BODIPY uptake was increased only slightly (Figure 4.11.A. and 4.11.B.). The 
increased uptake of fatty acids such as C16 and C11 could contribute to the 
increased LDQ observed in hypoxia. 
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Figure 4.10. Uptake of exogenous serum lipids is important in lipid droplet production 
in hypoxia. A) Confocal microscopy of nile red stained T98G and U87.1 cells incubated in 
21% or 0.3% O2 for 72 hours with DMEM or de-lipidated serum media. Incubation in de-
lipidated serum media decreased the LDQ of both cell lines in normoxia and hypoxia. 
Normoxic images are taken from Figure 4.1.A. B) Flow cytometric quantification of the 
decrease in LDQ observed with incubation in de-lipidated serum in hypoxia across all five 
nile red stained cell lines. Due to large error bars the T98G, U87.1 and U87.2 cell lines did 
not reach significance. Data shown as mean ±SEM, representative of several independent 
experiments (U343, U87, U87.2 n=3; T98G, U87.1 n=4), analysed with an unpaired t-test; 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 4.11. Hypoxia increases the uptake of exogenous serum lipids. A) Confocal 
microscopy of T98G and U87 cells incubated with C16 BODIPY after 16 hours incubation in 
21% or 0.3% O2. The uptake of C16 BODIPY was increased in both cell lines at 0.3% O2. B) 
Confocal microscopy of U87 cells incubated with C11 BODIPY after 16 hours incubation in 
21% or 0.3% O2. The uptake of C11 BODIPY was increased to a lesser extent in hypoxic 
conditions. 
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4.2.8. ATGL activity affects LDQ in hypoxia in a cell line-specific manner. 
Our data suggests that ATGL inhibition with atglistatin decreases LDQ in normoxia, 
potentially through preventing the release of fatty acids from cell membranes. In 
hypoxia, a decrease in LDQ following atglistatin treatment was observed with 
confocal microscopy in the U87.2 cell line (Figure 4.12.A.). In contrast, no effect on 
LDQ following atglistatin treatment was observed in the U87 cell line. In support of 
this, flow cytometry indicated cell line-specific differences in LDQ following treatment 
of hypoxic cells with atglistatin (Figure 4.12.B.). There was no significant difference 
in the FITC signal intensity following atglistatin treatment in the T98G, U87 and 
U87.1 cell lines and a small decrease in the FITC signal intensity in the U343 cell 
line. However, LDQ was considerably decreased in the U87.2 cell line indicating a 
key difference in the metabolic regulation of hypoxic lipid droplet metabolism 
between the cell lines. Moreover, cell specific differences may reflect the natural 
heterogeneity of GBM tumours. 
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Figure 4.12. ATGL has a cell line dependent role in lipid droplet production in 
hypoxia. A) Confocal microscopy of nile red stained U87 and U87.2 cells treated with 
DMSO or atglistatin at 21% or 0.3% O2. Atglistatin treatment decreased LDQ in both cell 
lines in normoxia but there was no clear change in hypoxia. Normoxic images are taken 
from Figure 4.2.A. B) Flow cytometric quantification of the effect of atglistatin treatment in 
hypoxia across all five nile red stained cell lines. Atglistatin did not significantly affect LDQ in 
the T98G, U87 and U87.1 cell lines. There was a small decrease in LDQ in the U343 cell 
line and a much larger decrease observed in the U87.2 cell line. Data shown as mean 
±SEM, representative of several independent experiments (U87.1, U87.2 n=3; U87 n=4; 
T98G, U343 n=5), analysed with an unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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4.2.9. The role of de novo fatty acid synthesis in lipid droplet production in hypoxia 
requires further exploration. 
Our data suggested that de novo fatty acid synthesis may impact lipid droplet 
production in normoxia, although the induction of a cell stress response confounded 
the results. Following treatment with BPTES and orlistat in hypoxia no change in 
LDQ was observed through analysis of confocal microscopy images (Figure 4.13.A.). 
In addition, BPTES did not significantly alter the FITC signal intensity of the T98G 
and U87 cell lines (Figure 4.13.B.). As observed in normoxia, orlistat increased LDQ 
in the T98G and U87 cell lines, as assessed by flow cytometry. This is likely 
attributable to the induction of cell stress by a non-FASN orlistat effect. Therefore, 
the importance of de novo fatty acid synthesis in lipid droplet production requires 
further investigation in hypoxia as well as normoxia. 
The role of cholesterol synthesis was not further investigated in hypoxia due to the 
minor role in lipid droplet metabolism observed in normoxia. 
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Figure 4.13. The role of de novo fatty acid synthesis in lipid droplet production in 
hypoxia requires further investigation. A) Confocal microscopy of nile red stained U87.1 
cells treated with DMSO, BPTES or orlistat at 21% or 0.3% O2. There was no clear change 
in LDQ in hypoxia with either treatment. Hypoxic cells treated with orlistat contain highly 
stained lipid structures which may be membrane blebs. Normoxic images are taken from 
Figure 4.4.A. B) Flow cytometric quantification of the effect of BPTES and orlistat treatment 
in hypoxia in the nile red stained T98G and U87 cell lines. BPTES did not significantly 
decrease LDQ. Orlistat significantly increased LDQ in the U87 cell line. Data shown as 
mean ±SEM, representative of several independent experiments (T98G BPTES n=2; T98G 
Orlistat, U87 BPTES and Orlistat n=3), analysed with an unpaired t-test; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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4.2.10. The effect of autophagy inhibition on LDQ in hypoxia is cell line dependent. 
In normoxia, we observed that lipid droplets were broken down through autophagy 
and therefore the effect of autophagy inhibition in hypoxia was investigated using 
confocal microscopy and flow cytometry. Analysis of confocal microscopy images did 
not suggest alterations in LDQ following chloroquine treatment in hypoxia in the U87 
and U87.2 cell lines (Figure 4.14.A.). In contrast, flow cytometry indicated that 
chloroquine has cell line-specific effects on LDQ (Figure 4.14.B.). The FITC signal 
intensity was increased in chloroquine treated cells in the T98G and U87 cell lines 
indicating decreased lipid droplet breakdown and increased accumulation. In 
contrast, chloroquine decreased the FITC signal intensity of the U343, U87.1 and 
U87.2 cell lines suggesting that autophagy inhibition paradoxically decreases lipid 
droplet accumulation in these cell lines. 
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Figure 4.14. Autophagy impacts lipid droplet breakdown in a cell line dependent 
manner. A) Confocal microscopy of nile red stained U87 and U87.2 cells treated with 
DMSO or chloroquine at 21% or 0.3% O2. Chloroquine treatment increased LDQ in the U87 
cell line; however, the effect is not clear in the U87.2 cell line. Normoxic images are taken 
from Figure 4.6.A. B) Flow cytometric quantification of the effect of chloroquine treatment in 
hypoxia across all five nile red stained cell lines. Chloroquine increased LDQ in the T98G 
and U87 cell lines; however, it decreased LDQ in the U343, U87.1 and U87.2 cell lines. 
Data shown as mean ±SEM, representative of several independent experiments (U87, 
U87.1, U87.2 n=3; T98G n=5; U343 n=6), analysed with an unpaired t-test; *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
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4.2.11. Lipid droplets are in a state of flux subject to metabolic demand. 
Starvation places a metabolic demand on the cell which can be sustained through 
lipid catabolism. HBSS was therefore used to mimic starvation conditions and its 
impact on fatty acid uptake and lipid droplets investigated using confocal 
microscopy. Incubation in HBSS increased the uptake and incorporation of C16 
BODIPY into cell membranes and lipid droplets in the T98G and U87 cell lines 
(Figure 4.15.A.). This was observed in both normoxia and hypoxia. In conjunction 
with Figure 4.9, hypoxia increased the uptake of C16 BODIPY in the T98G and U87 
cell lines in both DMEM and HBSS. Incubation in HBSS also increased the uptake of 
C11 BODIPY in the U87 cell line (Figure 4.15.B.). The intensity of fluorescent 
labelled fatty acid staining was increased in some cases to the extent that images in 
high uptake conditions are over exposed. 
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Figure 4.15. Starvation increases exogenous serum lipid uptake. A) Confocal 
microscopy images of T98G and U87 cells incubated with C16 BODIPY in DMEM or HBSS 
at 21% and 0.3% O2. HBSS increased the uptake of C16 BODIPY compared to DMEM at 
21% and 0.3% O2 in both cell lines. Hypoxia also increased uptake of C16 BODIPY in 
DMEM and HBSS in both cell lines as previously shown in Figure 4.9. B) Confocal 
microscopy images of U87 cells incubated with C11 BODIPY in DMEM or HBSS at 21% and 
0.3% O2. HBSS increased the uptake of C11 BODIPY compared to DMEM in both 21% and 
0.3% O2. 
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As lipid uptake is altered in starvation conditions we hypothesised that the other 
mechanisms governing lipid droplet metabolism would also be altered. Atglistatin 
treatment in HBSS further decreased the FITC signal intensity of the U87 and U87.2 
cell lines, but had no effect in the U343 and U87.1 cell lines (Figure 4.16.A.). In 
contrast, atglistatin treatment in HBSS increased the FITC signal intensity in the 
T98G cell line suggesting cell line-specific differences in the importance of ATGL in 
lipid droplet production under starvation conditions. Co-treatment with atglistatin and 
the autophagy inhibitor, 3-MA, in HBSS decreased the FITC signal intensity 
compared to the DMSO controls in the U343, U87 and U87.2 cell lines (Figure 
4.16.B.). No significant differences were observed in the FITC signal intensity of the 
T98G and U87.1 cell lines. Interestingly, the FITC signal intensity following atglistatin 
and 3-MA co-treatment was decreased compared to 3-MA treatment alone in all 5 
cell lines (Figure 4.16.C.). The extent of the decrease in LDQ varied between cell 
lines and defined whether LDQ was decreased compared to the DMSO control in 
Figure 4.16.B. This is further indication of cell line-specific differences in response to 
inhibition of lipid droplet metabolism pathways. 
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4.2.12. Lipid droplets are broken down for phospholipid membrane synthesis and 
fatty acid β-oxidation. 
Two major lipid utilising pathways are energy production through mitochondrial β-
oxidation and phospholipid synthesis for cell membranes (200,258). Confocal 
microscopy was used to investigate the fate of fatty acids originating from lipid 
droplets. In normoxic T98G and U87 cells under starvation conditions, C16 BODIPY 
was observed to accumulate in peri-nuclear regions that may be consistent with 
mitochondrial localisation (Figure 4.17.A.). This was not observed in hypoxia where 
C16 BODIPY was observed to instead accumulate in lipid droplets. Mitochondrial β-
oxidation is decreased in hypoxia (259) and it is unsurprising that saturated fatty 
Figure 4.16. Lipid droplets are in constant flux which is increased in starvation. A) 
Flow cytometry comparing the effect of atglistatin treatment in DMEM and HBSS in 
normoxia across all five nile red stained cell lines. The atglistatin treated FITC signal 
intensity in DMEM or HBSS was normalised to the DMSO control in DMEM or HBSS 
respectively. The resulting normalised population shifts in DMEM and HBSS induced by 
atglistatin treatment were plotted against each other. The atglistatin-induced decrease in 
LDQ was enhanced in HBSS in the U87 and U87.2 cell lines. This effect was not 
significant in the U343 and U87.1 cell lines and was reversed in the T98G cell line. Data 
shown as mean ±SEM, representative of several independent experiments (T98G n=3; 
U343, U87, U87.1, U87.2 n=4), analysed with an unpaired t-test; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. B) Flow cytometry comparing the effect of atglistatin and 3-MA 
co-treatment with DMSO controls in normoxia across all five nile red stained cell lines. 
Atglistatin and 3-MA co-treatment decreased LDQ compared to the DMSO control in the 
U343, U87 and U87.2 cell lines. LDQ was unchanged in the U87.1 cell line and increased 
in the T98G cell line. The sample FITC signal intensity shift was normalised to the DMSO 
controls. Data shown as mean ±SEM, representative of several independent experiments 
(U87, U87.2 n=3; U343, U87.1 n=4; T98G n=5), analysed with an unpaired t-test; *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. C) Flow cytometry comparing the effect of 3-MA with 
3-MA and atglistatin co-treatment in normoxia across all five nile red stained cell lines. 3-
MA and atglistatin co-treatment decreased LDQ compared to the 3-MA treatment alone in 
all five cell lines. The 3-MA and atglistatin co-treatment sample population shift, according 
to FITC signal intensity, was normalised to each 3-MA treatment population. Data shown 
as mean ±SEM, representative of several independent experiments (U343 n=4; T98G, 
U87, U87.1 U87.2 n=5), analysed with an unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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acids are targeted to this pathway in normoxia only. C11 BODIPY was not observed 
to accumulate in this mitochondrial region in the U87 cell line suggesting that the 
C11 unsaturated fatty acid is primarily incorporated into cell membranes and lipid 
droplets. Inhibition of autophagy and lipid droplet breakdown with 3-MA increased 
the localisation of C16 BODIPY to lipid droplets and decreased its localisation in cell 
membranes in both normoxia and hypoxia (Figure 4.17.B.). This suggests that C16 
BODIPY accumulates in lipid droplets prior to breakdown, conversion into 
phospholipids and subsequent incorporation in cell membranes. Inhibition of lipid 
droplet breakdown therefore would interrupt this pathway and prevent the integration 
of C16 BODIPY into the cell membrane. 
 
4.2.13. Incubation in hypoxia decreases proliferation 
Altered lipid droplet metabolism in hypoxia decreases β-oxidation energy production 
and membrane synthesis, impairing proliferation, although other mechanisms may 
be involved. Proliferation was assessed using cell growth curves across 144 hours. 
The proliferation of the T98G, U87, U87.1 and U87.2 cell lines was decreased upon 
incubation in hypoxia (Figure 4.18.).  
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Figure 4.17. Lipid droplet lipids are used for β-oxidation and membrane synthesis. A) 
Confocal microscopy images of T98G and U87 cells incubated with C16 BODIPY and U87 
cells incubated with C11 BODIPY in HBSS in 21% and 0.3% O2. In normoxia C16 BODIPY 
accumulated in a peri-nuclear region that may be consistent with mitochondrial localisation 
whereas in hypoxia C16 BODIPY was localised to lipid droplets. C11 BODIPY did not 
accumulate in this region at 21% or 0.3% O2. B) Confocal microscopy images of U87 cells 
incubated with C16 BODIPY prior to treatment with DMSO or 3-MA in DMEM at 21% and 
0.3% O2. 3-MA treatment increased the localisation of C16 BODIPY in lipid droplets and 
decreased localisation in cell membranes. 
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Figure 4.18. Hypoxia decreases proliferation. Cell count growth curves of T98G, U87, 
U87.1 and U87.2 cell lines at 21% and 0.3% O2. Incubation in 0.3% O2 significantly 
decreased the proliferation of all four cell lines compared to normoxia.  
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4.2.14 Lipid droplet saturation is altered in hypoxia. 
The balance of saturated and unsaturated lipids within a lipid droplet can change in 
response to cellular processes and environmental pressures; however, the effect of 
hypoxia upon lipid droplet lipid saturation is unknown. Hypoxic incubation increased 
the relative concentration of both the total saturated and total unsaturated lipid 
groups detected by HRMAS NMR (Figure 4.19.A.). Importantly, the proportion of 
total unsaturated lipid was increased in hypoxic cells in both the U87 and U87.2 cell 
lines (Figure 4.19.B) suggesting a greater localisation of unsaturated lipids to lipid 
droplets in hypoxia. The hypoxia-induced increased saturated and unsaturated lipid 
peaks are shown in the example HRMAS spectra (Figure 4.19.C.). This change in 
saturation state may reflect a response to hypoxia-induced stress. 
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Figure 4.19. Hypoxia increases the amount of unsaturated lipid present in lipid 
droplets. A) Total unsaturated and saturated mobile lipid groups in U87 and U87.2 cells 
incubated at 21% or 0.3% O2 for 24 hours, as measured by HRMAS NMR. Hypoxia 
increased the relative total unsaturated and total saturated lipid groups in both the U87 and 
U87.2 cell lines. Data shown as mean ±SEM, representative of several independent 
experiments (n=3); *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Unsaturated and saturated 
lipid group concentrations were normalised to the total metabolite concentration of each 
sample. B) Representation of saturated and unsaturated lipid group concentrations as a 
proportion of total lipid group concentration in U87 and U87.2 cells. Hypoxia increased the 
proportion of total lipid which is unsaturated in both cell lines. C) Representative HRMAS 
spectra demonstrating the increased lipid concentration in hypoxia (bottom) compared to 
normoxia (top). The lipid groups are noted on the spectra (for nomenclature see Table 2.5). 
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4.2.15. ATGL activity protects unsaturated fatty acids from hypoxia-induced lipid 
oxidation. 
C11 BODIPY undergoes a colour change from red to green upon oxidisation of its 
unsaturated carbon chain which can be caused by cellular oxidative stress. Confocal 
microscopy was used to observe the effect of atglistatin treatment on normoxic and 
hypoxic cells incubated with C11 BODIPY (Figure 4.20.). Hypoxia slightly increased 
the green C11 BODIPY stain intensity compared to the DMSO control. Hypoxia is 
known to increase ROS generation (225) and therefore increased oxidative damage 
is unsurprising. Interestingly, atglistatin treatment in hypoxia clearly increased the 
green C11 BODIPY stain intensity, representing a large increase in unsaturated fatty 
acid oxidative damage. Inhibition of ATGL activity could decrease the transport of 
unsaturated fatty acids to lipid droplets, preventing protective storage. Membrane 
unsaturated lipids are vulnerable to lipid oxidation and therefore increased damage 
would be observed. In contrast, atglistatin treatment in normoxia decreased the 
green C11 BODIPY signal intensity, indicating a different response to ATGL 
inhibition in the absence of oxidative stress, such as the upregulation of alternative 
anti-oxidant pathways. 
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Figure 4.20. ATGL function is important to protect against ROS-induced lipid 
oxidation in hypoxia. Confocal microscopy images of U87 cells incubated with C11 
BODIPY prior to 60 minute DMSO or atglistatin treatment. Atglistatin treatment increased 
the oxidation of C11 BODIPY in hypoxia resulting in a colour change of red to green, 
representative of increased lipid oxidation damage. There was a corresponding decrease in 
the non-oxidised C11 BODIPY in this sample. Atglistatin treatment decreased lipid oxidation 
damage in normoxia. There was no change in the non-oxidised C11 BODIPY in either 
normoxic sample or the hypoxic DMSO-treated sample. There was increased C11 BODIPY 
located in lipid droplets in the hypoxic DMSO-treated cells. 
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4.2.16. ATGL activity protects unsaturated fatty acids from ROS-induced lipid 
oxidation by H2O2 in normoxia. 
The importance of ATGL in protecting unsaturated fatty acids from H2O2, a potent 
ROS, was investigated with confocal microscopy. Cells were incubated with C11 
BODIPY prior to atglistatin, H2O2 or cisplatin treatment (Figure 4.21. and 4.22.). As 
seen in Figure 4.20, atglistatin treatment increased the green C11 BODIPY stain 
intensity in hypoxia reflecting increased oxidative damage. H2O2 increased the green 
C11 BODIPY stain intensity in normoxia and hypoxia, representing increased 
oxidation of the C11 unsaturated fatty acid. Interestingly, atglistatin and H2O2 co-
treatment in normoxia further increased the green C11 BODIPY stain intensity 
suggesting that ATGL activity can protect unsaturated fatty acids against ROS 
generated by H2O2 treatment as well as hypoxia. Indeed, in hypoxia, the combination 
of H2O2 and hypoxia-induced ROS further increased lipid oxidation upon ATGL 
inhibition, represented by increased green C11 BODIPY stain intensity, reflecting 
increased oxidative damage. 
In addition to damaging DNA the chemotherapeutic agent cisplatin is known to 
increase ROS generation (260). However, green C11 BODIPY stain intensity was 
decreased by cisplatin treatment alone and remained unchanged with atglistatin co-
treatment. The numerous cytotoxic effects of cisplatin are a probable confounding 
variable in this result and the effect of cisplatin and atglistatin treatment on C11 
BODIPY oxidation was not investigated in hypoxia. 
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Figure 4.21. ATGL function is important to protect against H2O2 ROS-induced lipid 
oxidation in normoxia. Confocal microscopy images of U87 cells incubated with C11 
BODIPY prior to treatment with DMSO, atglistatin, H2O2, cisplatin, atglistatin with H2O2 or 
atglistatin with cisplatin in normoxia for 60 minutes. C11 BODIPY lipid oxidation was 
increased by H2O2 treatment and further increased by co-treatment with atglistatin and 
H2O2. Cisplatin and atglistatin co-treatment had no effect on C11 BODIPY lipid oxidation 
whereas cisplatin treatment alone decreased lipid oxidation.  
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Figure 4.22. ATGL function is important to protect against H2O2 ROS-induced lipid 
oxidation in hypoxia. Confocal microscopy images of U87 cells incubated with C11 
BODIPY prior to treatment with DMSO, atglistatin, H2O2 or atglistatin with H2O2 in hypoxia for 
60 minutes. Atglistatin and H2O2 increased C11 BODIPY lipid oxidation compared to the 
DMSO-treated control. Co-treatment of atglistatin with H2O2 further increased C11 BODIPY 
lipid oxidation. 
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4.2.17. Genetic drift may be responsible for cell line specific differences 
RNAseq analysis was performed upon the U87 clonal mutant cell lines during their 
characterisation. Gene abundance in key metabolic and cancer pathways was 
significantly altered between the U87.1 cell line and the other cell lines (Figure 4.23. 
and Table 4.1.), suggesting that this cell line has undergone significant genetic drift. 
In contrast, the U87 and U87.2 cell lines remained similar according to gene 
abundance. Nevertheless, these cell lines show clear differences throughout this 
chapter, most notably in hypoxia (Figures 4.12 and 4.14), suggesting these cell lines 
may differ through a key mutation. Indeed, this data suggests the genetic differences 
between the clonal mutants may be responsible for cell line-specific effects 
throughout this chapter. 
 
 
Figure 4.23. The U87.1 cell line shows clear separation from the remaining two cell 
lines which show distinct overlap. Representative visualisation of Table 4.1. Genes in 
key cancer and metabolic pathways have significant differences in gene abundance 
between the U87.1 and the other two cell lines. Conversely the U87 and U87.2 cell lines 
have similar gene abundance profiles. 
U87.2 U87 
U87.1 
206 Metabolic pathways 
90 Cancer pathways 
210 Metabolic pathways 
90 Cancer pathways 
13 Cancer pathways 
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Cell line 
comparison 
Pathway 
name 
Number of 
alterations 
U87 and 
U87.1 
Metabolic 
pathways 
206 
Pathways 
in cancer 
90 
U87 and 
U87.2 
Pathways 
in cancer 
13 
U87.1 and 
U87.2 
Metabolic 
pathways 
210 
Pathways 
in cancer 
90 
Table 4.1. Alterations in key pathways 
define clonal mutant cell lines. The U87.1 
cell line clearly separates from the U87 and 
U87.2 cell lines. Table extracted from 
Appendix 7.11. 
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4.3. Discussion 
4.3.1. Introduction 
The pathways involved in lipid droplet metabolism have been partially characterised 
in a number of tissues and several cancers (248). Interestingly, whilst the 
involvement of each lipid droplet metabolic pathway is cell line-specific, several 
pathways including exogenous lipid uptake (123,152), de novo fatty acid synthesis 
(136,164,165), autophagy (174,179) and cytoplasmic lipases (174,196) are 
frequently observed to influence lipid droplet metabolism. However, despite 
characterisation in many cancers, lipid droplet metabolism remains poorly explored 
in gliomas. We therefore investigated and established the involvement of these 
metabolic pathways in GBM cell lines in both normoxic and hypoxic conditions. 
 
4.3.2. The U87 clonal mutant cell lines 
Animal models provide the most biologically relevant non-clinical model as implanted 
tumours will be exposed to many of the factors encountered in a human host such as 
the presence of other cell types, dietary nutrient supply and 3D structure. However, 
due to the high cost and ethical implications associated with these models, the 
majority of investigations are performed initially in cell lines. Cell lines provide a 
cheap, fast growing model to rapidly test perturbed cellular processes in pathological 
states; however, they are further removed from the clinical setting, increasing the 
chance of in vitro artefacts. Importantly, the intrinsic genetic instability of cancer cell 
lines ensures they are affected by genetic drift, wherein mutations accumulate over 
countless replication events, creating clonal mutant cell lines with an altered genetic 
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profile from the original line. These mutations are typically silent but can affect key 
cellular processes and identical cell lines can differ genetically between labs. 
Nevertheless, through genetic characterisation of serendipitous alterations in 
relevant genes, clonal mutant cell lines can become natural investigative resources 
and provide further insight into the mechanistic ‘wiring’ of near identical cells.  
Through STR profile analysis and RNA sequencing we sought to investigate this 
phenomenon in the U87, U87.1 and U87.2 cell lines. STR profile analysis can 
characterise a genetic ‘barcode’ individual to each cell line, found to be identical 
between the three cell lines (Appendix 7.10). Therefore, the three cell lines derive 
from the same original parent line; the U87 adult GBM cell line available from the 
ATCC. RNA sequencing revealed a high number of significantly altered gene 
abundance values between the U87.1 and the two other cell lines including genes 
impacting on many important metabolic pathways (Appendix 7.11.). This indicates 
increased genetic drift and an earlier divergence from the parent cell line (Figure 
4.24.). In contrast, the U87 and U87.2 cell lines have far fewer significant alterations 
in gene abundance indicating a more similar genetic profile. However, the 
contrasting response of these two cell lines to pharmacological manipulation, most 
notably in the case of atglistatin treatment in hypoxia (Figure 4.12.B.), rules out 
identical cell lines. Therefore, we propose that these cell lines are separated by 
currently unknown epigenetic alterations or a key metabolic mutation which may be 
revealed through further analysis of the RNA sequencing data. Despite being limited 
to gene abundance, the RNA sequencing data provides strong evidence that the 
U87, U87.1 and U87.2 cell lines are clonal mutants which may be vital tools in further 
understanding lipid droplet metabolism. 
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The creation of these clonal mutant cell lines serves to further highlight the role 
genetic drift can play in altering the biological activity of a cell line. Whilst measures 
exist to minimise the impact of genetic drift, cell lines originating from different labs 
may still contain influential genetic alterations. Therefore it remains essential to 
characterise cell lines prior to publication and to support this data with similar cell 
lines and more physiologically relevant models.  
This data also provides a strong explanation for the cell line-specific differences 
observed throughout this chapter. Importantly, the significant difference in response 
to atglistatin and chloroquine treatment in hypoxia between the U87 and U87.2 cell 
lines (Figures 4.12 and 4.14.), despite similar gene abundance values, suggests 
mutational status may be an important factor in determining lipid droplet metabolic 
pathway activity. In this case, the otherwise similar genetic profile of these clonal 
mutants may highlight the genes governing hypoxic lipid droplet metabolism. Future 
studies should therefore aim to utilise these cell lines to characterise critical 
regulatory genes, through associating altered responses to pharmaceutical 
manipulation of lipid droplet metabolic pathways with alterations in gene expression 
and mutation.  Elucidating this genetic control could have far reaching implications in 
Figure 4.24. The proposed differentiation pathway of the U87 clonal mutant cell lines 
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understanding patient-specific biology as well as identifying target groups for any 
resulting lipid droplet-related therapeutic strategies. Indeed, considering the 
importance of hypoxia in lipid droplet metabolism and its prevalence in GBMs, this 
may prove vital to the full manipulation of lipid droplet metabolism. 
Finally, through similar characterisation of the remaining 2 cell lines, a genetic profile 
data set could be created, allowing the investigation of cell-line specific differences in 
future studies of these 5 cell lines. As discussed for hypoxic lipid droplet metabolism 
in this study, the rapid identification of potential regulatory genes, followed-up with 
targeted gene silencing could prove a powerful investigative tool for future 
researchers. 
 
4.3.3. Lipid droplet production in normoxia – Exogenous serum uptake 
Activated charcoal is long established as a methodology for removing lipids from 
serum and other biological samples (261,262). Lipids are adsorped onto the porous 
surface of the charcoal which can then be filtered out. This produces lipid-free serum 
whilst preserving the many other important components of serum such as growth 
factors. Moreover, this step is performed prior to media supplementation preserving 
the media contents. 
It has been reported in many cell types that lipid droplet production may rely upon 
the uptake of exogenous serum lipids (123,150,152). Indeed, in chapter 3 we 
observed a correlation between gene expression of the exogenous lipid uptake 
transporter CD36 and the lipid droplet-associated proteins adipophilin and TIP47 
suggesting an important association between lipid droplets and exogenous lipid 
uptake. Interestingly, Bensaad et al. (123) reported that growth in de-lipidated serum 
   
186 
 
in normoxia resulted in increased accumulation of lipid droplets in the U87 cell line. 
However, in contrast to our experiment, they compared cells grown in media 
supplemented with 10% standard or 1% de-lipidated serum. The decreased 
supplementation will change the amount of metabolites and growth factors to which 
the cells are exposed, a factor known to alter LDQ (263,264). By maintaining 
supplementation at 10% we sought to avoid the introduction of this variable and 
potential cell stress responses. Using confocal microscopy and flow cytometry we 
demonstrated that, in the absence of the exogenous lipid pool, all 5 cell lines have a 
lower LDQ (Figure 4.1.). Moreover, C16 BODIPY, an exogenously supplied fatty 
acid, was taken up and incorporated into lipid droplets further supporting exogenous 
lipid uptake as a lipid droplet production mechanism (Figure 4.25.). Exogenous 
serum provides an excellent source of lipids for a rapidly proliferating cell as 
adequate access to blood vessels will ensure supply remains constant. However, in 
tumours such as GBM, increased cellularity and ineffective angiogenesis ensures 
blood supply is frequently insufficient and it is therefore unlikely that lipid droplet 
production would rely upon a single mechanism. Moreover, LDQ would therefore 
vary across the tumour, and this has been observed in in vivo MRS studies (94,265).  
 
 
 
 
 
Exogenous 
lipid uptake 
FABPs 
Lipid droplets 
Figure 4.25. Exogenous lipid uptake is an important lipid droplet production pathway 
in normoxia. Fatty acid binding protein (FABP). 
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4.3.4. Lipid droplet production in normoxia – The role of ATGL 
ATGL catalyses the rate-limiting step in the lipolysis of TAGs and has been reported 
in many cell types to have an important role in lipid droplet breakdown (174,194). 
Interestingly, we observed in chapter 3 that high expression of PNPLA2, the gene 
encoding ATGL, was associated with lipid droplet-associated genes and decreased 
survival, suggesting an important role in glioma lipid droplet metabolism and tumour 
viability. Atglistatin is a competitive ATGL inhibitor established to work in vitro and in 
vivo (266). Inhibition is selective for ATGL and has been reported to have no effect 
on hormone sensitive lipase, monoglyceride lipase, pancreatic lipase, lipoprotein 
lipase and other lysophospholipases. Although ATGL has previously been implicated 
in lipid droplet breakdown (174), we observed that ATGL inhibition decreased LDQ, 
suggesting a role for ATGL in lipid droplet production (Figure 4.2.). Interestingly, with 
the exception of the T98G cell line, this effect was enhanced in starvation conditions. 
As HBSS does not contain exogenous lipids, this enhanced decrease in LDQ is likely 
attributable to the combined effect of losing two lipid droplet sources simultaneously 
and emphasises the importance of these two pathways in lipid droplet metabolism.  
As the primary role of ATGL is to facilitate the degradation of lipids, a role in lipid 
droplet production was unexpected. However, ATGL is known to be associated with 
cell membranes as well as lipid droplets (189). Hofer et al. (192) found that CGI-58, 
a potent activator of ATGL activity, interacts with fatty acid binding proteins (FABPs) 
including H-FABP, also known as FABP3. Bensaad et al. (123) established that 
FABP3 was critical to lipid droplet production through the shuttling of lipids in the 
U87 cell line. We therefore propose that ATGL functions at the cell membrane to 
release fatty acids which are subsequently transported to lipid droplets by FABPs 
   
188 
 
(Figure 4.26). Thus inhibition of ATGL activity with atglistatin would result in 
decreased lipid droplet production. 
The effect of ATGL inhibition on unsaturated fatty acid release from cell membranes 
could not be confirmed using C11 BODIPY due to the weak signal intensity and 
oxidation-induced colour change in hypoxia (Figure 4.3.). However, inhibition of 
ATGL decreased the concentration of unsaturated fatty acids in lipid droplets 
suggesting that ATGL mediates the release of unsaturated fatty acids destined for 
lipid droplets. Similarly, the increase in cell membrane C16 BODIPY accumulation 
following atglistatin treatment further supports the release of fatty acids by ATGL at 
the cell membrane. However, saturated fatty acid concentration in lipid droplets was 
increased by ATGL inhibition suggesting that, although saturated fatty acids may be 
released from the cell membrane by ATGL, they are not destined for lipid droplets. 
Therefore, we suggest that ATGL can release both saturated and unsaturated fatty 
acids from the cell membrane but that the ATGL-mediated lipid shuttle is responsible 
for the specific transport of unsaturated fatty acids to lipid droplets (Figure 4.26). The 
reason for this lipid shuttle is discussed in section 4.3.14. 
ATGL 
Lipase 
mediated 
release 
FABPs & 
Unsaturated 
fatty acids 
Lipid droplets 
CGI56 
FABP 
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It is important to note that this work does not rule out an alternative source of 
unsaturated fatty acids which must be addressed in future experiments. Labelled 
unsaturated fatty acids should co-localise with FABPs in the cytoplasm as well as 
with ATGL, CGI58 and lipid droplets. Moreover, FABP knockdown should interrupt 
the lipid shuttle and result in a decreased lipid droplet unsaturated fatty acid 
concentration, although this may also impact other lipid droplet production 
mechanisms such as exogenous lipid uptake. Finally, alterations in lipid droplet 
saturation could be confirmed using mass spectrometry, providing greater insight 
into changes in the concentrations of specific fatty acids. Nevertheless, our data 
demonstrate an important role for ATGL in normoxic lipid droplet production. 
 
4.3.5. Lipid droplet production in normoxia – De novo lipid synthesis 
There is a growing body of evidence for the upregulation of enzymes involved in de 
novo fatty acid synthesis in many types of cancer (156,160,161) whilst lipid pre-
cursors such as glucose and glutamine have been reported as a source of lipid 
droplets in several cell lines (136,164,165). BPTES is a non-competitive inhibitor of 
GLS1, inhibiting the conversion of glutamine to glutamate for entry into the TCA 
cycle. The contrasting effects of BPTES treatment on LDQ in the T98G and U87 cell 
lines (Figure 4.4.) suggest cell line-specific differences in the importance of this 
pathway. The data suggests a minor role for glutamine in lipid droplet production in 
the U87 cell line whereas alternative lipid droplet production pathways may be 
Figure 4.26. The ATGL-mediated unsaturated fatty acid shuttle. ATGL is activated by 
CGI58 and releases unsaturated fatty acids from the cell membrane which are 
transported to lipid droplets by FABPs. Fatty acid binding protein (FABP). 
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upregulated in T98G cells or the cells may undergo a stress response. Interestingly, 
Bensaad et al. (123) reported that U87 GBM cells and MCF-7 breast cancer cells 
have an increased accumulation of lipid droplets in glutamine-free media in 
normoxia. However, GLS1 inhibition and the complete absence of glutamine in 
glutamine-free media may induce different cellular responses. Indeed, many 
cancers, including some gliomas, have been observed to be “glutamine addicted” 
(81,82), and this may account for these contrasting results.  
The FASN inhibitor, orlistat, increased LDQ in both the T98G and U87 cell lines 
(Figure 4.4.); however, this may be due to a cell stress response as orlistat is known 
to affect several off-target proteins including metabolic enzymes and heat shock 
proteins (267). Therefore, it cannot be concluded that fatty acid synthesis has no role 
in lipid droplet production; however, it would appear unlikely that it has a significant 
role in these cell lines under normoxic conditions. A more selective FASN inhibitor 
such as C75 may provide further information in future studies. 
Cholesterol constitutes an important component of lipid droplets and requires 
synthesis or uptake (255). We observed a small increase in LDQ in several of the 
cell lines upon inhibition of cholesterol synthesis with the HMG CoA reductase 
inhibitor, simvastatin (Figure 4.5.). A similar result was observed in embryonic kidney 
and pancreatic cancer cell lines wherein the authors propose compensatory 
upregulation of cholesterol uptake and fatty acid synthesis (268) whilst cholesterol 
uptake has been shown to be of vital importance in oestrogen receptor negative 
breast cancer (269). Although a similar compensatory upregulation of cholesterol 
uptake in these cell lines may be uncovered through further investigation, our data 
demonstrates that cholesterol synthesis is unlikely to have a major role in lipid 
droplet production in these cell lines. 
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The importance of de novo lipid synthesis precursors in many aspects of the cell 
metabolism hinders the interpretation of lipid droplet-specific effects. However, we 
observed in chapter 3 that increased expression of de novo fatty acid synthesis 
genes was associated with a better survival and lower clinical grades. Moreover, 
expression of these genes did not correlate with the expression of known lipid 
droplet markers such as the lipid droplet-associated proteins adipophilin and TIP47. 
This suggests that de novo fatty acid synthesis may not be of vital importance in lipid 
droplet metabolism, particularly in GBM cell lines. Therefore, whilst we can conclude 
that de novo lipid synthesis is important to the overall cell metabolism and may 
impact lipid droplet production in other cancers, we have been unable to characterise 
a major role for this pathway in glioma lipid droplet metabolism. 
 
4.3.6. Lipid droplet breakdown in normoxia – Autophagy 
The importance of autophagy in the production of lipid droplets has been noted in 
several cell types (174,175). However, its importance in the degradation of lipid 
droplets is also well established, most notably in hepatocytes (179). We chose to 
investigate this pathway, in the context of lipid droplet metabolism, using early and 
late stage autophagy inhibitors. 3-MA prevents autophagosome initiation through 
inhibition of type III phosphatidylinositol 3 kinases (270) whilst chloroquine inhibits 
late stage autophagy through the prevention of autophagosome-lysosome binding 
(271). By targeting different stages of autophagy we hoped to decrease the risk of 
off-target drug effects. Moreover, this could be further tested through siRNA 
knockdown of the vital autophagy protein Atg5. All three methods of autophagy 
inhibition resulted in increased LDQ (Figures 4.6. and 4.7.) strongly implicating 
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autophagy as a lipid droplet breakdown mechanism (Figure 4.27.). Moreover, 
autophagy inhibition caused the accumulation of C16 BODIPY in lipid droplets 
(Figure 4.7.) further demonstrating the inhibition of lipid droplet turnover. 
Interestingly, autophagy inhibition in HBSS continued to increase LDQ (Figure 4.6.), 
despite the absence of the exogenous serum lipid pool, suggesting that the loss of 
one lipid droplet production mechanism may be compensated for using alternative 
pathways. Taken together our data suggests that lipid droplet breakdown in GBM 
cell lines occurs through autophagy and that inhibition of this pathway can cause the 
accumulation of lipid droplets.  
 
4.3.7. The role of hypoxia in lipid droplet metabolism 
In line with the current literature (123), we found that hypoxia increased LDQ in a 
HIF1α-dependent manner in all 5 of our cell lines (Figures 4.8. and 4.9.), indicating 
this is a common feature of GBM. This was further supported by HRMAS NMR, 
providing an important link between in vitro studies of lipid droplet biology and in vivo 
MRS. This data also shows the increased effect of hypoxia upon total lipid 
concentration relative to metabolite concentration, further demonstrating the scale of 
increase in hypoxic lipid droplet metabolism and its clear importance. Moreover, this 
Autophagy Lipid droplets Autophagosomes 
Lipid 
release 
Figure 4.27. Lipid droplets are broken down by autophagy in these cell lines. 
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dramatic increase may reflect a response to hypoxia-induced stress, as discussed 
further in section 4.3.14. 
 
4.3.8. Lipid droplet production in hypoxia – Exogenous serum uptake 
In chapter 3, we observed a correlation between lipid droplet-associated proteins 
including the hypoxic lipid droplet protein HIG2 and the lipid uptake transporter 
CD36, further suggesting lipid droplets may be associated with exogenous lipid 
uptake in hypoxia. Indeed, as exogenous lipid uptake contributed to lipid droplet 
production in normoxia, we investigated its role in the increased LDQ in hypoxia. 
Although significance was not reached in every cell line, a clear trend is 
demonstrated (Figure 4.10.), suggesting access to the exogenous lipid pool is 
important to maintaining lipid droplet production. Bensaad et al. (123) also reported a 
role for exogenous lipid uptake in hypoxic lipid droplet production in the U87 cell line 
although, as previously noted, this relied upon decreased supplementation as well as 
de-lipidation of serum. Interestingly, we observed a greater LDQ decrease in cells 
incubated in de-lipidated serum in hypoxia in the majority of the cell lines compared 
to the corresponding experiment in normoxia. This implies hypoxic lipid droplet 
breakdown continues in the absence of the exogenous lipid pool, depleting the 
increased hypoxic LDQ. Moreover, the increased uptake of the saturated C16 
BODIPY fatty acid, and to a lesser extent the unsaturated C11 BODIPY fatty acid, in 
hypoxia (Figure 4.11.) suggest that increased uptake from this exogenous lipid pool 
may contribute to increased LDQ in hypoxia. Therefore, the uptake of exogenous 
serum lipids appears to be an important factor in lipid droplet production in hypoxia 
as well as normoxia. 
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4.3.9. Lipid droplet production in hypoxia – The role of ATGL 
The role of ATGL in hypoxia is relatively unexplored, remaining limited to adipocytes 
in hypoxic exercise (272) and cardiac myocytes in ischaemia (273). Importantly a 
role for ATGL in hypoxic lipid droplet metabolism has not been investigated. The 
U343 cell line demonstrated a similar role for ATGL in lipid droplet production as in 
normoxia (Figure 4.12.). Similarly, this is supported by the non-significant trend 
observed in the T98G, U87 and U87.1 cell lines. The effect of ATGL inhibition in 
hypoxia may be smaller in these cell lines due to a compensatory increase in 
exogenous lipid uptake in hypoxia. In contrast, the significant decrease in LDQ in the 
U87.2 cell line could suggest that ATGL is the main lipid droplet production pathway 
in this cell line under hypoxic conditions, without which the cell cannot adequately 
compensate. Moreover, it could indicate increased importance for the shuttling of 
fatty acids to lipid droplets in hypoxia within this cell line. The different response of 
this cell line to ATGL inhibition emphasises the importance of understanding cell line-
specific differences in lipid droplet metabolic pathway activity. Moreover, further 
comparison with the U87 clonal mutant may reveal genetic factors influencing ATGL 
activity in hypoxic lipid droplet metabolism. 
 
4.3.10. Lipid droplet production in hypoxia – De novo synthesis 
Hypoxia has been shown to induce a switch from pyruvate metabolism to reductive 
carboxylation as the major source of de novo fatty acid synthesis (31). Although 
Bensaad et al. (123) observed decreased labelled pyruvate incorporation in lipids in 
hypoxia in the U87 cell line, they found culturing U87 cells in glutamine-free media in 
hypoxia increased lipid droplet accumulation, suggesting glutamine was not used to 
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produce lipid droplets in this cell line. In conjunction with this, we found no clear role 
for GLS1 in lipid droplet production in hypoxia (Figure 4.13.).  Moreover, inhibition of 
FASN in hypoxia with orlistat did not decrease LDQ; however, as previously 
discussed, we cannot discount off target effects. Nevertheless, the literature 
(123,155) strongly indicates de novo fatty acid synthesis does not have a major role 
in hypoxic lipid droplet metabolism in glioma cell lines, further supporting our data. 
This also supports the importance of other lipid droplet production mechanisms, such 
as increased exogenous lipid uptake.  
Cholesterol synthesis was not further investigated in hypoxia due to the small LDQ 
effects observed in normoxia (Figure 4.5). Whilst the relationship between hypoxia, 
cholesterol synthesis and lipid droplets could be further investigated in future studies 
with drugs such as simvastatin, GBMs have been shown to downregulate cholesterol 
synthesis in favour of uptake (274). Taken together with the data regarding de novo 
fatty acid synthesis in GBMs and the small effect on LDQ in normoxia, this suggests 
a role in lipid droplet metabolism is likely to continue to be minor and was, therefore, 
not further investigated within this project. 
 
4.3.11. Lipid droplet breakdown in hypoxia – Autophagy 
We observed a clear role for autophagy as a lipid droplet breakdown mechanism in 
normoxia; however, its role in hypoxia is less clear. In the T98G and U87 cell lines 
autophagy inhibition caused lipid droplet accumulation (Figure 4.14.) suggesting a 
continued role in lipid droplet breakdown. In contrast, LDQ was decreased by 
autophagy inhibition in hypoxia in the U343, U87.1 and U87.2 cell lines. Decreased 
LDQ from autophagy inhibition could suggest that autophagy becomes a lipid droplet 
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production mechanism in hypoxia. Indeed, autophagy has been reported as an 
important mechanism for lipid droplet production in several cell types (174,175), 
although this would require significant metabolic alterations. Alternatively, a 
compensatory lipid droplet breakdown mechanism may catabolise lipid droplets in 
the absence of autophagy. Indeed, cytoplasmic lipases have been observed as lipid 
droplet breakdown mechanisms in several cancers (195-197) and are interlinked 
with the process of autophagy (198,199). An alternative lipid droplet breakdown 
pathway with increased lipid droplet clearance, activated by autophagy inhibition, 
may explain the decreased LDQ observed in these cell lines. Interestingly, increased 
LDQ is frequently associated with higher clinical grades (240,241) and hypoxia 
(94,123) implying that hypoxic lipid droplet accumulation must confer a survival 
benefit. Indeed, in chapter 3, high expression of autophagy proteins was associated 
with poor survival and correlated with high HILPDA expression. A compensatory 
pathway would be suppressed in favour of autophagy; however, excessive 
intracellular lipid accumulation induces lipotoxicity and therefore autophagy inhibition 
may necessitate the activation of this pathway. Nevertheless, establishing an 
alternative pathway in these cell lines for hypoxic lipid droplet breakdown requires 
further investigation. 
 
4.3.12. Lipid droplet flux may be maintained during metabolic pathway inhibition 
through alternative pathway upregulation. 
Starvation increases the metabolic demand placed upon cellular pathways to 
maintain energy production which can be achieved through upregulating the 
catabolism of cellular components including lipid droplets (174). Starvation 
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conditions can be mimicked using HBSS which contains no exogenous lipid pool or 
de novo fatty acid precursors. As expected, uptake of the C16 and C11 BODIPY 
fatty acids was increased in starvation conditions (Figure 4.15.) reflecting the 
importance of the exogenous lipid pool in the cell metabolism. Interestingly, despite 
increased metabolic demand, LDQ was at least partially maintained under starvation 
conditions suggesting compensation with alternative lipid droplet production 
mechanisms. 
Starvation conditions increased the effect of atglistatin by decreasing LDQ (Figure 
4.16.). Lipid droplets could be further depleted in this case by increased starvation-
induced lipid droplet breakdown during impaired lipid droplet production. 
Alternatively, simultaneous loss of exogenous lipid uptake, ATGL activity and the 
exogenous de novo fatty acid synthesis pre-cursors may further impair lipid droplet 
production (Figure 4.28). Indeed, the increased LDQ in the T98G cell line may 
represent a stress response to the combined loss of these pathways. 
If starvation increases the metabolic need for lipid droplet breakdown then flux may 
continue until lipid droplet depletion, despite impaired lipid droplet production (Figure 
4.29). 3-MA inhibits autophagosome initiation and, until all pre-existing 
autophagosomes are exhausted, lipid droplet breakdown would continue. Upon 
depletion of this pool, alternative lipid droplet production mechanisms such as ATGL 
and de novo fatty acid synthesis may compensate for the loss of the exogenous lipid 
pool and replenish lipid droplet stores. This would result in lipid droplet accumulation 
(Figure 4.29), as seen with 3-MA treatment in HBSS in our cell lines (Figure 4.16). 
When ATGL activity is also inhibited through co-treatment with atglistatin and 3-MA 
there may be inadequate compensation for the loss the exogenous lipids and 
metabolites. Lipid droplets depleted prior to the inhibition of lipid droplet breakdown 
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with 3-MA may not be replenished due to impaired lipid droplet production. 
Therefore, LDQ would be decreased in response to 3-MA and atglistatin in 
comparison to 3-MA treatment alone (Figure 4.29), as observed in our cell lines 
(Figure 4.16.). The extent to which lipid droplets are depleted would rely upon the 
number of pre-existing autophagosomes and the ability of the cell to compensate 
using lipid synthesis from intracellular pre-cursors. Thus LDQ in atglistatin and 3-MA 
co-treated cells may be decreased to different extents in our cell lines.  
 
 
Figure 4.28. Compensatory activity of lipid droplet production pathways can maintain 
LDQ to an extent. DMEM: LDQ is maintained by exogenous lipid uptake and lipase 
mediated lipid release. De novo fatty acid synthesis does not play a major role. HBSS: No 
access to exogenous lipid pool or extracellular lipid pre-cursors in HBSS. Lipase mediated 
lipid release and de novo fatty acid synthesis from intracellular pre-cursors are increased to 
maintain LDQ. HBSS + Atglistatin: All three mechanism of lipid droplet production are 
unavailable or impaired and LDQ is decreased, increasing the effect of atglistatin. “X” 
denotes fully inhibited pathway, “/” denotes impaired pathway. 
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Figure 4.29. Lipid droplet metabolism is in constant flux. DMEM: Lipid droplet production 
occurs through exogenous lipid uptake and lipase-mediated lipid release. Lipid droplet 
breakdown occurs through autophagy. HBSS: Increased metabolic demand from starvation 
increases lipid droplet breakdown. LDQ is maintained by lipase-mediated lipid release and 
de novo synthesis from intracellular precursors. HBSS and 3-MA: Lipid droplet breakdown is 
halted once the pre-existing autophagosomes are exhausted. Lipids droplets are replenished 
by the two active production pathways and accumulate. HBSS + 3-MA + Atglistatin: The pre-
existing autophagosomes, initiated prior to 3-MA treatment, catabolise lipid droplets due to 
the increased metabolic demand in starvation. The lipid droplet production pathways are 
impaired or halted and cannot sustain lipid droplet replenishment resulting in decreased 
LDQ. “X” denotes fully inhibited pathway, “/” denotes impaired pathway. 
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Compensatory pathway activation requires further investigation. However, this has 
proved difficult as pharmacological targeting of two pathways simultaneously 
frequently resulted in a cell stress response or cell death (data not shown). Future 
experiments should aim to remove the activity of one pathway whilst non-invasively 
monitoring the activity of others. For example de novo fatty acid synthesis could be 
monitored using 13C labelled glucose and glutamine whilst inhibiting ATGL or lipid 
uptake. Alternatively, lipid uptake could be monitored with 13C labelled fatty acid 
mass spectrometry by assessing changes in 13C label accumulation in lipid droplets 
following inhibition of ATGL or de novo fatty acid synthesis. By targeting a single 
pathway, stress-induced lipid droplet changes may be avoided and pathway 
compensation may be better understood. 
 
4.3.13. The fates of lipid droplets 
The importance of maintaining lipid droplet metabolism is clear, although we are yet 
to understand why. Lipids can be used for four main functions; energy production, 
membrane phospholipid synthesis, lipid signalling rafts and protein modification. The 
lipid requirements of protein modification are too small to be the primary demand for 
lipid droplet metabolism, whilst the investigation of lipid signalling rafts requires far 
greater exploration than allowed within this investigation. We therefore chose to 
focus upon energy production and membrane phospholipid synthesis which are 
suggested outcomes of lipid droplet metabolism in other cell types (92,149,174). 
C16 BODIPY was observed to accumulate in normoxia in a peri-nuclear region 
associated with mitochondrial localisation (Figure 4.17.), suggesting that C16 
BODIPY may be transported to the mitochondria for β-oxidation. Indeed, C16 
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BODIPY does not localise to this region in hypoxia which is known to decrease 
mitochondrial β-oxidation (259). However, accumulating C16 BODIPY may also 
originate from non-lipid droplet sources and this requires further investigation. In 
contrast, C11 BODIPY did not accumulate in this peri-nuclear region suggesting that 
unsaturated fatty acids may not be used for β-oxidation to the same extent. 
Unsaturated fatty acid β-oxidation requires two additional enzymes and therefore 
saturated fatty acids may provide a more optimal lipid source for mitochondrial β-
oxidation. Importantly C16 and C11 BODIPY differ by chain length as well as 
saturation. However, lipid metabolism is more dependent on saturation rather than 
chain length and therefore the altered metabolism of these two fatty acids is more 
likely attributable to saturation status. 
This methodology remains limited as co-localisation of mitochondrial dyes is required 
to confirm that labelled fatty acid is present in mitochondria. Moreover, the 
fluorescent label interferes in the processing of these fatty acids and may alter their 
metabolism. Indeed, prolonged exposure to the C11 BODIPY fatty acid induced cell 
death (data not shown). In addition to co-localisation of mitochondria and lipid droplet 
derived lipids, alterations in respiration rate and mitochondrial β-oxidation enzyme 
activity following lipid droplet depletion could further support the role of lipid droplets 
as a mitochondrial energy source. This avoids altering lipid metabolism with 
fluorescent labels and provides a quantitative comparison of mitochondrial β-
oxidation activity. Moreover, this can be combined with 13C metabolic tracer studies 
(275) to better track the metabolism of lipid droplet derived lipids. 
Lipid droplets also provide an excellent source of pre-assembled lipids for 
phospholipid synthesis. Upon the inhibition of lipid droplet breakdown C16 BODIPY 
was observed to accumulate in lipid droplets with decreased accumulation at the cell 
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membrane (Figure 4.17.). Inhibited lipid droplet breakdown could prevent the release 
of lipids from lipid droplet stores for the synthesis of membrane phospholipids. 
Indeed, in chapter 3, we observed correlations between expression of autophagy 
and phospholipid synthesis genes suggesting a link between lipid droplet breakdown 
and membrane synthesis. Alternatively, the inhibition of lipid droplet breakdown may 
induce a compensatory increase in ATGL activity, releasing labelled fatty acids from 
cell membranes and causing accumulation in lipid droplets. However, this appears 
less likely as earlier data suggested that ATGL-released saturated fatty acids may 
not be destined for storage in lipid droplets. Therefore, we suggest that lipid droplet-
derived lipids are also used in membrane synthesis in these cell lines. 
A role for lipid droplet-derived lipids in membrane synthesis could be further 
investigated through knockdown of phospholipid synthesis enzymes which may 
replicate the shift in C16 BODIPY accumulation from membranes to lipid droplets. 
However, the use of fluorescent labelled fatty acids has the same limitations as 
noted previously whilst lipid droplet-derived lipids remain difficult to track. Therefore, 
the impact of lipid droplet metabolism on membrane synthesis must also be 
confirmed using alternative methodologies in future investigations.  
As discussed above, hypoxia can alter lipid droplet metabolism and was observed to 
decrease proliferation in several GBM cell lines (Figure 4.18.). Decreased 
phospholipid production would slow membrane synthesis whilst decreased β-
oxidation would alter energy metabolism. Therefore, if increased lipid droplet 
accumulation in hypoxia is the result of decreased lipid droplet catabolism, 
proliferation may be suppressed through these proliferative pathways. However, this 
is speculative and requires further investigation. 
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We present preliminary data which suggests a possible role for lipid droplets as a 
lipid source for mitochondrial β-oxidation and membrane phospholipid synthesis in 
these cell lines (Figure 4.30). Whilst several reports in the literature support this 
theory (174,215), further in depth investigation is required. 
 
4.3.14. Lipid shuttling is an important oxidative damage protection mechanism 
We observed that the unsaturated fatty acid concentration was increased 
significantly in hypoxia (Figure 4.19). Interestingly, hypoxic cancer cells have been 
shown to acquire unsaturated fatty acids through increased uptake as opposed to de 
novo desaturase activity (168). Moreover, desaturase enzymes require oxygen, 
limiting their use in hypoxia (276). Therefore, it is likely that the unsaturated fatty acid 
concentration of lipid droplets is not changed by desaturase activity but by increased 
intra- and extra-cellular unsaturated fatty acid uptake, driven by an unknown factor. 
ROS is a well-known source of oxidative damage and will readily oxidise unsaturated 
fatty acids. Hypoxia is known to increase the generation of ROS (225) and was 
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Figure 4.30. The fates of lipid droplet lipids. Lipid droplet lipids can be used for energy 
production through mitochondrial β-oxidation and the production of membranes through 
phospholipid synthesis. 
   
204 
 
observed to increase C11 BODIPY unsaturated fatty acid oxidation (Figure 4.20.). 
ATGL inhibition in hypoxia further increased unsaturated fatty acid oxidation, 
specifically at cell membranes, suggesting a role for ATGL in preventing hypoxic 
oxidative damage. In combination with our previous findings regarding the role of 
ATGL in lipid droplet production (Figure 4.26.), we propose that unsaturated fatty 
acids are released from cell membranes by ATGL, transported by FABPs and 
sequestered in lipid droplets, thereby preventing oxidative damage (Figure 4.31). A 
similar mechanism was reported by Bailey et al. (226) in Drosophila glial cells. Using 
mass spectrometry, poly-unsaturated fatty acids were shown to increase in lipid 
droplets following exposure to oxidative stress with higher unsaturated fatty acid 
oxidation occurring at cell membranes compared to lipid droplets. The authors 
concluded that unsaturated fatty acids may be transported from cell membranes to 
lipid droplets to protect against ROS damage in the Drosophila model, supporting 
our proposed pathway in GBM.  
H2O2 is a potent ROS and was used to further investigate this pathway. Similarly, to 
hypoxia, H2O2 treatment increased unsaturated fatty acid oxidative damage, which 
was further increased by simultaneous ATGL inhibition (Figure 4.21.). This was 
observed in normoxia and hypoxia suggesting that ATGL is important in the 
prevention of unsaturated fatty acid oxidation regardless of oxygen concentration. 
Interestingly, H2O2 treatment should induce an increase in the unsaturated fatty acid 
concentration of lipid droplets, as was observed with hypoxia, and investigation of 
this may provide further evidence to support this pathway. 
The chemotherapeutic agent cisplatin is known to increase the concentration of poly-
unsaturated fatty acids in lipid droplets (98) and can induce ROS as well as DNA 
damage (260). Therefore, we hypothesised that cisplatin, as with hypoxia and H2O2, 
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may induce the protective shuttling of unsaturated fatty acids to lipid droplets. 
Moreover, this may be inhibited by ATGL inhibition, increasing cell membrane fatty 
acid oxidation. However, cisplatin did not induce unsaturated fatty acid oxidation 
(Figure 4.21.) and we therefore did not test the effect of cisplatin and atglistatin co-
treatment as we cannot confirm ROS induction. Moreover, cisplatin is associated 
with many mitochondrial effects as well as ROS induction which may confound these 
results. 
It is unclear why ATGL inhibition in normoxia decreased unsaturated fatty acid 
oxidation as this would not be expected to alter the amount of oxidative stress to 
which the cell is exposed. Indeed, no change in lipid oxidation was expected and this 
requires further investigation. Nevertheless, the induction of lipid oxidation by H2O2 
treatment in normoxia was increased by ATGL inhibition (Figure 4.21.) confirming 
that this pathway remains important in preventing oxidative damage under oxidative 
stress in normoxia. 
Taken together our results suggest that the ATGL-mediated unsaturated fatty acid 
shuttle sequesters unsaturated fatty acids in lipid droplets in response to oxidative 
stress (Figure 4.31). This is supported by the literature (226) and highlights a 
potential new therapeutic target in GBM. Therefore, future experiments should aim to 
explore the impact of ATGL inhibition and oxidative damage on cell viability.  
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Figure 4.31.  The ATGL-mediated unsaturated fatty acid shuttle protects cell membrane 
lipids from oxidative damage. Oxidative stress, such as the induction of ROS by hypoxia or 
H2O2, induces the movement of unsaturated fatty acids from vulnerable cell membranes to 
protective lipid droplets through the ATGL-mediated unsaturated fatty acid shuttle. However, 
atglistatin treatment inhibits this pathway resulting in oxidative lipid damage at the cell 
membranes. This causes the C11 BODIPY to undergo a red to green colour shift. Fatty acid 
binding protein (FABP). 
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4.3.15. Summary 
In chapter 3 we highlighted the expression of many genes including those 
representing lipid droplets, exogenous lipid uptake, ATGL, phospholipid synthesis 
and mitochondrial lipid transporters as important aspects of glioma biology with 
significant association to survival. In this chapter, we have confirmed and defined the 
role of several of these pathways as important aspects of lipid droplet metabolism. 
Lipid droplets are produced by the uptake of exogenous lipids; however, there is also 
contribution from the ATGL-mediated release of fatty acids from the cell membrane. 
Interestingly, our data suggests that the loss of a single pathway may be 
compensated for through increased activity in alternative pathways. We further 
defined a role for autophagy in the breakdown of lipid droplets which may fuel 
mitochondrial β-oxidation and membrane phospholipid synthesis. Furthermore, these 
pathways are also involved in lipid droplet metabolism in hypoxia. However, the 
importance of each pathway appears cell line-specific. Finally, we suggest an ATGL-
mediated unsaturated fatty acid shuttle for the sequestration of unsaturated fatty 
acids in lipid droplets to reduce oxidative damage. 
Understanding lipid droplet metabolism provides greater insight into the overall 
metabolic profile of GBM tumours and may highlight potential therapeutic targets. 
Notably, the roles of autophagy in lipid droplet breakdown and of ATGL as a 
protective mechanism under oxidative stress may be of particular interest. Lipid 
droplets have been associated with treatment efficacy (234,238,239,277) and, 
through pharmacological targeting of lipid droplet metabolic pathways, they may be 
manipulated to improve the cytotoxicity of current therapies. 
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Chapter 5 
 
Manipulating lipid droplets for therapeutic effect in 
high grade glioma cell lines 
  
   
209 
 
5.1. Introduction 
Non-curative therapeutic options remain a major factor in the high mortality 
associated with gliomas, particularly at higher grades. Current treatment regimens 
are composed of three main factors: surgery, radiotherapy and chemotherapy. 
Surgical resection has the greatest clinical impact through removal of the bulk 
tumour mass. However, despite extensive resection, tumours frequently reoccur in 
peripheral post-operative areas due to infiltration (57). Adjuvant radiotherapy 
constitutes the second most important aspect of glioma therapy and causes cell 
death through direct DNA damage and ROS generation. However, through 
adaptation to the tumour microenvironment and several cellular mechanisms; 
including upregulated DNA repair enzymes and cancer stem cell intrinsic radio-
resistance (58,62,63), radiation remains non-curative. Although recent interest has 
focussed on proton beam therapy, current research implies this may decrease side 
effects as opposed to improving survival (278,279). The final component of glioma 
treatment regimens is chemotherapy. In 2005, temozolomide became the major 
chemotherapeutic agent in glioma therapy and, in combination with surgery and 
radiotherapy, increased median survival (20,280). Temozolomide is an alkylating 
agent which predominantly methylates DNA at the O6 position on guanine, triggering 
apoptosis. However, the DNA repair enzyme MGMT removes this lesion and is 
frequently highly expressed in high grade gliomas, limiting temozolomide efficacy 
(65). As discussed in Chapter 1, novel therapeutics have resulted in limited 
improvements to treatment regimens and therefore new approaches are required.  
Lipid droplets are an important component of tumour biology and may represent an 
interesting and relatively unexplored therapeutic target. Associated with apoptosis 
(138) and necrosis (94), they are increased in response to a number of cytotoxic 
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treatments in many cancers including GBM (98). Whilst it has been suggested that 
lipid droplets are part of the cell death process and are increased in response to 
cytotoxic insult, lipid droplets could instead form part of a drug resistance pathway, 
increased in the prevention of cell death. Indeed, lipid droplet accumulation was 
increased in a number of drug resistant cells (235-237). Moreover, several studies 
have suggested that lipid droplets influence drug resistance through sequestration of 
cytotoxic compounds. In acute myeloid leukaemia, an aminopeptidase inhibitor pro-
drug was prevented from activation through lipid droplet sequestration (238) whilst 
docetaxel was observed within drug resistant breast cancer lipid droplets (239). 
Indeed, curcumin was observed to co-localise with lipid droplets in GBM, although 
this study remains limited by the shared fluorescence of both curcumin and the 
selected lipid droplet marker (277). 
Conversely, the importance of lipid droplets in metabolism and proliferation could be 
significant. Lipid droplets provide increased metabolic plasticity and disruption of lipid 
droplet metabolism has been shown to decrease growth and survival in many cancer 
cell lines and xenografts (123,165). Through increased understanding of lipid droplet 
metabolic pathways, we may better appreciate the role lipid droplets play within cell 
death and drug resistance and facilitate the improvement of current therapies. In 
Chapter 4 we observed important roles for the uptake of exogenous lipids, ATGL and 
autophagy in lipid droplet metabolism suggesting manipulation of lipid droplet flux 
through subversion of these pathways may influence cell death and drug efficacy. 
In this Chapter we investigate the effect of reducing lipid droplet flux through 
pharmacological inhibition of lipid droplet metabolic pathways with regards to 
temozolomide and radiation efficacy. Moreover, we assess the relevance of co-
treatment in hypoxia and address its potential for clinical application. 
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5.2. Results 
5.2.1. Chloroquine pre-treatment can increase temozolomide cytotoxicity in 
normoxia. 
Based upon the role of autophagy in lipid droplet breakdown observed in Chapter 4, 
we sought to investigate the effect of the late-stage autophagy inhibitor chloroquine 
on the cytotoxicity of temozolomide. Pre-treatment with the autophagy inhibitor 
chloroquine decreased cell viability in temozolomide-treated cells compared to the 
DMSO-only and drug-only conditions at 21% O2, as assessed by SRB proliferation 
assays (Figure 5.1.A.). This was observed in the T98G, U87 and U87.2 cell lines 
suggesting that manipulation of lipid droplet breakdown can influence temozolomide 
efficacy. Moreover, decreased cell viability in the chloroquine-only condition 
indicated sensitivity to autophagy inhibition whilst temozolomide cytotoxic activity 
was confirmed by decreased cell viability in the temozolomide-only condition. The 
temozolomide dose required to induce cytotoxicity is much higher than in vivo 
concentrations, as expected in vitro, reflecting the inherent resistance of these cell 
lines and GBM tumours. These findings were confirmed with AnnexinV-FITC/PI flow 
cytometry apoptosis assays (Figure 5.1.B.). Therefore, manipulation of lipid droplet 
metabolism using the autophagy inhibitor chloroquine may increase the cytotoxicity 
of temozolomide in normoxia.  
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A 
U87 U87.2 B 
U87 U87.2 T98G 
Figure 5.1. Chloroquine pre-treatment can increase the cytotoxicity of temozolomide 
in normoxia. A) SRB viability assays of T98G, U87 and U87.2 cells treated with DMSO, 
chloroquine, temozolomide or chloroquine and temozolomide at 21% O2. Chloroquine pre-
treatment 24 hours prior to temozolomide treatment decreased the cell viability of all three 
cell lines. Data shown as mean ±SEM representative of several independent experiments 
(U87, U87.2 n=2; T98G n=3), each composed of 3 technical replicates. B) Flow cytometric 
AnnexinV-FITC/PI cell death assay of U87 and U87.2 cells treated with DMSO, chloroquine, 
temozolomide or chloroquine and temozolomide at 21% O2.  Chloroquine pre-treatment prior 
to temozolomide treatment decreased the viability of the U87 and U87.2 cell line. Data 
shown as mean ±SEM representative of several independent experiments (U87, U87.2 
n=3). Statistical analysis in (A) and (B) was performed using a one-way ANOVA with Tukey 
post-hoc test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Due to the hypoxia-induced alterations in lipid droplet metabolism observed in 
Chapter 4, we investigated the effect of chloroquine pre-treatment with 
temozolomide in hypoxia. In contrast to normoxia, the combination of temozolomide 
and chloroquine pre-treatment did not decrease cell viability at 0.3% O2 compared to 
the drug-only conditions, as assessed via SRB proliferation assays (Figure 5.2.A.). 
Indeed, the cell viability in chloroquine and temozolomide-treated cells was observed 
to mirror the chloroquine-only condition suggesting that any effects observed in cells 
exposed to both chloroquine and temozolomide in hypoxia were attributable to 
chloroquine alone. Moreover, there was no effect on cell viability in the 
temozolomide-only condition further supporting this theory. Interestingly, cell viability 
in the chloroquine-only condition varied between cell lines. Chloroquine treatment 
decreased cell viability in the T98G cell line suggesting a high sensitivity to 
autophagy inhibition when compared to the other cell lines, in particular the U87.2 
cell line. Moreover, chloroquine treatment increased the viability of the U87 cell line 
suggesting that autophagy inhibition may increase proliferation under some 
conditions or genetic backgrounds. AnnexinV-FITC/PI apoptosis assays confirmed 
that chloroquine pre-treatment with temozolomide does not further decrease cell 
viability in the U87.2 cell line in hypoxia (Figure 5.2.B.). 
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As lipid droplet metabolism is altered in hypoxia, we hypothesised that inhibition of 
lipid droplet flux may be required prior to hypoxia. Therefore, cells were incubated 
with chloroquine for 24 hours prior to hypoxic incubation and subsequent 
temozolomide treatment. There was a non-significant trend towards a decrease in 
cell viability following temozolomide treatment with prior normoxic chloroquine 
treatment in the U87 and U87.2 cell lines (Figure 5.2.C.). However, cell viability was 
decreased in cells pre-treated with chloroquine in normoxia (Figure 5.2.C.) compared 
to those pre-treated with chloroquine in hypoxia (Figure 5.2.A.), particularly in the 
U87 cell line. The T98G cell line was highly sensitive to hypoxic autophagy inhibition 
(Figure 5.2.C.), as observed in Figure 5.2.A, further supporting cell line-specific 
differences in chloroquine sensitivity. This data demonstrates that temozolomide 
efficacy is lost in hypoxia and cannot be rescued with hypoxic chloroquine pre-
treatment. Whilst normoxic chloroquine pre-treatment comparatively improved 
temozolomide cytotoxicity, viability remained high, presenting a complicated 
challenge to improve drug efficacy through reduced lipid droplet flux in hypoxia. 
Figure 5.2. Prior normoxic chloroquine pre-treatment may improve temozolomide 
cytotoxicity; however, hypoxic chloroquine pre-treatment does not. A) SRB viability 
assays of T98G, U87 and U87.2 cells treated with DMSO, chloroquine, temozolomide or 
chloroquine and temozolomide at 0.3% O2. Chloroquine pre-treatment affected cell viability 
in a cell line dependent manner but did not improve the cytotoxicity of temozolomide. Data 
shown as mean ±SEM representative of several independent experiments (U87, U87.2 n=2; 
T98G n=3), each composed of 3 technical replicates. B) Flow cytometric AnnexinV-FITC/PI 
cell death assay of U87.2 cells treated with DMSO, chloroquine, temozolomide or 
chloroquine and temozolomide at 0.3% O2.  Chloroquine treatment decreased cell viability; 
however, pre-treatment did not improve temozolomide cytotoxicity. Data shown as mean 
±SEM representative of several independent experiments (U87.2 n=3). C) SRB viability 
assays of T98G, U87 and U87.2 cells pre-treated with chloroquine for 24 hours at 21% O2 
prior to incubation in 0.3% O2 and treatment with DMSO or temozolomide. Chloroquine pre-
treatment partly restored the increased temozolomide cytotoxicity in the U87 and U87.2 cell 
lines; however, did not reach significance. Data shown as mean ±SEM representative of 
several independent experiments (U87, U87.2 n=2; T98G n=3), each composed of 3 
technical replicates. Statistical analysis in (A), (B) and (C) was performed using a one-way 
ANOVA with Tukey post-hoc test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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5.2.2. Atglistatin-induced reduction of lipid droplet flux does not improve 
temozolomide cytotoxicity to the same extent as observed with chloroquine. 
Using SRB proliferation assays, we investigated the impact of impairing a lipid 
droplet production pathway on temozolomide efficacy through ATGL inhibition. 
Treatment with the ATGL inhibitor atglistatin 24 hours prior to temozolomide 
treatment in the U87 and U343 cell lines significantly decreased cell viability 
compared to the DMSO condition suggesting a co-treatment effect (Figure 5.3.A). 
However, in contrast to chloroquine, atglistatin and temozolomide treatment had no 
significant effect on cell viability in normoxia compared to the drug-only conditions 
suggesting a smaller increase in cytotoxicity. This trend was not observed in the 
T98G cell line; however, cell viability was not decreased in the atglistatin-only 
condition in this cell line. As with chloroquine, cells were also treated with atglistatin 
for 24 hours in normoxia or hypoxia prior to temozolomide treatment in hypoxia. Both 
normoxic and hypoxic atglistatin pre-treatment had no significant effect on cell 
viability in any of the cell lines (Figures 5.3.B. and 5.3.C. respectively). Moreover, no 
effect on cell viability was observed in any of the drug-only conditions. Therefore, 
impairment of lipid droplet flux, through impairing lipid droplet production with 
atglistatin, may marginally improve temozolomide cytotoxicity in normoxia but has no 
effect on cell viability in hypoxia. 
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5.2.3. Chloroquine can improve the cytotoxicity of irradiation in normoxia. 
Radiotherapy is an integral part of GBM treatment regimens and therefore we 
investigated the impact of lipid droplet manipulation on irradiation treatment using 
AnnexinV-FITC flow cytometry apoptosis assays.  Pre-treatment with chloroquine 
prior to irradiation decreased the viable cell population compared to the DMSO-only 
and treatment-only conditions in normoxia in the T98G and U87 cell lines (Figure 
5.4.). Despite the high dosage of radiation, there was only a small decrease in the 
viable cell population in the irradiation-only condition representing the inherent radio-
resistance of these cell lines. Due to logistical problems in maintaining hypoxic 
conditions during irradiation, the effect of chloroquine pre-treatment on irradiation 
cytotoxicity was only investigated in normoxia. 
 
 
 
 
Figure 5.3. Atglistatin pre-treatment did not improve temozolomide cytotoxicity to the 
same extent as chloroquine. SRB viability assays of T98G, U87 and U87.2 cells treated 
with DMSO, atglistatin, temozolomide or atglistatin and temozolomide. Cells were pre-
treated for 24 hours with atglistatin prior to temozolomide or DMSO treatment. Cells were 
treated at 21% O2 (A), at 21% O2 for 24 hours prior to 0.3% O2 (B) and at 0.3% O2 (C). 
Atglistatin pre-treatment significantly increased temozolomide cytotoxicity compared to the 
DMSO-only condition in normoxia but not compared to the drug-only conditions. Cell line-
specific co-treatment effects were also indicated. No significant differences were observed 
following hypoxic temozolomide treatment. Data shown as mean ±SEM representative of 
several independent experiments (T98G, U343 n=3; U87 n=4), each composed of 3 
technical replicates. Statistical analysis in (A), (B) and (C) was performed using a one-way 
ANOVA with Tukey post-hoc test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 5.4. Chloroquine pre-treatment can improve the cytotoxicity of irradiation. Flow 
cytometric AnnexinV-FITC/PI cell death assay of T98G and U87 cells treated with DMSO, 
chloroquine, irradiation or chloroquine and irradiation at 21% O2.  Chloroquine pre-treatment 
prior to irradiation significantly decreased the viability of both cell lines. Data shown as mean 
±SEM representative of several independent experiments (n=3). Statistical analysis was 
performed using a one-way ANOVA with Tukey post-hoc test; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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5.3. Discussion 
5.3.1. Introduction 
Lipid droplets have previously been suggested as an important consideration in GBM 
treatment due to potential roles in drug response, resistance and sequestration. 
Indeed, lipid droplets have become a target for manipulation to improve 
chemotherapy, an important component of GBM treatment regimens.  Zhang et al. 
(277) attempted to deplete lipid droplets through phospholipase A2 inhibition and, 
despite several experimental issues, their data suggest that lipid droplet depletion 
may decrease sequestration of curcumin, improving cytotoxicity. However, whist 
Zhang et al. argue that lipid droplets influence cell viability through their physical 
presence; we propose that the cytotoxicity of chemotherapeutic agents may be 
improved through impairing lipid droplet flux. Impaired lipid droplet flux will affect 
downstream processes and impair the full utilisation of lipid droplets in aiding cell 
survival during cytotoxic stress. Indeed, lipid droplets were observed to provide a 
catabolic energy source to aid in survival during re-oxygenation-induced stress in 
prostate cancer cells (151) whilst inhibition of lipid droplet metabolic pathways 
decreased growth and survival during re-oxygenation-induced stress (123).  
Lipid droplet flux can be disrupted through inhibition of the lipid droplet metabolic 
pathways observed in Chapter 4 and can result in decreased or increased LDQ 
depending upon the inhibition of lipid droplet production or breakdown respectively. If 
cell viability is influenced by effective lipid droplet flux then chemotherapeutic 
cytotoxicity may be improved in conditions of both high and low LDQ. This is distinct 
from the drug sequestration hypothesis suggested by Zhang et al. (277) which 
predicts that only decreased LDQ will increase cytotoxicity. We therefore sought to 
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investigate the effect of reduced lipid droplet flux on cell viability during cytotoxic 
insult through inhibiting lipid droplet metabolic pathways. 
 
5.3.2. The impact of impairing lipid droplet breakdown on the cytotoxicity of the 
chemotherapeutic agent temozolomide 
Autophagic lipid droplet breakdown was investigated because autophagy inhibition 
had the clearest effect upon lipid droplet metabolism in our earlier investigations. 
Moreover, lipid droplet production can be influenced by multiple pathways and 
displayed compensatory action from alternative pathways which could complicate 
the investigation. Autophagy inhibitors are established within the clinic and provide a 
good opportunity for high translational impact. Indeed, the autophagy inhibitor 
chloroquine is a commonly used anti-malarial drug with a high tolerability and could 
be swiftly implemented in clinical trials. Moreover, chloroquine was selected as 
opposed to 3-MA as less toxicity was induced following longer drug exposure (data 
not shown).  
Chloroquine pre-treatment increased the cytotoxicity of the chemotherapeutic agent 
temozolomide in normoxia in our GBM cell lines (Figure 5.1.). This indicates that 
chloroquine pre-treatment may improve the efficacy of chemotherapeutic agents in 
normoxic GBM tumour cells. These cell lines displayed an intrinsic temozolomide 
resistance which is commonly observed in GBM tumours, emphasising the impact of 
improving temozolomide efficacy. Interestingly, autophagy inhibition halts lipid 
droplet breakdown and causes lipid droplet accumulation implying that the improved 
temozolomide cytotoxicity is due to increased lipid droplet presence or decreased 
lipid droplet flux. Previous studies (238,239,277) have suggested that lipid droplet 
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accumulation may hinder drug efficacy through drug sequestration. In this case, the 
induction of increased LDQ by autophagy inhibition would be expected to increase 
cell viability; however, we observe a contrasting effect. In addition to increasing LDQ, 
inhibition of lipid droplet breakdown impairs lipid droplet flux. If cell viability is 
affected by the impairment of effective lipid droplet flux then cytotoxicity would be 
increased by lipid droplet breakdown inhibition regardless of the increased LDQ. 
Therefore, we propose that autophagy inhibition improves temozolomide cytotoxicity 
through hindering lipid droplet flux. 
As established in Chapter 4, lipid droplet metabolism is altered in hypoxia and it is 
therefore unsurprising that the effect of autophagy inhibition on temozolomide 
cytotoxicity was correspondingly altered in hypoxia (Figure 5.2.). GBM tumours 
contain highly hypoxic regions and therefore the lack of effect of chloroquine pre-
treatment on temozolomide efficacy in hypoxia could present difficulties in clinical 
application. However, our data also suggests it may be possible to partially rescue 
temozolomide cytotoxicity in hypoxia with prior normoxic chloroquine pre-treatment 
(Figure 5.2.). Although cell viability is not significantly different to the DMSO-only 
condition following temozolomide and normoxic chloroquine pre-treatment, cell 
viability is clearly decreased compared to temozolomide and chloroquine pre-
treatment in hypoxia. We can therefore conclude that the cytotoxicity of 
temozolomide in hypoxia is not increased by hypoxic chloroquine pre-treatment and 
suggest partial restoration of cytotoxicity in hypoxia through prior normoxic 
impairment of lipid droplet flux. However, these results could be attributable to 
alternative effects from autophagy inhibition or chloroquine treatment and require 
further investigation. Lipid droplet flux is altered in hypoxia and therefore improved 
understanding of altered hypoxic lipid droplet metabolism will better inform our 
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conclusions regarding co-treatment in hypoxia. Moreover, it may indicate additional 
therapeutic targets to further restore hypoxic temozolomide cytotoxicity.  
Interestingly, we observe cell line-specific differences in chloroquine sensitivity in 
hypoxia (Figure 5.2.) which could be due to sensitivity to inhibited autophagy activity 
or sensitivity to inhibited lipid droplet breakdown. In Chapter 4 we observed cell line-
specific differences in LDQ following hypoxic chloroquine treatment suggesting that 
the differences in cell viability are attributable to sensitivity to lipid droplet breakdown 
inhibition. GBMs are heterogeneous tumours and therefore understanding different 
drug responses between patients and within tumours will be important to successful 
therapies. The high chloroquine sensitivity observed in the T98G cell line may offer a 
therapeutic benefit through targeting hypoxic tumour cells which are not affected by 
combined chloroquine and temozolomide treatment. However, hypoxic chloroquine 
treatment increased proliferation in the U87 cell line emphasising the importance of 
understanding case-specific alterations in lipid droplet metabolism in hypoxia. 
Interestingly, in contrast to SRB proliferation assays, the AnnexinV-FITC/PI flow 
cytometry apoptosis assay indicated that cell viability was decreased by hypoxic 
chloroquine treatment in the U87.2 cell line (Figure 5.2.B.). The difference may be 
because the AnnexinV-FITC-PI assay reports cytotoxicity earlier than the SRB 
proliferation assay as it detects the initial molecular events that lead to cell death. 
This suggests that, in our assay timeframe, we observed a greater number of early 
cytotoxic events than cell death events, and that by increasing the length of time of 
the assay, the SRB assay would detect further cell death. It appears from our data 
that different hypoxic chloroquine sensitivities may stem from the cell line-specific 
capacity to compensate for lipid droplet breakdown inhibition. Further investigation is 
required to confirm the association of this response to impaired lipid droplet 
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metabolism as opposed to autophagy inhibition whilst hypoxia-induced alterations in 
lipid droplet metabolism remain unclear. However, this cell line-specific response to 
chloroquine treatment could represent a potential therapeutic target for exploitation 
and further emphasises the importance of understanding the genetic background 
and microenvironment of each patient. 
Despite intrinsic drug resistance, manipulation of lipid droplets with chloroquine pre-
treatment improved temozolomide cytotoxicity in normoxia. We suggest that drug 
efficacy is increased through impaired lipid droplet flux and that this may be used to 
improve the clinical therapeutic efficacy of temozolomide under normoxic conditions. 
However, the lack of efficacy from chloroquine pre-treatment in hypoxia suggests 
applying this theory in a clinical setting may prove challenging due to the highly 
hypoxic nature of GBM. Despite this, the improved efficacy of temozolomide in 
hypoxia with prior normoxic chloroquine pre-treatment suggests that a clinical benefit 
can be sought through further understanding of altered hypoxic lipid droplet 
metabolism. Alternatively, if normoxia is required for treatment efficacy, therapies 
such as cediranib and bevacizumab can decrease tumour hypoxia by normalising 
tumour vasculature (281-284). Therefore, lipid droplet manipulation through inhibited 
lipid droplet breakdown and flux represents an exciting opportunity in the treatment 
of GBM.  
 
5.3.3. The effect of reducing lipid droplet flux through ATGL inhibition on the 
cytotoxicity of the chemotherapeutic agent temozolomide 
We sought to impair lipid droplet flux through an alternative pathway to confirm that 
the increased temozolomide cytotoxicity with chloroquine pre-treatment was due to 
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reduced lipid droplet flux as opposed to altered LDQ. There was a non-significant 
increase in temozolomide cytotoxicity following pre-treatment with the ATGL inhibitor 
atglistatin in normoxia in the U343 and U87 cell lines (Figure 5.3.) suggesting that 
normoxic temozolomide cytotoxicity may be improved through impaired lipid droplet 
flux from lipid droplet production inhibition. However, the increased temozolomide 
cytotoxicity following atglistatin pre-treatment is notably smaller than observed with 
chloroquine pre-treatment. In Chapter 4 our data suggested that inhibition of lipid 
droplet production pathways such as ATGL induced compensatory activation of 
alternative lipid droplet production pathways. This compensation would limit the 
effect of atglistatin in reducing lipid droplet flux, possibly accounting for the smaller 
improvement in temozolomide cytotoxicity. Nevertheless, despite the comparatively 
smaller non-significant improvement in temozolomide cytotoxicity observed with 
atglistatin pre-treatment, our data suggests that reducing lipid droplet flux through 
inhibiting production and breakdown pathways with atglistatin and chloroquine 
respectively can increase temozolomide cytotoxicity in normoxia. This further 
supports the importance of functional lipid droplet flux in cell viability.  
Hypoxic temozolomide cytotoxicity was not improved by either normoxic or hypoxic 
atglistatin pre-treatment, although, as with autophagy inhibition, we observed in 
Chapter 4 that the role of ATGL in lipid droplet metabolism may be altered in 
hypoxia. Most notably, LDQ was significantly decreased by hypoxic ATGL inhibition 
in the U87.2 cell line (Figure 4.12.). If ATGL inhibition further impairs lipid droplet flux 
in these cells, an improved response to atglistatin pre-treatment in hypoxia may be 
observed in this cell line; however, this was not investigated. Atglistatin pre-treatment 
did not increase temozolomide cytotoxicity in the T98G cell line in any oxygen 
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concentration; however, this cell line has been noted previously to have a different 
LDQ response to atglistatin treatment in several other experiments in Chapter 4. 
Due to the non-significant decrease in cell viability following ATGL inhibition on 
temozolomide cytotoxicity, this approach would not be appropriate for clinical 
investigation. Instead, the capacity of ATGL inhibition to increase the cytotoxicity of 
ROS producing therapies, as discussed in Chapter 4, should be further investigated. 
Nevertheless, the trend towards improved temozolomide cytotoxicity in normoxia, 
following prior inhibition of a lipid droplet production pathway, further suggests that 
reduced lipid droplet flux, rather than single pathway inhibition, is responsible for 
improved drug efficacy. Therefore, we again propose that lipid droplet manipulation 
can affect cell viability and temozolomide resistance in normoxia through impeding 
lipid droplet flux and that this is of greater importance than total LDQ.  
 
5.3.4. The effect of reducing lipid droplet flux through lipid droplet breakdown 
inhibition on the cytotoxicity of irradiation 
Following our findings regarding the impact of inhibiting lipid droplet breakdown on 
temozolomide cytotoxicity we investigated whether irradiation cytotoxicity, 
representative of radiotherapy, may also be increased. Exposure to 40Gy of 
radiation induced a small decrease in cell viability (Figure 5.4.) indicating intrinsic 
resistance to high doses of irradiation, a common feature of GBM tumours and 
derived cell lines. However, despite this, inhibition of lipid droplet breakdown through 
chloroquine pre-treatment increased the cytotoxicity of irradiation in normoxia 
suggesting that inhibiting lipid droplet flux could improve radiotherapy efficacy in 
normoxic tumour cells (Figure 5.4.). As with temozolomide, chloroquine pre-
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treatment increased LDQ and improved cytotoxic treatment efficacy further 
supporting that lipid droplets do not provide increased protection through their 
physical presence. Whilst it is possible that radiation of a larger lipid pool increases 
the production of toxic lipid groups, radiation-induced lipid damage is predominantly 
oxidative (285). In contrast to this, we demonstrated a protective role for lipid 
droplets in the prevention of oxidative lipid damage in Chapter 4. Therefore, as the 
increased presence of lipid droplets induced by chloroquine pre-treatment is unlikely 
to directly affect radiation cytotoxicity, we instead propose that this data further 
supports the importance of effective lipid droplet flux in surviving cytotoxic insult. 
As with temozolomide, the improvement of radiation cytotoxicity through inhibition of 
lipid droplet production could provide further evidence for the importance of lipid 
droplet flux in maintaining viability. However, in Chapter 4 we demonstrated the role 
of ATGL in the prevention of unsaturated lipid oxidation, a confounding variable in 
testing the combination of atglistatin pre-treatment with an oxidative treatment such 
as irradiation. Therefore, the importance of effective lipid droplet flux in radiation 
cytotoxicity should be further tested by impairing alternative lipid droplet production 
pathways such as exogenous lipid uptake.   
Due to logistical problems in maintaining hypoxic conditions during irradiation, the 
effect of chloroquine pre-treatment in hypoxic cells proved impossible to test as cells 
would have been exposed to re-oxygenation. Re-oxygenation generates ROS and 
alters cellular metabolism and therefore this investigation was only carried out in 
normoxia. However, despite demonstrating efficacy in normoxia, chloroquine pre-
treatment did not improve temozolomide cytotoxicity in hypoxia and therefore the 
combination of irradiation and chloroquine pre-treatment in hypoxia must be further 
investigated. Nevertheless, this data suggests that impairment of lipid droplet flux 
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can improve the cytotoxicity of irradiation in normoxia and indicates an exciting 
clinical opportunity to improve radiotherapy efficacy in GBM. Moreover, impairment 
of lipid droplet flux may prove a useful strategy to improve treatment regimen 
efficacy in non-hypoxic tumours.  
 
5.3.5. Potential for clinical application 
Pharmacological manipulation of LDQ and flux through lipid droplet metabolic 
pathways provides relevant therapeutic targets with the potential for clinical 
application. Through inhibition of just one of these pathways, autophagy, the efficacy 
of two separate therapeutic approaches could be improved, further demonstrating 
the importance of GBM lipid droplet metabolism. Indeed, autophagy inhibition is not 
a new concept in cancer therapy and provides a particularly good clinical target for 
lipid droplet manipulation due to readily available drugs for translational 
investigations. Several clinical trials have been carried out or are underway 
investigating chloroquine in GBM treatment regimens. Chloroquine has been shown 
to improve brain metastases treatment with whole brain irradiation (286) and there 
are current ongoing trials in both the UK and Netherlands investigating the effect of 
chloroquine with GBM treatments (287,288). Indeed, inclusion of chloroquine in GBM 
treatment regimens was observed to improve survival in a small sample of GBM 
tumours (289). Despite areas of significant hypoxia, other areas of the tumour will 
remain less hypoxic and these may be more susceptible to the pharmacological 
impairment of lipid droplet flux with chloroquine. 
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5.3.6. Summary 
Our data suggests that impairing lipid droplet flux through inhibition of lipid droplet 
metabolic pathways can improve the cytotoxicity of temozolomide and irradiation, 
representative of chemotherapy and radiotherapy, in normoxia. Indeed, 
temozolomide cytotoxicity was improved by inhibition of lipid droplet breakdown, 
despite increased LDQ, further suggesting that the efficacy of treatment is due to 
lipid droplet flux rather than the physical presence of lipid droplets. However, further 
investigation is required to confirm that this effect is lipid droplet-specific and not due 
to autophagy inhibition. We hypothesise that impairment of lipid droplet breakdown 
through alternative methodologies would induce a similar increase in treatment 
cytotoxicity. Du et al. (290) demonstrated that lipid droplets accumulate in renal 
cancer cells in response to HIF-mediated inhibition of mitochondrial β-oxidation 
through CPT1 down-regulation. Similarly, lipid droplet breakdown may be impaired 
through targeting regulatory genes uncovered through the RNAseq analysis. This 
data could also be further supported through concurrently quantifying alterations in 
LDQ during chloroquine and temozolomide treatment, simultaneously demonstrating 
impaired lipid droplet breakdown and improved cytotoxicity. Irrespective of this, the 
evidence emerging from recent clinical trials may support the improvement of 
treatment efficacy through impaired lipid droplet flux via lipid droplet breakdown 
inhibition, further demonstrating the clinical importance of lipid droplet metabolism. 
However, our results also suggest that therapeutic efficacy would not be improved by 
chloroquine pre-treatment in hypoxia and this will hinder the effectiveness of 
targeting lipid droplet metabolism in vivo. This is particularly true of the highly 
hypoxic GBM tumours; however, as discussed in Section 5.3.5, the inclusion of 
chloroquine in current GBM treatment regimens has shown improved survival in a 
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small number of cases (289). It is possible that chloroquine co-treatment may 
improve therapeutic efficacy in peripheral, better oxygenated tumour cells; however, 
21% O2 is not a physiological oxygen concentration and this would require further 
investigation. Moreover, the partial rescue of cytotoxicity in hypoxia through prior 
normoxic manipulation of lipid droplet breakdown suggests that efficacy may be 
restored through improved understanding of hypoxic lipid droplet metabolism. 
Indeed, this may also reveal complimentary pharmaceutical targets to further 
improve combined treatment. Our research also revealed cell line-specific sensitivity 
to autophagy inhibition in hypoxia and this may contribute to the improved survival in 
some patients. However, we also observed that autophagy inhibition could increase 
proliferation in some cells and therefore care must be taken to avoid adversely 
promoting tumour growth. Finally, tumour hypoxia can be decreased through anti-
angiogenic therapies potentially enabling normoxic lipid droplet manipulation to 
influence chemo- and radio-therapy efficacy. 
Therefore, we propose that pharmacological manipulation of lipid droplet metabolism 
enhances temozolomide and radiation cytotoxicity through hindering lipid droplet 
flux. This will impair down-stream processes such as mitochondrial β-oxidation and 
membrane synthesis and prevents the full utilisation of lipid droplets in promoting cell 
viability. Whilst further investigation into this effect is required, impairment of lipid 
droplet flux represents an exciting prospect for enhancing GBM therapeutic regimens 
and may provide an increased understanding of basic tumour biology. 
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Chapter 6 
 
Conclusions 
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6.1. Summary of project aims 
In this project we aimed to investigate the pathways influencing lipid droplet 
metabolism and their importance in glioma biology. Although lipid droplet metabolic 
pathways have been defined in other cancers they are yet to be fully explored in 
glioma. Through the analysis of online clinical data sets and biological in vitro 
investigation we sought to better understand these pathways in glioma and elucidate 
possible approaches to improve current therapies. 
 
6.2. Summary of data 
6.2.1. The importance of lipid droplet metabolic pathways in glioma prognosis 
We defined a gene list representing different aspects of lipid droplet biology and 
metabolism using the current literature and investigated its importance in glioma 
survival. Genes representative of ATGL, autophagy, membrane synthesis, 
mitochondrial β-oxidation and lipid droplet-associated proteins were associated with 
poor prognosis and an increased expression in higher clinical grades. In contrast, 
high expression of de novo fatty acid synthesis genes was associated with good 
survival and increased expression in lower clinical grades. Representative genes 
from other pathways that have been observed as important in lipid droplet 
metabolism in other cancers, such as cholesterol uptake, showed no association 
with survival. Interestingly, the expression of the different ‘survival-associated’ genes 
was found to correlate with each other, indicating that they may represent a coherent 
aspect of glioma biology. Moreover, gene expression did not cluster when subjected 
to cluster analysis, suggesting that this common factor is shared between all gliomas 
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and not limited to a tumour sub-group. These pathways were selected due to their 
association with lipid droplet metabolism in other cancers and it is therefore likely 
they are interlinked through lipid droplets. 
Gene expression also separated survival curves across grades 2 and 3 in grade-
specific a manner; however, this was not observed at grade 4. Although this could 
suggest that these genes become unimportant in grade 4 tumours, expression of 
many poor prognosis genes increased greatly in grade 4 tumours suggesting that 
grade 4 represents an end point for altered gene expression in these pathways. 
Gene expression would therefore tend towards a similar point in all tumours upon 
progressing to grade 4 and not separate survival curves. Alternatively, this contrast 
in survival prediction may represent differences between primary GBM, which 
comprises the majority of grade 4 tumours, and grade 2 and 3 gliomas and 
secondary GBM. However, this assumes that these genes are associated with the 
IDH and TP53 mutations which define secondary GBM, whereas we observed an 
association between high gene expression in the poor prognosis genes and IDH1 
wildtype tumours. Moreover, analysing the expression of a combination of genes 
within a defined ‘gene set’ increased the prognostic value of gene expression and 
separated survival curves in our GBM cohort. Therefore, expression of these genes 
is important across all glioma grades further supporting the importance of these 
pathways in glioma biology. 
Interestingly, poor prognosis grade 2 tumours could be predicted by a “grade 3 like” 
gene expression profile. As poor prognosis indicates an increased chance of 
recurrence and increased clinical grade this suggests a role for lipid droplet-
associated genes in influencing or responding to tumour progression. However, our 
data compares gene expression from different tumours across clinical grades as 
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opposed to measuring tumour gene expression throughout progression and 
therefore this hypothesis requires further investigation. 
We have therefore demonstrated the importance of gene expression in glioma 
survival across the tumour grades and hypothesise that gliomas refocus their 
metabolism from pathways such as de novo fatty acid synthesis to autophagy, ATGL 
and lipid droplet metabolism as they increase in clinical grade and severity.  
 
6.2.2. Biological characterisation of the underlying lipid droplet metabolic pathways in 
GBM cell lines 
Having established a strong basis for a hypothesis that lipid droplets play a 
significant role in the pathogenesis of gliomas, we further sought to test this through 
a number of biological investigations. Using confocal microscopy, flow cytometry and 
NMR-based methods we explored the pathways governing lipid droplet metabolism 
in GBM cell lines. In conjunction with our observations regarding the lipid uptake 
transporter CD36 in glioma survival and its correlation with lipid droplet markers such 
as PLIN2, we found that lipid droplets were predominantly produced through uptake 
of exogenous lipids in both normoxia and hypoxia. 
Similarly, the gene encoding ATGL, which correlated with lipid droplet markers and 
glioma survival, was found to have a role in lipid droplet metabolism in our cell lines. 
In other cell types, ATGL is frequently associated with lipid droplet breakdown. 
However, ATGL inhibition decreased LDQ, suggesting a role in lipid droplet 
production. Due to the localisation of ATGL at cell membranes as well as lipid 
droplets (189) and the impact of ATGL inhibition on lipid droplet unsaturated content, 
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we hypothesised an ATGL-mediated unsaturated lipid shuttle system from cell 
membranes to lipid droplets. Interestingly, this process would require the 
participation of FABPs which are known to associate with ATGL through CGI58 
(192). Moreover, they have been shown to be important factors in GBM cell line lipid 
droplet production (123). Lipid droplets provide a protective store for vulnerable 
unsaturated fatty acids during oxidative stress in Drosophila glial cells (226). Our 
data suggest a similar function for lipid droplets in GBM cell lines through this ATGL-
mediated lipid shuttle. Indeed, we further observed that oxidative damage could be 
increased through ATGL inhibition and this may present an interesting clinical target. 
In contrast to exogenous lipid uptake and ATGL, our data did not indicate a major 
role for de novo fatty acid synthesis in lipid droplet production. This is supported by 
Bensaad et al. (123) who similarly did not observe a role for de novo fatty acid 
synthesis in lipid droplet production in GBM cell lines. Moreover, in Chapter 3 we 
demonstrated an association between expression of the de novo fatty acid synthesis 
gene set and improved survival. In combination with the decreased gene expression 
observed in higher grade gliomas, this further supports a decreased reliance upon 
this pathway in high grade glioma lipid droplet metabolism. Interestingly, our data 
suggests this pathway may compensate for compromised lipid uptake and ATGL 
activity, a response that has been similarly observed in other cancers (166,167). 
Therefore, although de novo fatty acid synthesis is not the preferred pathway for lipid 
droplet production, a possible role in maintaining LDQ further demonstrates the 
importance of effective lipid droplet metabolism.  
As in many other cell types and cancers (179,184-188), the major lipid droplet 
breakdown mechanism in our cell lines was autophagy, although this was less clear 
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in hypoxia. This finding mirrored our gene expression data as the vital autophagy 
gene MAP1LC3A was associated with survival in grade 2, 3 and 4 gliomas and 
strongly correlated with lipid droplet-associated genes. Moreover, autophagy is 
known to be an important part of glioma biology (172) and, whilst this was presumed 
to be through cell death prevention, it may be attributable to a role in lipid droplet 
metabolism. Perhaps most importantly, pharmacological targeting of autophagy is 
effective and easily translational, as inhibitors have already been through clinical 
trials for other diseases, increasing the relevance of autophagy and lipid droplet 
metabolism as clinical targets. 
The function of lipid droplets in gliomas has remained largely unaddressed in cancer. 
However, our preliminary data suggests they provide a source of lipids for 
mitochondrial β-oxidation and membrane synthesis. Although this data is limited to 
one qualitative technique in our investigation, this concept is supported in other 
cancers by the literature wherein lipid droplets fuel energy production and 
phospholipid synthesis (92,149,215). Moreover, expression of mitochondrial β-
oxidation and membrane synthesis genes correlated with lipid droplet-associated 
markers and was associated with poor survival in Chapter 3, further supporting the 
importance of these interlinked pathways in glioma. 
In summary, our data suggests that lipid droplet metabolism in gliomas occurs 
through the uptake of exogenous lipids, ATGL-mediated lipid shuttling and 
autophagic lipid droplet breakdown (Figure 6.1.). Whilst de novo fatty acid synthesis 
may compensate for decreased activity of other pathways, our data does not 
suggest a major role for this pathway in lipid droplet metabolism and this is 
supported by the literature (123). Importantly these results correlate with our 
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observations in Chapter 3, supporting the increased importance of pathways such as 
autophagy and ATGL in higher grade gliomas as opposed to de novo fatty acid 
synthesis. Therefore, we have further characterised the metabolic pathways 
underlying lipid droplet production and breakdown in gliomas and suggest that lipid 
droplet metabolic pathways, as well as lipid droplets, may represent glioma 
biomarkers and influence tumour survival.  
 
 
 
 
Figure 6.1. A summarised diagram of lipid droplet metabolic pathways in these GBM 
cell lines. Lipid droplets are produced by exogenous lipid uptake and ATGL-mediated lipid 
shuttling. De novo fatty acid synthesis can contribute to lipid droplet production but does not 
have a major role in lipid droplet production. Autophagy is the main route of lipid droplet 
breakdown. Lipid droplet derived lipids can be used to synthesis phospholipids for 
membranes or produce energy through mitochondrial β-oxidation. 
Exogenous 
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mediated 
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6.2.3. The cytotoxicity of temozolomide and radiation in normoxia can be increased 
through lipid droplet manipulation 
As well as elucidating a relatively unexplored area of glioma metabolism, a better 
understanding of lipid droplet metabolic pathways in gliomas would enable us to 
better target lipid droplet metabolism, with the aim to improve current clinical 
therapies. Lipid droplets have been suggested as important factors in treatment 
response and resistance, although attempts to target this in GBM have been limited 
by poor methodology (277). We therefore sought to manipulate LDQ to improve 
current therapies using the pathways defined in Chapter 4. Despite intrinsic 
temozolomide and radiation resistance, autophagy inhibition increased 
temozolomide and irradiation cytotoxicity in normoxia suggesting that lipid droplet 
manipulation may be of clinical relevance in glioma treatment. Previous studies 
(238,239,277) suggested that drug efficacy may be improved by inhibiting lipid 
droplet production, thus decreasing LDQ and drug sequestration. However, we 
propose that cytotoxicity is improved through interrupted lipid droplet flux as 
autophagy inhibition impairs lipid droplet breakdown and increases LDQ. As 
observed in Chapter 4, lipid droplets provide an important source of lipids for energy 
production and membrane synthesis, and interruption of these processes will further 
impair cell viability during cytotoxic stress. 
Although hypoxia is well established in gliomas and the improved drug cytotoxicity 
was negated in hypoxia, the partial rescue of this effect by normoxic pre-treatment 
helps retain the possibility of applying this theory within the clinic. Moreover, tumour 
hypoxia can be pharmacologically decreased if required whilst tumour resection 
removes the most significant areas of hypoxia, further supporting the clinical 
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relevance of lipid droplet manipulation. Finally, this data also highlights the need for 
in vitro studies to be performed in hypoxia when investigating hypoxic tumours. 
Interestingly, chloroquine sensitivity varied between cell lines in hypoxia, perhaps 
reflecting cell line-specific LDQ differences in response to hypoxic autophagy 
inhibition. Indeed, this may be due to the extent for which impaired lipid droplet 
metabolism can be compensated for as our data indicated cell death occurs 
following extended autophagy inhibition. This is further evidence that maintaining 
effective lipid droplet metabolism is vital in cell survival, particularly during cytotoxic 
insult. Whilst it could be suggested that the increased cytotoxicity of temozolomide 
and irradiation is due to the inhibition of general autophagy as opposed to interrupted 
lipid droplet flux, we have clearly demonstrated the major role autophagy plays in 
lipid droplet breakdown in these cell lines. Moreover, the correlation between the 
vital autophagy gene MAP1LC3A and lipid droplet markers and its association with 
poor survival and increased glioma grade further support the importance of 
autophagy in lipid droplet metabolism in these cell lines. Therefore, whilst the 
determination of this effect as lipid droplet-specific requires further confirmation, we 
suggest that the improved cytotoxicity of temozolomide and irradiation is attributable 
to inhibition of lipid droplet-specific autophagy. 
Temozolomide cytotoxicity was increased through disruption of lipid droplet 
production with ATGL inhibition, supporting the importance of effective lipid droplet 
flux in resisting cytotoxic insults. Although we established a role for ATGL in the 
shuttling of unsaturated fatty acids and the prevention of oxidative stress, as well as 
lipid droplet production, temozolomide is not thought to cause oxidative stress so this 
effect is likely due the impairment of lipid droplet flux. Importantly, improved 
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temozolomide cytotoxicity could be achieved through impaired lipid droplet 
production as well as breakdown, further supporting interrupted lipid droplet 
breakdown as the cause for improved temozolomide cytotoxicity with chloroquine 
treatment, as opposed to general autophagy inhibition. 
The improvement of temozolomide and irradiation cytotoxicity by impairing lipid 
droplet flux represents an exciting clinical opportunity to improve two major aspects 
of glioma treatment regimens; chemotherapy and radiotherapy. Although this 
approach remains limited in hypoxia, pharmacological manipulation of hypoxia and 
further investigation of hypoxic lipid droplet metabolism may reveal alternative and 
improved strategies to increase treatment efficacy and extend the clinical 
applicability of combined treatment.  
 
6.3. Future studies 
There are several areas within this work which require addressing in future 
experiments: 
Although we show gene expression to alter across tumour grades and be a predictor 
of survival and prognosis, proving an association with tumour progression requires 
follow-up gene expression for tumours before and after progression. In such a data 
set, we hypothesise that expression of the poor prognostic markers; such as PLIN2, 
PLIN3, MAP1LC3A and PNPLA2, would increase as the tumour progresses, with a 
corresponding decrease in expression of the good prognostic markers; such as de 
novo fatty acid synthesis enzymes. However, these data are rare and analysis 
presents its own challenge of separating alterations which are associated with 
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increased clinical grade and tumour progression versus the effects of exposure to 
cytotoxic therapies during treatment. Given that paediatric glioma lipid content has 
been shown to change with treatment (98), there are considerable confounders that 
would require addressing. Nevertheless, a data set such as this remains vital in 
monitoring the alterations occurring at each tumour grade and could be further 
supported using mouse models. 
We also need to further explore pathway compensation and the altered lipid droplet 
metabolism observed in hypoxia. We hypothesise that inhibition of a lipid droplet 
metabolic pathway will result in a corresponding increase in the activity of alternative 
pathways. Indeed, this is supported by the minor or conflicting effects on LDQ from 
inhibiting individual lipid droplet metabolic pathways in hypoxia. We attempted to 
investigate this through simultaneously inhibiting multiple pathways; however, our 
results were hindered by the induction of cell stress and death, an effect also 
observed by Lewis et al. (155). Therefore, future investigations of pathway activity in 
hypoxia should aim to observe the activation of compensatory pathways non-
invasively, for example, through the use of stable isotope-enriched nutrients, such as 
13C16-palmitate, 
13C-glucose and 13C-glutamine, to monitor their use by lipid utilising 
pathways. In these cases, labelled glucose and glutamine incorporation into lipid 
droplets would be expected to increase upon inhibition of exogenous lipid uptake, 
with a similar response expected from labelled palmitate upon inhibition of the ATGL-
mediated shuttle. Similarly, gene expression of compensatory pathways may 
increase upon initial pathway inhibition. Lipid droplet breakdown compensation could 
be further investigated using a pan-lipase inhibitor such as DEUP. We hypothesise 
that this inhibitor would have no effect on LDQ unless autophagy was simultaneously 
inhibited, implicating cytoplasmic lipases as a compensatory lipid droplet 
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mechanism. We further hypothesise that this inhibitor would prevent the LDQ 
decrease observed upon hypoxic autophagy inhibition in the U343, U87.1 and U87.2 
cell lines (Figure 4.14) through preventing the compensatory activation of this 
pathway as a lipid breakdown mechanism. 
The occurrence of cell line-specific responses to lipid droplet metabolic pathway 
inhibition may reflect the inherent heterogeneity of GBM tumours and could also be 
further explored through additional RNAseq characterisation of the cell lines. Despite 
similar gene abundances, the U87 and U87.2 cell lines notably differ in their 
response to chloroquine or atglistatin treatment in hypoxia, suggesting important 
mutational or epigenetic differences. We hypothesise that characterisation of these 
differences may indicate a small list of potential regulatory genes which could be 
associated with different responses to drug treatment, particularly in hypoxia. This 
list could then be refined and assessed through targeted gene silencing. Thus, 
through further characterisation of the genetic profiles of all 5 cell lines, we may 
extend our understanding of the genetic control underlying lipid droplet metabolic 
pathways. This could prove vital in maximising the efficacy of impairing lipid droplet 
flux and in determining effective patient sub-groups for lipid droplet metabolism-
associated therapies. Moreover, this data may better inform and caution future 
studies regarding the significant biological effects that may occur from genetic drift 
and heterogeneity.  
The ATGL-mediated lipid shuttle and its protective role in oxidative stress are 
supported by both the literature (226) and our investigation, but this area requires 
considerable further work. We hypothesise that fluorescent-labelled unsaturated fatty 
acids, ATGL and FABPs will co-localise at membranes, in the cytoplasm during 
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transport and at lipid droplets providing qualitative evidence for their involvement in a 
shuttle system. In conjunction with this, we predict that FABP and ATGL knockdown 
should disrupt this system and decrease unsaturated lipid droplet content, 
particularly in hypoxia. Finally, as observed with ATGL, inhibition of FABPs should 
increase ROS damage and therefore interruption of this unsaturated lipid shuttle 
should decrease viability under oxidative stress. Taken together these experiments 
could further support our findings and better establish this uncharacterised 
unsaturated lipid shuttle system.  
Our data regarding the use of lipid droplet-derived lipids for mitochondrial β-oxidation 
and membrane synthesis remains preliminary due the use of a single qualitative 
technique and therefore requires support from alternative quantitative 
methodologies. The proportion of lipid droplet-derived lipids catabolised for 
mitochondrial β-oxidation can be quantified by pharmacologically inhibiting lipid 
droplet metabolic pathways and observing alterations in oxygen consumption with 
oxygen probes, such as the Oroboros. Alternatively, the activity of mitochondrial β-
oxidation enzymes may also be assessed when deprived of lipid droplet flux. In this 
case, we hypothesise that mitochondrial β-oxidation would be decreased upon 
interruption of lipid droplet flux in normoxia but not hypoxia, reflecting the localisation 
of C16 BODIPY to mitochondria-associated regions in normoxia only. 
Correspondingly, the role of lipid droplets in membrane synthesis may be 
investigated through knockdown of membrane synthesis enzymes. We hypothesise 
that this will result in decreased incorporation of lipid-droplet derived lipids in the cell 
membrane lipid pool. These experiments could support our data concerning the 
downstream use of lipid droplets but were not achievable within the timeframe of this 
project. 
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We have established the importance of these metabolic pathways in grade 4 glioma 
cell lines and their relevance in grade 2 and 3 gliomas should also be investigated. 
From our grade 2 and 3 gene expression data, we would hypothesise an increased 
reliance upon de novo fatty acid synthesis in the lipid droplet metabolism of lower 
grade tumours and decreased maintenance of lipid droplet flux. Therefore, the 
experiments of Chapter 4 should be repeated using grade 2 and 3 glioma cell lines 
to further support the evidence provided in Chapter 3. Moreover, lipid droplet 
manipulation may also improve current therapies in lower grade tumours, particularly 
as these tumours are markedly less hypoxic. Similarly, understanding lipid droplet 
metabolic pathways in grade 2, 3 and 4 glioma cell lines may provide further 
evidence regarding an association between lipid droplets and tumour progression. 
Finally, the clinical significance of this investigation’s findings should be further 
tested using more physiologically relevant models, such as primary cell lines, stem 
cells and neurospheres, which we predict will continue to demonstrate the 
importance of these findings.  
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6.4. Conclusion 
Lipid droplets are important metabolically-active structures, capable of impacting a 
diverse range of processes. Their clinical importance in glioma is well established 
but the underlying metabolic pathways have remained relatively unexplored. Using 
gene expression, we demonstrated that lipid droplets and lipid droplet-associated 
pathways can predict survival and indicate a possible association with tumour 
progression. Moreover, we demonstrated that glioma lipid droplet production occurs 
through exogenous lipid uptake and ATGL-mediated unsaturated fatty acid shuttling 
whilst lipid droplet breakdown occurs through autophagy. We further suggest that 
lipid droplets can be used to fuel mitochondrial β-oxidation and membrane synthesis 
and may play a further role in the prevention of oxidative lipid damage. Importantly, 
we showed that lipid droplet manipulation can improve the current therapies for 
glioma treatment suggesting that, although they require greater investigation, lipid 
droplets represent a therapeutic target to complement current treatment regimens. 
Through analysis of clinical data sets, biological investigation and therapeutic 
studies, we have elucidated many key areas of lipid droplet metabolism in gliomas 
and predict that lipid droplets are an important aspect in the improved future 
treatment of gliomas.  
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Chapter 7 
 
Appendices 
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Appendix 7.1. Scripts for generating the correlation heat map in “R” 
 
The correlation heat map was generated using the following script: 
test.data<-read.table(*data file location*, header=T) 
corr.data<-cor(test.data, use="all.obs", method="spearman") 
corrplot(corr.data, method="color", type="upper", col=colorRampPalette(c("indian 
red", "white", "dark green"))(200)) 
 
The significance of the correlations was assessed using the following script: 
test.data<-read.table(*data file location*, header=T) 
z<-rcorr(as.matrix(test.data), type="spearman") 
 
Appendix 7.2. Correlation heat map data tables 
 
Spearman’s rank r-value correlations 
 
PLIN2 PLIN3 PNPLA2 CD36 HILPDA MAP1LC3ACEPT1 CPT2 ETNK1 PTDSS1 PLIN1 PLIN4 PNPLA3 PNPLA4 ACACA FASN SLC25A20
PLIN2 1 0.43 0.17 0.16 0.35 0.17 0.31 0.24 -0.13 -0.03 0.03 0 -0.3 0.27 -0.44 -0.44 0.25
PLIN3 0.43 1 0.19 -0.07 0.25 -0.01 0.51 0.56 -0.13 -0.22 0.22 -0.03 -0.4 0.17 -0.53 -0.52 0.14
PNPLA2 0.17 0.19 1 -0.02 0.14 0.13 -0.07 0.01 -0.32 -0.16 0.01 0.07 -0.24 -0.05 -0.42 -0.06 0.01
CD36 0.16 -0.07 -0.02 1 0.05 -0.17 0.04 0.04 -0.03 0.01 -0.14 -0.16 -0.05 -0.11 -0.01 -0.02 -0.08
HILPDA 0.35 0.25 0.14 0.05 1 0.04 0.27 0.24 -0.11 -0.01 0.03 -0.09 -0.37 0.1 -0.35 -0.34 0.13
MAP1LC3A 0.17 -0.01 0.13 -0.17 0.04 1 -0.1 -0.18 -0.13 0.21 0.08 0.36 0.11 0.66 -0.12 -0.1 0.5
CEPT1 0.31 0.51 -0.07 0.04 0.27 -0.1 1 0.69 0.25 -0.08 0.18 0.08 -0.47 0.19 -0.47 -0.63 0.03
CPT2 0.24 0.56 0.01 0.04 0.24 -0.18 0.69 1 0 -0.08 0.26 0.04 -0.42 0.11 -0.39 -0.5 0.04
ETNK1 -0.13 -0.13 -0.32 -0.03 -0.11 -0.13 0.25 0 1 0.07 -0.09 -0.03 0.05 -0.04 0.1 -0.02 -0.14
PTDSS1 -0.03 -0.22 -0.16 0.01 -0.01 0.21 -0.08 -0.08 0.07 1 -0.3 -0.01 0.21 0.25 0.17 0.05 0.21
PLIN1 0.03 0.22 0.01 -0.14 0.03 0.08 0.18 0.26 -0.09 -0.3 1 0.42 -0.22 0.11 -0.16 -0.14 0.09
PLIN4 0 -0.03 0.07 -0.16 -0.09 0.36 0.08 0.04 -0.03 -0.01 0.42 1 -0.05 0.38 -0.03 -0.02 0.15
PNPLA3 -0.3 -0.4 -0.24 -0.05 -0.37 0.11 -0.47 -0.42 0.05 0.21 -0.22 -0.05 1 0.09 0.62 0.57 0.09
PNPLA4 0.27 0.17 -0.05 -0.11 0.1 0.66 0.19 0.11 -0.04 0.25 0.11 0.38 0.09 1 -0.1 -0.25 0.5
ACACA -0.44 -0.53 -0.42 -0.01 -0.35 -0.12 -0.47 -0.39 0.1 0.17 -0.16 -0.03 0.62 -0.1 1 0.7 -0.09
FASN -0.44 -0.52 -0.06 -0.02 -0.34 -0.1 -0.63 -0.5 -0.02 0.05 -0.14 -0.02 0.57 -0.25 0.7 1 -0.18
SLC25A20 0.25 0.14 0.01 -0.08 0.13 0.5 0.03 0.04 -0.14 0.21 0.09 0.15 0.09 0.5 -0.09 -0.18 1
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Adjusted p-values (significant correlations are highlighted in red) 
 
 
Appendix 7.3. Scripts for generating the cluster analysis 
 
The cluster analysis was generated using the following script: 
test.data<-read.table(*data file location*, header=T) 
heatmap.2(t(test.data),distfun=function(x)dist(x,method="euclidean"),hclustfun=functi
on(x)hclust(x,method="ward.D2"),dendrogram="column",col=redgreen(75),key=TRU
E,symkey=FALSE,density.info="none",trace="none",cexRow=1,srtCol=45,labCol=NA
) 
 
  
PLIN2 PLIN3 PNPLA2 CD36 HILPDA MAP1LC3ACEPT1 CPT2 ETNK1 PTDSS1 PLIN1 PLIN4 PNPLA3 PNPLA4 ACACA FASN SLC25A20
PLIN2 0.0001 0.0001 0.0003 0.0001 0.0001 0.0001 0.0001 0.0020 0.4741 0.5054 0.9523 0.0001 0.0001 0.0001 0.0001 0.0001
PLIN3 0.0001 0.0001 0.1191 0.0001 0.8475 0.0001 0.0001 0.0035 0.0001 0.0001 0.4849 0.0001 0.0001 0.0001 0.0001 0.0016
PNPLA2 0.0001 0.0001 0.6472 0.0017 0.0033 0.1058 0.8270 0.0001 0.0002 0.8472 0.1283 0.0001 0.3024 0.0001 0.1882 0.7865
CD36 0.0003 0.1191 0.6472 0.2155 0.0001 0.3440 0.4074 0.4360 0.8925 0.0012 0.0002 0.2457 0.0132 0.7767 0.6683 0.0693
HILPDA 0.0001 0.0001 0.0017 0.2155 0.4141 0.0001 0.0001 0.0090 0.8306 0.5361 0.0302 0.0001 0.0282 0.0001 0.0001 0.0033
MAP1LC3A 0.0001 0.8475 0.0033 0.0001 0.4141 0.0244 0.0001 0.0025 0.0001 0.0729 0.0001 0.0159 0.0001 0.0063 0.0201 0.0001
CEPT1 0.0001 0.0001 0.1058 0.3440 0.0001 0.0244 0.0001 0.0001 0.0685 0.0001 0.0695 0.0001 0.0001 0.0001 0.0001 0.5067
CPT2 0.0001 0.0001 0.8270 0.4074 0.0001 0.0001 0.0001 0.9638 0.0563 0.0001 0.3899 0.0001 0.0099 0.0001 0.0001 0.3911
ETNK1 0.0020 0.0035 0.0001 0.4360 0.0090 0.0025 0.0001 0.9638 0.1285 0.0436 0.4699 0.2898 0.3879 0.0220 0.6927 0.0011
PTDSS1 0.4741 0.0001 0.0002 0.8925 0.8306 0.0001 0.0685 0.0563 0.1285 0.0001 0.8513 0.0001 0.0001 0.0001 0.2466 0.0001
PLIN1 0.5054 0.0001 0.8472 0.0012 0.5361 0.0729 0.0001 0.0001 0.0436 0.0001 0.0001 0.0001 0.0089 0.0002 0.0010 0.0356
PLIN4 0.9523 0.4849 0.1283 0.0002 0.0302 0.0001 0.0695 0.3899 0.4699 0.8513 0.0001 0.2791 0.0001 0.4272 0.6830 0.0004
PNPLA3 0.0001 0.0001 0.0001 0.2457 0.0001 0.0159 0.0001 0.0001 0.2898 0.0001 0.0001 0.2791 0.0389 0.0001 0.0001 0.0418
PNPLA4 0.0001 0.0001 0.3024 0.0132 0.0282 0.0001 0.0001 0.0099 0.3879 0.0001 0.0089 0.0001 0.0389 0.0232 0.0001 0.0001
ACACA 0.0001 0.0001 0.0001 0.7767 0.0001 0.0063 0.0001 0.0001 0.0220 0.0001 0.0002 0.4272 0.0001 0.0232 0.0001 0.0380
FASN 0.0001 0.0001 0.1882 0.6683 0.0001 0.0201 0.0001 0.0001 0.6927 0.2466 0.0010 0.6830 0.0001 0.0001 0.0001 0.0001
SLC25A20 0.0001 0.0016 0.7865 0.0693 0.0033 0.0001 0.5067 0.3911 0.0011 0.0001 0.0356 0.0004 0.0418 0.0001 0.0380 0.0001
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Appendix 7.4. Survival analysis of genes not included in Figure 3.1. 
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Appendix 7.5. Survival analysis of genes not included in Figure 3.2. 
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Appendix 7.6. Survival analysis of genes not included in Figure 3.3 
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Appendix 7.7. Gene expression boxplots not included in Figure 3.4. 
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Appendix 7.8. Survival analysis of genes not included in Figure 3.5. 
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Appendix 7.9. Gene expression boxplots of genes not included in Figure 3.6. 
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Appendix 7.10. STR profile results 
The U87.1 and U87.2 cell lines were found to have the same STR profile. Upon 
comparison with known STR profiles they were found to match the U87 cell line. 
 
DNA-System U87.1 U87.2  U87 
AM X, X X, X  X, X 
D3S1358 16, 17 16, 17  16, 17 
D1S1656 15, 15 15, 15  15, 15 
D6S1043 11, 18 11, 18  11, 18 
D13S317 8, 11 8, 11  8, 11 
Penta E 7, 14 7, 14  7, 14 
D16S539 12, 12 12, 12  12, 12 
D18S51 13, 14 13, 14  13, 14 
D2S1338 20, 23 20, 23  20, 23 
CSF1PO 10, 11 10, 11  10, 11 
Penta D 9, 14 9, 14  9, 14 
TH01 9.3, 9.3 9.3, 9.3  9.3, 9.3 
vWA 15, 17 15, 17  15, 17 
D21S11 28, 32.2 28, 32.2  28, 32.2 
D7S820 8, 9 8, 9  8, 9 
D5S818 11, 12 11, 12  11, 12 
TPOX 8, 8 8, 8  8, 8 
D8S1179 10, 11 10, 11  10, 11 
D12S319 18, 21 18, 21  18, 21 
D19S433 15, 15.2 15, 15.2  15, 15.2 
FGA 18, 24 18, 24  18, 24 
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Appendix 7.11. Justification of clonal mutant cell lines 
There were 3572 significantly differentially expressed genes between the U87 and 
U87.1 cell lines. There were 256 significantly differentially expressed genes between 
the U87 and U87.2 cell lines. There were 3573 significantly differentially expressed 
genes between the U87.1 and U87.2 cell lines. 
 
 
DAVID biochemical pathway analysis of the differentially expressed genes revealed 
several alterations in key metabolic pathways. 
Cell line 
comparison 
Pathway name Number of alterations 
U87 and U87.1 
Metabolic pathways 206 
Pathways in cancer 90 
PI3K-Akt signalling 68 
MAPK signalling 47 
Oxidative phosphorylation 32 
HIF-1 signalling 29 
AMPK signalling 25 
Glycolysis/Gluconeogenesis 17 
U87 and U87.2 Pathways in cancer 13 
U87.1 and 
U87.2 
Metabolic pathways 210 
Pathways in cancer 90 
PI3K-Akt signalling 64 
Oxidative phosphorylation 35 
AMPK signalling 26 
HIF-1 signalling 25 
Glycolysis/Gluconeogenesis 18 
 
First cell 
line 
Second cell 
line 
Significantly differentially 
expressed genes 
Pathways alterations 
detected by DAVID 
U87 U87.1 3572 73 
U87 U87.2 256 3 
U87.1 U87.2 3573 72 
   
259 
 
An example metabolic Kegg pathway demonstrating significant alterations in gene 
expression. The image below shows the glycolysis/gluconeogenesis pathway.  Red 
stars denote genes with significant alterations. 
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The images below show print screens of the pathways detected by DAVID as 
containing significant alterations in gene expression. The comparison order is as 
follows: 
U87 vs U87.2 
U87 vs U87.1 
U87.1 vs U87.2 
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Appendix 7.12. siRNA knockdown band densitometry raw data. 
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Keystone Metabolism and Hypoxia – Whistler, Canada 2017 
Metabolic pathways influencing glioblastoma lipid droplet biology 
Lipid droplets are rapidly emerging as key components of cancer metabolism 
however the cellular pathways governing these dynamic organelles remain unclear. 
Although preferred mechanisms are often tissue specific, they can include uptake of 
exogenous serum lipids, lipophagy, lipase activity and de novo lipid synthesis. A 
number of tumour types exhibit an increase in lipid droplets in hypoxia, notably 
glioblastoma (GBM), where they are associated with treatment resistance and poor 
survival. Our understanding of lipid droplet biology remains incomplete and we 
therefore investigated potential mechanisms using four human GBM cell lines 
(T98G, U87, HGG01 and HGG03). We found that lipid droplets were increased in 
hypoxia (0.3% O2) in all cell lines, measured using microscopy, flow cytometry and 
NMR-based methods. We show a role for adipose triglyceride lipase (ATGL) and a 
cellular reliance upon the uptake of exogenous serum lipids in lipid droplet 
production and maintenance. Lipid droplet degradation was observed through the 
combined action of lipophagy (lipid droplet-specific autophagy) and ATGL. We 
suggest that the action of these mechanisms provide the core of a lipid droplet 
metabolic pathway within these cell lines and that the hypoxia-induced lipid droplet 
increase is reliant upon differential activity of these mechanisms. Therapeutic options 
remain highly limited in GBM and our data suggest that manipulation of lipid droplets 
with pharmacological inhibitors can alter the in vitro cytotoxic efficacy of 
temozolomide, the major chemotherapeutic agent. Our data further illuminates the 
metabolic mechanisms governing lipid droplet metabolism in GBM and suggests the 
application of lipid droplet manipulation may greatly improve current and future 
clinical therapies. 
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International Symposium on Paediatric Neuro-Oncology (ISPNO) – Liverpool, UK 
2016 
Hypoxia and lipid droplets in glioblastoma: A story of two paths. 
Glioblastoma is a highly malignant disease with limited therapeutic options and a 
poor prognosis which affects both children and adults. An area of recent interest in 
glioblastoma is lipid droplets which are quickly emerging as an influential facet of 
cancer cell biology. Considered dynamic organelles composed of a neutral lipid core 
and single-layer phospholipid membrane they are associated with higher grade and 
poorer prognosis in astrocytomas. Furthermore, highly hypoxic areas in 
glioblastomas are known to alter lipid metabolism as well as being resistant to 
treatments such as radiotherapy.  However the impact of hypoxia on lipid droplets 
and the mechanisms for lipid droplet formation in glioblastoma is yet to be 
elucidated. Changes in lipid droplet number between normoxia and hypoxia (0.3% 
O2) were investigated using confocal fluorescence microscopy. Pharmacological 
targeting of autophagy and lipid synthesis and degradation was employed to 
investigate the cellular role of lipid droplets in both adult (T98G and U87) and 
paediatric (HGG01 and HGG03, Hulleman VUMC, NL) immortalised glioblastoma 
cell lines. Acute and chronic hypoxic incubation significantly increased lipid droplet 
expression whilst pharmacological inhibition of lipid synthesis failed to abrogate lipid 
droplet formation. Instead lipid droplet formation was reliant upon autophagy and 
lipase function in the U87 and HGG03 cell lines and exogenous uptake from serum 
in the T98G and HGG01 cell lines. Taken together our data suggests that hypoxia 
induces an increased level of lipid droplet expression through either autophagy or 
exogenous uptake from serum and raises the possibility of pharmacological 
targeting. 
 
Mitox – Oxford, UK 2015 
The Role of Hypoxia on Lipid Droplet Production in Glioblastoma. 
Lipid droplets are quickly emerging as an important and influential facet of cancer 
cell biology. Composed of a neutral lipid core and single-layer phospholipid 
membrane, they were originally considered simple energy stores but are now 
thought of as dynamic organelles with a significant impact upon cellular metabolism. 
Lipid droplets have been particularly linked to glioblastoma, a very severe and 
malignant form of brain cancer, and are shown to increase with clinical grade and 
chemotherapeutic response.  Moreover glioblastomas contain very hypoxic areas 
which are known to alter lipid metabolism and are believed to influence lipid droplet 
expression. The impact of hypoxia on lipid droplets has been only briefly investigated 
and the methods by which any alterations could occur remain unknown. 
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We investigated changes in lipid droplet number between normoxia and hypoxia 
(0.3% O2) using confocal fluorescence microscopy and observed that, in both adult 
and paediatric immortalised glioblastoma cell lines (U87, T98G, HGG01 and 
HGG03), lipid droplet number increased significantly in acute hypoxia (16 hours). 
Chronic hypoxic incubation further increased lipid droplet number whilst 
pharmacological inhibition of both glutaminolysis, through BPTES, and fatty acid 
synthesis, through Orlistat, failed to abrogate lipid droplet formation. Where possible 
we used data acquired through high-resolution magic-angle spinning (HRMAS) 
nuclear magnetic resonance spectroscopy (NMR) and analysed with Mestrenova 
peak analysis to support induced metabolic alterations. 
Taken together our data suggests that hypoxia induces an increasing level of lipid 
droplet expression through a cellular mechanism other than de novo synthesis, 
indicating an alternative and potentially pharmacologically-targetable pathway for 
investigation. 
 
